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CHAPTER 1 
Introduction 
Although the age-specific mortality rates from cardiovascular diseases (CVD) 
are decreasing, CVD are still the number one cause of death in the Netherlands, with 
yearly over 50,000 deaths from these diseases.1 The most important CVD are 
coronary heart disease (CHD) and cerebrovascular accidents (CVA). In 1999, CHD 
constituted 36% (n=18,304), and CVA 25% (n=12,501) of total CVD deaths in the 
Netherlands.' 
One of the major risk factors for CVD in general and for CVA in particular is 
elevated blood pressure.2 Until recently, elevated blood pressure or hypertension 
was defined as a systolic blood presssure (SBP) of 160 mmHg or greater and/or a 
diastolic blood pressure (DBP) of 95 mmHg or greater3 In the Netherlands, the 
prevalence of hypertension according to this definition was 9.2% in men and 7.1% in 
women aged 20-59 years from 1993 to 19954 The prevalence of hypertension 
increases with age. Among Dutch men and women aged 55 years and over living in 
Rotterdam, 22.6% respectively 27.1% had systolic or diastolic blood pressure levels 
of ~160/95 mmHg from 1990 to 19934 Recently the WHO classification was revised 
and the threshold for hypertension was lowered to 140/90 mmHg5 However every 
threshold is arbitrary, as results from most large observational studies have 
demonstrated that there is no clear threshold below which a lower level of blood 
pressure is not associated with a lower risk of CHD or CVA.2·"'" 
A recent reanalysis of Framingham data contests this viewpoint and suggests 
that systolic blood pressure is not related to mortality from CVD and all-causes for all 
pressures below an age- and sex-dependent threshold9 As this finding could have 
implications for targeting risk groups for blood-pressure-lowering intervention, 
examining the threshold hypothesis in other populations than in Framingham is 
required. 
For public health purposes, it is important to quantify blood pressure related 
risk in terms of excess numbers of CVD events in the population due to elevated 
blood pressure. This requires accurate estimation of the strength of the relationship 
between blood pressure and CVD, expressed by the relative risk. This is the risk to 
7 
develop CVD for an individual with a defined or high level of blood pressure divided 
by that for an individual with a reference or low level of blood pressure.10 
An individual's blood pressure varies substantially over time, due to 
imperfections in measurement and biological variability." A single measurement will 
therefore not accurately represent a person's average, or usual blood pressure level. 
When single measurements of blood pressure are used to estimate the relative 
increase in risk of CVD for a given increase in blood pressure, results will be 
biased. 6•11 •12 Relative risk estimates adjusted for within-person variability in blood 
pressure are thus needed, but are scarce. 
It is not clear whether the strength of the relation between blood pressure and 
CVD differs among subjects from different cultures, and what the impact of 
adjustment for within-person variability on this relation will be. In addition, studies on 
blood pressure and CVD incidence in different populations will give more insight into 
the impact of blood pressure, relative to that of other risk factors, on CVD incidence 
in different cultures. 
There is strong evidence both from observational studies and clinical trials 
that elevated systolic blood pressure remains an important risk factor for CVD up to 
at least 75 years of age.1s-14 Whether diastolic blood pressure is positively related to 
CVD in the elderly is less well established. Positive relations have been observed in 
most's-18, but not all13 longitudinal studies. In some studies among elderly 
populations, J- or U-shaped relations have been found showing an increased risk at 
low diastolic blood pressure levels compared to higher levels.14·1s-20 This paradoxa! 
finding may be explained by low diastolic blood pressure due to a poor general 
health status prior to disease21 However, J- or U-shaped relations have also been 
found in some observational studies that adjusted for poor health status.14·20 It has 
been suggested that due to increased large-artery stiffness with aging, systolic blood 
pressure continues to rise while diastolic blood pressure falls, making low diastolic 
blood pressure and pulse pressure (=SBP minus DBP) indicators of elevated 
cardiovascular risk.14'22 
The beneficial effect of pharmacological treatment of hypertension on the 
incidence of CVA and CHD has been demonstrated in several randomized clinical 
trials.23-25 In spite of the potential reduction of CVD by pharmacological treatment, 
from 1987 to 1995 47% of Dutch hypertensive men and 30% of Dutch hypertensive 
women still had elevated blood pressure levels despite pharmacological treatment, 
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or were not treated while they should have been treated according to the guideline of 
the Dutch society of general practitioners (1997)26 In 2000, the Dutch consensus 
guideline for blood pressure lowering therapy has been revised. 27 The new guideline 
prescribes drug therapy to hypertensive individuals with a high short-term absolute 
risk of CVD27 The absolute risk of CVD defines the probability of an individual to 
develop CVD over a finite period of time. 10 Besides blood pressure, the absolute risk 
of CVD is determined by the presence of other risk factors such as sex, age, 
totai/HDL cholesterol ratio, smoking and diabetes mellitus. In the guideline, a blood 
pressure above 140/90 mmHg till age 60, and above 160/90 mmHg after age 60, in 
combination with a 1 0-year multifactorial absolute risk of CVD of 20% or greater is 
defined as a risk sufficiently high to justify the use of antihypertensive drug therapy. 27 
Because of the high prevalence of undertreatment of hypertension in the Dutch 
population, the potential reduction in number of CVD events by adequate 
pharmacological treatment according to the revised guideline is expected to be high, 
but unknown. Quantification of this number clarifies the extent of elevated blood 
pressure as a public health problem. 
Current guidelines focus on treatment of individuals with severe hypertension 
and treatment of individuals with mild or moderate hypertension (140-179 systolic or 
90-109 diastolic or both) in combination with a high short-term (<:20% within 10 
years) absolute risk of CVD27·28 These guidelines reflect the general belief that the 
absolute level of risk can be reversed by modifying risk factors later in life. 29 
Insight in long-term persistence of the effects of blood pressure on CVD, i.e. 
whether elevated blood pressure levels at younger age lead to increased risk of 
cardiovascular events at old age, could support a policy aimed at population-wide 
reductions in blood pressure. Such a policy has two advantages. First, it will lead to 
prevention, not merely treatment of elevated blood pressure, and to subsequent 
prevention or postponement of CVD on the long-term.29•30 Second, it has a greater 
potential for reducing the burden of CVD in the total population than a policy that is 
mainly focused on treatment of the relatively small proportion of patients at high 
short-term risk.31 This can be illustrated by the population attributable risk (PAR). In 
case of blood pressure, the PAR is the proportion of CVD events in the population 
attributable to (suboptimal) blood pressure levels. 10 The PAR depends both on the 
relative risk and on the proportion of individuals with blood pressure levels above 
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optimal (SBP ~ 120 mmHg or DBP ~ 80 mmHg or both). As this proportion is high in 
the Netherlands, and because of the continuous relation of blood pressure with CVD, 
the total burden of CVD among this group is considerable. A population strategy, 
aimed at blood pressure reductions in the population as a whole, will therefore 
theoretically result in a much larger absolute decline in number of CVD cases than a 
high risk strategy, even at moderate blood pressure reductions.31 Small population-
wide reductions of blood pressure may be reached by stimulating lifestyle changes, 
such as changes in diet and increased physical activity, in the total population.32-36 
The number of CVD events that could be prevented in this way in the Netherlands is 
unknown. Quantification of this number could enlarge commitment of physicians, 
policy makers and scientists in the field of public health to population-wide strategies 
of intervention. 
Aim and outline of the thesis 
The aim of the observational studies described in this thesis was to study the 
(strength and nature of) the relation between blood pressure and CVD, and to 
quantify the achievable health benefit in the population by different blood pressure 
lowering strategies. In chapter 2 the relations between blood pressure and CVD 
mortality with an emphasis on coronary death among middle-aged men from the 
Seven Countries Study (SCS) are quantified. In chapter 2.1 persistence of the 
relation between blood pressure and mortality from CHD with time is studied, using 
repeated measurements from the SCS. In chapter 2.2 we used the SCS data to 
examine whether there is a threshold in the relation between blood pressure and 
mortality from CVD and all-causes. In chapter 2.3 the relative and absolute impact of 
blood pressure on long-term mortality from CHD was compared between men from 
the different populations of the SCS. In chapter 2.4 the implications of the findings 
from the SCS for treatment and prevention of hypertension in relation to CHD are 
discussed. 
In chapter 3 the relations between blood pressure and CVD in the elderly are 
described. In chapter 3.1, the relation between blood pressure and risk of myocardial 
infarction among men and women aged 55 years and over from the Rotterdam Study 
is described. The relation between blood pressure and mortality from CVD among 
men aged 65-84 years from different European countries is described in chapter 3.2. 
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In chapter 4, the impact of different blood pressure lowering interventions on the 
primary prevention of CVD and on healthy life expectancy in the Netherlands is 
quantified. A general discussion of the different topics presented in this thesis is 
given in chapter 5. 
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CHAPTER 2.1 
The persistence of the effect of blood pressure on coronary heart 
disease mortality risk 
Abstract 
The authors tried to separate an independent effect of past systolic blood pressure 
(SBP) on coronary heart disease (CHD) mortality from a proxy effect through 
"currenf' SBP, i.e. SBP close to time of death, taking into account both within-person 
variation and the correlation structure of blood pressure. SBP was measured at 
enrolment and at 5-year follow-up in 9,444 middle-aged men from the Seven 
Countries Study. During 20 years of follow-up, 1,000 men died from CHD. An 
independent effect of past SBP was estimated using a survival model including both 
past SBP and the best predictor of "currenf' SBP, given the correlation between 
repeated SBP measurements. Including "current'' SBP into the model, the relative 
risk of death from CHD per 10 mmHg increase in past SBP was 1.03 (95% Cl 0.89 -
1.19). This cohort study suggests that past SBP does not predict long-term risk of 
CHD mortality, after adjustment for a proxy effect of 'current' SBP. 
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Introduction 
Results from epidemiological studies have established clear associations 
between single or casual blood pressure measurements and subsequent risk of 
death from coronary heart disease (CHD).1·2 However, the interpretation of such 
associations in terms of etiological mechanisms is not unequivocal. One can 
distinguish two competing hypotheses: 
• hypothesis 1 stating that elevated past blood pressure levels (i.e. near the time of 
enrolment) cause accumulated damage to the circulatory system which leads to 
increased risk of coronary events in subsequent years. Effects of blood pressure 
on the risk of CHD mortality persist for many years or decades. 
• hypothesis 2 stating that risk of mortality from CHD is largely determined by 
"current" blood pressure levels (i.e. in the years before death), that is the effects 
of blood pressure on mortality risk are transient and reversible. The apparent 
effect of past blood pressure on future risk is caused by the fact that blood 
pressure is correlated over time, and past blood pressures therefore act as proxy 
variables for "current" pressures. Elevated blood pressure levels mainly act as 
triggers for the occurrence of acute complications of already existing 
atherosclerotic disease, such as coronary trombosis and arrhythmias. 
These two hypotheses have analogues in the relationship between smoking and 
CHD and lung cancer respectively. While the effects of smoking on lung cancer 
persist long after cessation of smoking, the effects of smoking on CHD appear to be 
short lived and reversible. 3•4 Thus, current smoking is the major determinant of CHD 
death, while a history of smoking is not. 
Continuous blood pressure levels over prolonged periods of time (decades), 
up to the time of death, of a large cohort, are needed to distinguish between the two 
hypotheses directly. While smoking behaviour is relatively easy to monitor 
continuously, and can even be ascertained retrospectively, this is not feasible for 
blood pressures. In most cohort studies, at most several blood pressure 
measurements, usually long before death, are available. This makes "current" blood 
pressure levels in the years before death unavailable for most participants. This 
would appear to make the problem of which of the two competing hypotheses is valid 
undecidable. 
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As the different hypotheses may have important implications for blood 
pressure intervention strategies this is hard to accept. In order to circumvent this 
problem, we used a statistical model of the development of blood pressure over time. 
Using this model, we estimated (predicted) "current" blood pressure levels, i.e. 
beyond the latest of two repeated blood pressure measurements taken at fixed 
points in time. These estimated levels were used in lieu of actual measurements in 
standard survival analysis of CHD mortality. This approach allowed us to separate 
an independent effect of past systolic blood pressure (SSP) on CHD mortality from a 
proxy effect through "current" SSP. We tried to distinguish the two competing 
hypotheses as follows. If the best predictor of "current" levels summarizes all 
information contained in the blood pressure measurement about future risk of death, 
then the data support hypothesis 2. If, by contrast, the earlier of the two 
measurements has an independent additional (i.e. in addition to its effect through the 
best linear predictor of "current" levels) effect on the risk of death, then this should be 
considered as evidence supporting hypothesis 1. In summary, if estimated "current" 
blood pressure would appear to be the only determinant of CHD death then this 
should be construed as supporting hypothesis 2. However, if a history of high blood 
pressure would also be a determinant of CHD death then this would lend weight to 
hypothesis 1. Data from the Seven Countries Study were used for this purpose. 
Two features of blood pressure are essential for a correct analysis of repeated blood 
pressure measurements. First, blood pressure has substantial within-person 
variations Second, blood pressure levels in individuals over time are correlateds 
These two features formed the basis of our statistical model of the development of 
blood pressure over time. 
Materials and methods 
Study population 
Between 1958 and 1964, 12,761 men aged 40 through 59 years from seven 
countries were enrolled in the study.6 A total of 16 cohorts were examined in the 
following countries: the United States, Finland (eastern and western), the 
Netherlands (Zutphen), Italy (Rome Railroad, Crevalcore and Montegiorgio), Greece 
(Crete and Corfu), former Yugoslavia (Dalmatia, Slavonia, Zrenjanin, Velika Krsna 
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and Belgrade), and Japan (Tanushimaru and Ushibuka). Overall, the participation 
rate was over 90 percent, with several cohorts reaching almost 100 percent. In the 
present paper, only the pooled cohorts of the United States and Europe were used. 
The Japanese cohorts were excluded (n = 1,010) because blood pressure was not 
remeasured after five years in Japan. 
Measurements 
In all cohorts the major cardiovascular risk factors were measured in a 
standardized way at enrolment and at five years. Details of the methods used have 
been reported elsewhere6 ·7 Blood pressure was measured on the right arm, in 
supine position, with a calibrated mercury sphygmomanometer at the end of the 
physical examination by trained physicians, following the methods described in the 
World Health Organization (WHO) manual Cardiovascular Survey Methods8 
Readings were taken to the nearest two mmHg. At each point in time, the average of 
two measurements taken one minute apart was computed for systolic and diastolic 
(fifth Korotkoff phase) blood pressure, and these average values were used in the 
analyses. In this paper, the analysis is confined to systolic blood pressure (SBP) 
because SBP is measured with less intra-individual variation (relative to total 
population variation) than diastolic blood pressure5 At the enrolment survey, 
information on the use of antihypertensive drugs was not collected. However, during 
the period 1958 to 1964 these drugs were rarely prescribed in the participating 
countries. 
Total cholesterol was measured in a nonfasting blood sample according to the 
Abeii-Kendall method, modified by Anderson and Keys, in standardized 
laboratories6 Current cigarette smoking (no/yes) was established by means of a 
standardized questionnaire. Presence of CHD at enrolment was defined by definite 
and possible myocardial infarction based on pre-defined clinical and EGG criteria, 
definite angina pectoris based on the Rose questionnaire and chronic CHD 
manifested as heart failure or chronic arrhythmia based on pre-defined clinical 
criteria.7·9 
Mortality follow-up 
All men were followed for mortality during 25 years but 56 (0.4 percent) were 
lost to follow-up. The underlying cause of death was coded in a standardized way by 
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a single reviewer, using the eighth revision of the WHO International Classification of 
Diseases.10 The final cause of death was adjudicated on the basis of information 
from the official death certificate, in combination with information from medical and 
hospital records and from relatives or any other witnesses of the dead person. The 
coder of the causes of death was blinded to the risk factor status of the subject. In 
the case of multiple causes of death, priority was given to violent death, followed by 
cancer in advanced stages, CHD, and stroke. In this study, the endpoint was a fatal 
CHD occuring during 20 years of follow-up (from year 5 to 25), defined as primary 
cause of death with ICD-8 codes 410-414 or primary cause of sudden cardiac death 
with ICD-8 code 795 when a coronary origin was mentioned. 
Statistical methods 
In order to predict "currenf' SSP we used both the measurement of SSP at 
enrolment [m(O)] and at five year follow-up [m(5)]. Our statistical model used to 
predict blood pressure levels had two components, one relating true SSP to its 
measurements, and one describing the development of true blood pressure over 
time. The following simple model was used to relate measurements to true levels: 
m(t) = fl(t) + >: , 
where m(t) is the measured value at time t, fl(t) denotes the "true" blood pressure 
level at timet, and" is short-term within-person variation in blood pressure (including 
measurement error due to imperfect instruments or observers). We assume that 
successive values of >: are uncorrelated (note, that this is probably only true for 
measurements taken a reasonable period, e.g. days, apart). Thus the correlation 
between successive values of m(t) is induced by the correlation between 
corresponding values of fl(t). To model this correlation (the second component of our 
model) we assumed that fl(t) behaves like a Gauss-Markov (G-M) model, implying 
that the correlation of fl(t) declines exponentially, 
i.e. r(fl(t1),fl(t2))= exp(-a(tz-t1))-" Under this model, the variance in blood pressure 
measurements <rm 2(t)= rr"2(t) + rr,2(t), and the correlation between measurements 
m(t1) and m(tz) (t1 < tz) is given by r.exp (-a(tz-t1)), 
with r = rr}(t) I {rr"2(t) + rr/(t)}. 
Under the G-M model, using standard multivariate theory12, one can show that the 
best predictor of SSP at timet (t :2: 5; given m(O) and m(5)) is: 
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E(f!(t)Jm(O),m(5)) = (y0m(O) + y5m(5))e(t) + n(t)(1-e(t)) 
Where: 
n(t) denotes the population average SSP in year t; e(t) = exp(-at); and 
Yo= r(1-r)/(1-,-2(e(5lh Ys = r(e(-5)-re(5))/(1-,-2(e(5))2). 
In a subgroup of men, SSP was also remeasured at ten years of follow-up (n 
= 7,031; 60.1 percent). To obtain estimates for rand a, the G-M model was fitted to 
the observed five and ten year interval correlations in this group of men with three 
blood pressure measurements (i.e. at enrolment, at five, and ten year follow-up). In 
estimating r and a we ignored the problem of intervening, possibly selective, 
mortality. As this mortality was low, we did not expect this to seriously bias our 
estimates. 
To distinguish the two competing hypotheses for the effect of SSP on CHD 
mortality we used a Cox model with time dependent SSP covariables. The predictor 
E(l'(t)Jm(O),m(5)) was used as a time dependent covariable representing 'current' 
SSP levels. As indicator of past SSP we used the average M(0,5) of m(O) and m(5). 
A fatal CHD event occurring between five and 25 years of follow-up was used as 
endpoint. "Current" SSP values were obtained by taking t = time of such event, in the 
above expressions. Our method is illustrated in figure 1. 
We excluded men with prevalent CHD at year 5 (n=353;3 percent) and men 
with missing data on SSP at enrolment (n = 12) or five year follow-up (n = 1 ,232;10.5 
percent) or on one of the covariates (n = 1,971;16.9 percent). In total 2,251 men 
were excluded (19.2 percent), leaving 9,444 for analysis. Of these 1,000 (8.6 
percent) died from CHD. In addition, the possible confounders cohort, age (years), 
total cholesterol (mmoi/L) at 5 year follow-up, and current cigarette smoking (no/yes) 
at 5 year follow-up, were included. Relative risks were calculated per 10 mmHg 
increase in M(0,5) and E{f!{t)Jm(O),m{5)). A pos·~ive effect of M(0,5) on survival would 
be consistent with hypothesis 1, whereas no effect of M(0,5) on survival would 
suggest that only hypothesis 2 is true. 
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Figure 1. Used method for separating an independent effect of past SBP on long term mortality from 
CHD, from a proxy effect through "current" SBP: the pooled American and European cohorts of the 
Seven Countries Study, 1960 and 1965. 
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CHD, coronary heart disease; SBP, systolic blood pressure; X, blood pressure measurement; m(O), measured 
SSP at enrolment; m(5), measured SBP at 5-year follow-up; E(J.l(t)lm(O),m(5), the best predictor of "current" SSP, 
i.e. the expected SBP at t = time of a fatal CHD event (t ~ 5 years of follow-up), given measured SSP at 
enrolment and at 5-year follow-up. 
Results 
Average SBP measured at enrolment and at five year follow-up was 139.0 
(19.6) mmHg and 140.0 (21.4) mmHg respectively (table 1). The correlation between 
SBP measured at enrolment and at five and ten year follow-up is shown in table 2. 
Table 1. Characteristics of men aged 40 to 59 years: the pooled American and European cohorts of 
the Seven Countries Study, 1960 and 1965. 
Characteristic 
Systolic blood pressure (mmHg) 
Enrolment 
5-year follow-up 
Age (years/ 
Total cholesterol (mmoi/L)t 
Current smokingt (%) 
Mean±SD 
139.0±19.6 
140.0±21.4 
53.9±5.5 
5.8±1.3 
56.0 
SO, Standard deviation; t Measured at 5-year follow-up 
21 
This table demonstrates that the correlation decreases with time. Fitting the Gauss-
Markov model to the correlations as observed in table 2 yielded an estimate of 0.76 
for r and of 0.028 for a. As among the survivors of the Finnish, Dutch and Italian 
cohorts, SBP was also remeasured at 25 (n = 1 ,659) and 30 (n = 988) years of 
follow-up, we could validate the Gauss-Markov model. The predicted correlation 
between SBP measured at enrolment and at 25 and 30 years of follow-up was 0.38 
and 0.33 respectively, whereas values of 0.22 and 0.19 were observed. This 
suggests that the Gauss-Markov model for SBP performs reasonably well over a 
period of several decades. The somewhat lower observed than predicted correlation 
may be due to the increasing use of antihypertensive drugs after 1980 and to 
selective mortality. 
Table 2. Correlation between repeated measurements of systolic blood pressure among the subgroup of 
men with three measurements (n = 7,031). 
Measurement period 
Enrolment and 5-year follow-up 
5- and 1 0-year follow-up 
Enrolment and 1 0-year follow-up 
Correlation 
0.65 
0.67 
0.58 
Knowing the model parameters r and a, and given measured SBP at enrolment 
[m(O)] and at five year follow-up [m(5)], the obtained best predictor of "true" SBP at t 
year follow-up was exp(-0.028(t))(0.67m(5) + 0.33m(O)) + n(t)(1-exp(-0.028(t)) 
(where n(t) denotes the population average SBP in year t). 
Cox proportional hazard's analysis with M(0,5) and E(J.t(t)lm(O),m(5)) as 
covariates and a fatal CHD event occurring in 20 years of follow-up yielded a relative 
risk estimate [RR] of 1.03 (95 percent confidence interval [CI] 0.89- 1.19) per 10 
mmHg increase in past SBP and of 1.24 (95 percent Cl 1.03- 1.51) per 10 mmHg 
increase in "current" SBP (table 3). 
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Table 3. Results from a multivariate Cox mode! including past SBP and the best predictor of current 
SSP: the pooled American and European cohorts of the Seven Countries Study. 
M(0,5) § 
E(~(t)lm(O),m(5)) II 
Regression coefficient t (SE) 
0.03 (0.08) 
0.22 (0.10) 
Rate ratio + (95% Cl) 
1.03 (0.89- 1.19) 
1.24 (1.03 -1.51) 
SBP, systolic blood pressure; SE, standard error; Cl, confindence interval; t Besides the blood pressure 
variables also age, total cholesterol at 5-year fol!ow~up and smoking at 5-year follow-up were included in the Cox 
model; :j: Per 10 mmHg increase in systolic blood pressure; § Indicator of past SBP, i.e. (measured SBP at 
enrolment+ measured SBP at 5-year fol!ow-up)/2; II Best predictor of "current" SBP, i.e. the expected SBP at 
t ~time of a fatal CHD event (t 2:: 5 years of fo!!ow~up), given measured SBP at enrolment and at S~year fo!!ow~up. 
Discussion 
Continuous monitoring of blood pressure is not feasible in large observational 
studies. Therefore, understanding the effect of this variable on subsequent mortality 
from CHD will be based on - at best - several measurements, often taken a 
substantial time before the endpoint occurs. In this study, we used repeated 
measurements from the Seven Countries Study to explore a novel approach to study 
the effect of blood pressure on the development of fatal CHD during follow-up. In 
this approach we tried to separate an independent effect of past SBP on subsequent 
fatal CHD from a proxy effect through its correlation with "currenf' SBP. Taking into 
account both within-person variation and the correlation structure of blood pressure 
over time, our data suggest that the effects of past blood pressure on later risk of 
CHD mortality are transient. However, confidence limits around the relative risk 
estimate of past blood pressure in the present study do not completely exclude 
possible presence of some long-term effect of past blood pressure. 
Previous analyses on the effect of repeated measurements of blood pressure 
have mainly focused on the effect of changes in blood pressure over time on disease 
risks. 13-17 Many of these analyses have fit some type of regression model that 
included both the observed change in blood pressure and the measured value at 
enrolment as covariate.1s-17 Their results have suggested that blood pressure 
changes are independent predictors of cardiovascular diseases. However, this 
method of adjustment for the baseline level can produce misleading results when the 
measured values differ from the 'true' values due to substantial within-person 
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variation, as is always the case for blood pressure.18 What may appear as a 
statistically significant relationship between change in risk factor and outcome may in 
fact be merely a statistically artefact of within-person variation. 18 In the Framingham 
Heart Study, repeated measurements of blood pressure over time were used to 
estimate the effect of past blood pressure experience on future development of 
cardiovascular diseases.19 It was suggested from that study that past SBP history, 
especially if it averages 160 mmHg or more, is a weak but significant estimator of 
future cardiovascular diseases, in addition to current measured SBP level.19 
However, even if within-person variation had been completely adjusted for in 
the Framingham Study, it is not clear whether the observed relation between past 
SBP and future cardiovascular risk was causal. In fact, past SBP may only-appear to 
be a risk factor for subsequent disease because it is correlated with attained blood 
pressure levels later in life, which are the "true" risk factors. 
Although the difference in used methodology may fully explain the 
discrepancy between results from the present study and those from the Framingham 
Study, other explanations are possible. In the Framingham Study past blood 
pressure levels were calculated as the average of two to 11 measurements, each 
taken 2 years apart. 19 Therefore, in the Framingham Study past levels may better 
reflect someone's true lifetime exposure, whereas in the present study past levels 
may present an individual's blood pressure status during too short a period for 
deleterious effects to become apparent (measurable). It is thus possible that 
elevated blood pressure levels mainly exert their deleterious effects when they 
persist for a prolonged period of time. Nevertheless, our feilure to detect a long-term 
detrimental effect caused by past elevated blood pressure levels is surprising, as 
there is a strong biological rationale for this hypothesis. Hypertension has been 
clearly established as a major promoting factor for the development of coronary 
atherosclerosis and its complications.20 ·21 As the development of atherosclerosis 
takes some decades, 20 the duration of hypertension is expected to be directly related 
to the amount of atherosclerosis and thereby to the risk of CHD in current life. 
Nevertheless, the results from the present cohort study suggest that past SBP 
does not strongly predict long-term risk of CHD mortality, after adjustment for a proxy 
effect of "current" SBP. Application of the methodology developed in this paper to 
other cohort studies is required to decide whether this is a consistent finding. 
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CHAPTER 2.2 
Relation between blood pressure and mortality: is there a 
threshold? 
Research letter 
Data from observational studies and clinical trials have consistently shown 
that higher blood pressure implies higher (cardiovascular and all-cause) mortality 
risk. 1•2 However, recent reanalysis of the 18-year Framingham data demonstrated a 
threshold in the relation, with risk being unrelated to systolic blood pressure below 
(at least) the 70th percentile, corresponding to 150 mmHg for 60-year old men.3.4 
This implies that with the currently used cut-off value for hypertension of 140 mmHg, 
many people are incorrectly considered to be at increased risk. We used the Seven 
Countries Study to examine whether the threshold hypothesis also applies to other 
populations than Framingham's. We studied both systolic and diastolic blood 
pressure in relation to 25-year cardiovascular and all-cause mortality. Repeated 
measurements of blood pressure at baseline and at five year follow-up were 
available to obtain better estimates of usual blood pressure. 
Of the 12,250 men without a history of cardiovascular disease who were 
included in the analyses, 5722 died during follow-up, 2783 (48.6%) from 
cardiovascular causes. Details of the study have been described previously-' Per 
age group (40 to 49 years and 50 to 59 years old), mortality risk was determined for 
each of the 10 decile classes and then these age group-specific risks were pooled by 
decile class to plot the relation of risk of death as a function of blood pressure. Both 
the logistic- and the Cox proportional hazard-spline model, with cohort and age as 
stratification variables, were used to analyze whether there is a threshold in the 
relation between blood pressure and mortality risk3 Since results were similar, 
reported results are based on the Cox proportional hazard-spline model3 To 
demonstrate existence of a threshold, thereby invalidating the conventional linear 
model, it suffices to show that for some choice of the knot in the spline model the left 
and right slopes differ significantly. For this knot we chose the 70th percentile of 
either blood pressure, i.e. 141 mmHg systolic and 86 mmHg diastolic blood pressure 
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for 40-49 years and 150 mmHg systolic and 88 mmHg diastolic blood pressure for 
50-59 years. Additionally, we fitted the model with the knot at the 50th, 60th, 80th 
and 90th percentile for each age group, and at pressure levels between the 70th and 
80th percentile. 
The relation between blood pressure and all-cause mortality was stronger at 
the higher end of the blood pressure distribution (figure 1). The right slopes were 
1.85 (systolic) and 2.27 (diastolic) times larger than the left slopes (p<O.OOOS) (table 
1 ). The relation between blood pressure and all-cause mortality was weaker for 
pressures below the 70th percentile, but still significant (p<O.OOOS for both systolic 
and diastolic blood pressure). With other choices of the knot, the slope of the relation 
below the threshold remained highly significant (all p<O.OOOS). The Cox proportional 
hazard-spline model fitted the data better than the conventional linear Cox 
proportional hazard -model (p<O.OOOS for both systolic and diastolic blood pressure, 
maximum likelihood ratio (MLR) test). 
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Figure 1 Age-adjusted death rates related to percentiles of blood pressure among men aged 40-59 
years from the Seven Countries Study. 
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Table 1. Estimates of left and right stapes t (SE) for the relation between blood pressure and mortality 
from cardiovascular and all causes; Seven Countries Study, 25 years of follow-up. 
N;12,250 Systolic blood pressure Diastolic blood pressure 
25-year left+ Right§ Difference Left+ Right§ Difference 
Mortality Slope Slope Between Slope Slope Between 
(SE) (SE) Slopes (SE) (SE) Slopes 
All causes 0.0117* 0.0216* • 0.0201* 0.0456* 
(0.0017) (0.0045) (0.0037) (0.0095) 
Cardiovascular 0.0247* 0.0294* ns 0.0526* 0.0607* ns 
(0.0026) (0.0065) (0.0057) (0.0140) 
SE, standard error; ns, non-significant * p < 0.0005; t Estimates are adjusted for total cholesterol and smoking 
status and pooled after stratification by age group and cohort; + Below 70th percentile, i.e. 141 mmHg systolic 
and 86 mmHg diastolic blood pressure for 40-49 years and 150 mmHg systolic and 88 mmHg diastolic blood 
pressure for 50-59 years; §Above 70tt-. percentile 
By contrast, the relative increase in risk of cardiovascular death for a specified 
increase in blood pressure was similar below and above the 70th percentile of blood 
pressure (table 1). Absence of a threshold is also suggested by visual inspection 
(figure 1 ). There was no choice of the knot for which the left and right slopes differed 
significantly. In addition, the Cox proportional hazard -spline model did not improve 
the fit of the linear Cox proportional hazard -model (p>0.2 for both systolic and 
diastolic blood pressure; MLR test). 
In conclusion, the Seven Countries Study corroborates the conventional 
"linear" model for the relation of cardiovascular mortality with systolic and diastolic 
blood pressure, but not for the relation of these pressures with all-cause mortality. 
Higher blood pressure is related to higher risk of all-cause mortality over the whole 
range of blood pressure, but this association is weaker for moderately elevated 
pressures. The difference with Framingham may be due to the greater power of the 
present study and to differences in study populations. Considering that 
antihypertensive treatment is currently prescribed on the basis of multiple risk 
factors, our results do not suggest a direct need to reassess current hypertension 
guidelines. 
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CHAPTER2.3 
The relation between blood pressure and mortality due to coronary 
heart disease among men in different parts of the world 
Abstract 
Background. Elevated blood pressure is known to be a risk factor for death from 
coronary heart disease (CHD). However, it is unclear whether the risk of death from 
CHD in relation to blood pressure varies among populations. 
Methods. In six populations in different parts of the world, we examined systolic and 
diastolic blood pressures and hypertension in relation to long-term mortality from 
CHD, both with and without adjustment for variability in blood pressure within 
individual subjects. Blood pressure was measured at base line in 12,031 men (age 
range, 40 to 59 years) who were free of CHD. During 25 years of follow-up 1,291 
men died from CHD. 
Results. At systolic and diastolic blood pressures of about 140 and 85 mmHg, 
respectively, 25-year rates of mortality from CHD (standardized for age) varied by a 
factor of more than three among the populations. Rates in the United States and 
northern Europe were high (approximately 70 deaths per 10,000 person-years), but 
rates in Japan and Mediterranean southern Europe were low. However, the relative 
increase in 25-year mortality from CHD for a given increase in blood pressure was 
similar among the populations. The overall unadjusted relative risk of death due to 
CHD was 1.17 (95 percent confidence interval, 1.14 to 1.20) per 10 mmHg increase 
in systolic pressure, and 1.13 (95 percent confidence interval, 1.1 0 to 1.15) per 5 
mmHg increase in diastolic pressure, and it was 1.28 for each of these increments 
after adjustment for within-subject variability in blood pressure. 
Conclusions. Among the six populations we studied, the relative increase in long-
term mortality due to CHD for a given increase in blood pressure is similar, whereas 
the absolute risk at the same level of blood pressure varies substantially. These 
findings may have implications for antihypertensive therapy in different parts of the 
world. 
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Introduction 
Blood pressure is directly related to mortality from coronary heart disease 
(CHD), 1-4 and previous results from the Seven Countries Study have suggested that 
the relative increase in mortality from CHD for a given increase in blood pressure is 
similar among different populations5 In the current investigation, we further explored 
this relation by investigating whether the relative risk of death due to CHD in relation 
to systolic and diastolic blood pressures and hypertension is similar among different 
populations. Because absolute risks are more important than relative risks from the 
perspective of public health and treatment, we also compared the absolute risk of 
death due to CHD at a given level of blood pressure among different populations. 
Since an individual person's blood pressure can vary substantially, a single 
measurement will not accurately represent a person's average, or usual, blood 
pressure level. When single measurements of blood pressure are used at base line, 
results with respect to the effect of blood pressure on the risk of death will be 
biased.1·6 
In our investigation, data from repeated measurements of blood pressure 
were available for use in examining the effects of within-subject variability. 
Methods 
Study populations 
Between 1958 and 1964, 12,761 men 40 to 59 years old who resided in seven 
countries were enrolled in the study.7 A total of 16 cohorts were included in the 
United States, Finland (eastern and western), the Netherlands (Zutphen), Italy 
(Rome, Crevalcore, and Montegiorgio), Greece (Crete and Corfu), the former 
Yugoslavia (Dalmatia, Slavonia, Zrenjanin, Velika Krsna and Belgrade), and Japan 
(Tanushimaru and Ushibuka). In the United States and Rome, railroad workers were 
recruited. In the fonmer Yugoslavia, workers from a large cooperative in Zrenjanin 
and professors from the University of Belgrade were invited. In the town of Zutphen, 
the Netherlands, for every nine men, four were invited to participate. In the remaining 
11 cohorts (all rural), all men 40 to 59 years old who were listed in official registries 
were invited. Overall, the participation rate was greater than 90 percent, with several 
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cohorts reaching participation rates of almost 100 percent. To increase the power of 
the statistical analyses, the cohorts were pooled into six populations: the United 
States, northern Europe (eastern and western Finland and Zutphen), Mediterranean 
southern Europe (Montegiorgio, Crete, Corfu and Dalmatia), inland southern Europe 
(Rome, Crevalcore, Slavonia, and Belgrade), rural Serbia (Zrenjanin and Velika 
Krsna), and Japan (Tanushimaru and Ushibuka)8 The criteria for pooling were 
similarities among cohorts in rates of mortality from CHD and similarities among 
cohorts in culture (such as dietary patterns) and geographic features. 
Measurement of blood pressuse and clinical assessment 
In all 16 cohorts, major cardiovascular risk factors were measured according 
to standardized methods at enrollment, after 5 years (except in Japan), and after 10 
years (except in the United States). Details of the methods used have been 
described previously.7·9 Blood pressure was measured by a trained physician using a 
calibrated mercury sphygmomanometer on the right arm, with the subject in the 
supine position, at the end of the physical examination, according to the method later 
described in the World Health Organization (WHO) manual Cardiovascular Survey 
Methods. 10 Readings were taken to the nearest 2 mmHg. The mean of two 
measurements, taken one minute apart, was computed for both the systolic and the 
diastolic blood pressure; for the diastolic pressure, the fifth-phase Korotkoff sound 
was assessed. Hypertension was defined as a systolic blood pressure of 160 mmHg 
or higher, a diastolic blood pressure of 95 mmHg or higher, or both. During the base-
line period (1958 to 1964), medications designed to lower the blood pressure were 
rarely prescribed in any of the seven countries, and therefore use of medicarition 
was not included in the definition of hypertension. 
Nonfasting blood sample were drawn and serum total cholesterol levels were 
measured in standardized fashion at all laboratories according to the Abeii-Kendall 
method, as modified by Keys et al. 7 Current cigarette smoking was identified by a 
positive response on a standardized questionnaire. CHD at enrollment was defined 
as the presence of definite or possible myocardial infarction, according to predefined 
clinical and electrocardiographic criteria; definite angina pectoris, according to 
responses on the WHO questionnaire; or chronic CHD manifested as heart failure or 
chronic arrhythmia, according to predefined clinical criteria9 ·11 When the Seven 
Countries Study began, it was not standard practice in clinical research to ask 
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participants for written informed consent and to ask for approval from medical ethics 
committees. 
Assessment of mortality during follow-up 
To assess mortality in the study populations, all 12,761 subjects were 
followed for 25 years; 56 men (0.4 percent) were lost to follow-up. The underlying 
cause of death was coded by a single reviewer according to the criteria of the WHO 
lntemational Classification of Diseases, 8"' Revision.12 The reviewer who coded the 
cause of death was blinded with respect to the subjects' cardiovascular risk factors. 
The final cause of death was established on the basis of information from the official 
death certificate (without other infonmation in not more than 15 percent of all cases), 
from medical and hospital records, and from relatives of the person deceased or 
other witnesses and with use of a list of predefined criteria prepared by the primary 
investigators. The coder of the causes of death was blinded to the risk factor status 
of the subject. In cases in which multiple causes of death were possible, priority was 
given to violent death, followed by cancer in advanced stage, CHD, and stroke. The 
endpoint of the study was death during 25 years of follow-up, with the primary cause 
established as CHD (ICD-8 codes 410 to 414), or sudden death from cardiac causes 
(JCD-8 code 795) when a coronary origin was mentioned. 
Statistical methods 
Among the 12,705 subjects with complete follow-up data, 246 (1.9 percent) 
had CHD at enrollment and for 16 (0.1 percent) data on CHD at enrollment were 
missing; these subjects were excluded from the analyses. We also excluded 412 
subjects (3.2 percent) for whom data on covariates were missing, leaving 12,031 
subjects in the analysis. For each population, the age-standardized 25-year rate of 
death due to CHD was computed by the direct standardization method, with use of 
the total study population as the reference population. In addition, for each 
population, the 25-year mortality from CHD, adjusted for age (in years) , total 
cholesterol level (in millimoles per liter), and current cigarette smoking status(no or 
yes), was computed per quartile of usual systolic blood pressure and usual diastolic 
blood pressure (with usual pressures calculated as described below). To do so, we 
first perfonmed regression analyses for mortality due to CHD to obtain population-
specific and quartile-specific regression coefficients for the three covariates (age, 
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total cholesterol and current smoking status). With these regression coefficients, we 
estimated multivariate-adjusted, population-specific mortality from CHD for each 
blood-pressure quartile, given the assumption that the mean level of the covariates 
for each population-specific quartile was equal to the mean level of the covariates for 
the total study population. 
Cox proportional-hazards analysis, with the cohort as a stratification variable, 
was performed to estimate relative risks (SAS statistical package, release 6.12, 
procedure PHREG). Relative risks of death from CHD were estimated by including 
either systolic blood pressure (in increments of 10 mmHg) or diastolic blood pressure 
(in increments of 5 mmHg) as a continuous variable in the model. Relative risks of 
death from CHD were also estimated with respect to the presence or absence of 
hypertension. In the multivariate analyses, adjustment was made for age and cohort 
as well as for age, cohort, total cholesterol concentration, and current cigarette-
smoking status. To examine whether the relative risks differed among populations 
with different absolute risks of death due to CHD, we first created an ordinal 
population variable scored from 1 to 6, where 1 represented the population with the 
lowest age-standardized 25-year mortality due to CHD and 6 the population with the 
highest mortality. We subsequently tested for a significant interaction between this 
ordinal population variable and the blood-pressure variables (where P-values of<0.1 
by the likelihood-ratio test indicated significance, with one degree of freedom). 
Short-term variations in blood-pressure values in individual subjects, resulting 
from imperfections in measurement or true biologic variability, bias the relation 
between usual blood pressure and mortality from CHD. 1•6·13 We corrected for this 
bias in two steps. First, for each subject, the usual, or average, blood pressures 
during the first five years of follow-up were estimated from a linear regression model, 
given the values obtained at enrollment and at five-year follow-up for systolic and 
diastolic blood pressures, body-mass index and cholesterollevel. 14 For each subject, 
the presence or absence of hypertension was then reassessed according to these 
estimates of usual blood pressures over the first five years. Second, the estimates of 
usual blood pressures and the new hypertension variable were analyzed in a Cox 
survival model to estimate regression coefficients for systolic and diastolic blood 
pressures and hypertension, with adjustment for within-subject variability. To 
examine the effect of within-person variability in blood pressure on estimated 
regression coefficients for systolic and diastolic blood pressures, we divided the 
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adjusted regression coefficients by the unadjusted regression coefficients from the 
survival analysis to obtain population-specific adjustment factors. 
Results 
The base-line characteristics of each of the six study populations are shown in 
Table 1. The average systolic blood pressure at base line ranged from 132.5 mmHg 
in Serbia to 143.7 mmHg in northern Europe. The average diastolic blood pressure 
at base line ranged from 75.7 mmHg in Japan to 86.6 mmHg in both northern 
Europe and inland southern Europe. The proportion of men with hypertension was 
lowest in Serbia and Japan (15.7 percent and 16.2 percent, respectively) and highest 
in northern Europe (29.8 percent). The age-standardized 25-year rate of death due 
to CHD was low in Japan and Mediterranean southern Europe, intermediate in inland 
southern Europe and Serbia, and high in the United States and northern Europe. 
In Figure 1, 25-year rates of death from CHD, adjusted for age, serum total 
cholesterol and current smoking status, are plotted against the mean level of usual 
systolic blood pressure within the quartile. This plot shows that the absolute risk of 
death at a given value for usual systolic blood pressure varied strongly among 
populations. For a usual systolic blood pressure of about 140 mmHg, mortality varied 
by a factor of more than three, from approximately 20 per 10,000 person-years in 
Japan and Mediterranean southern Europe, to approximately 70 per 10,000 person-
years in northern Europe and the United States. A similar pattern of variation in the 
absolute risk was observed for a usual diastolic blood pressure of about 85 mmHg 
(Fig. 2). 
For an increase of 10 mmHg in systolic blood pressure, the multivariate-
adjusted relative risk of death from CHD ranged from 1.09 in inland southern Europe 
to 1.25 in Serbia and Japan (Table 2). The multivariate-adjusted relative risk for all 
the populations combined was 1.17 before adjustment for within-subject variability in 
blood pressure and 1.28 after adjustment. For an increase of 5 mmHg in diastolic 
blood pressure, the relative risk of death ranged from 1.06 in inland southern Europe 
to 1.19 in Mediterranean southern Europe, with a relative risk for the total population 
of 1.13 before adjustment for within-subject variation in blood pressure and 1.28 after 
adjustment. No significant differences were observed among the populations with 
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Table 1. Base-line characteristics of men in the Seven Countries Study and age-standardized 25-year mortality from coronary heart disease·* 
Age-
Systolic Diastolic Total No. of Standardized 
No. of Blood Blood Cholesterol Cigarette Deaths due 25-y mortality 
Population Subjects Age Pressure Pressure Level Hypertension smoking toCHD from CHD 
years mmHg mmo!lliter %of men no./10,000 
person-yr 
United States 2416 49.2± 5.7 139.0±20.6 86.0±11.6 6.19±1.16 25.5 59.4 354 73 
Northern Europe 2377 49.3± 5.5 143.7±20.0 86.6±11.9 6.51±1.32 29.8 66.6 461 100 
Mediterranean southern 2516 49.3± 5.3 136.9±19.3 82.1±11.0 5.17±1.08 17.3 59.2 116 22 
Europe 
Inland southern Europe 2870 48.7± 5.4 141.2±20.6 86.6±12.0 5.28±1.08 27.5 59.3 253 46 
Serbia 981 49.3± 5.6 132.5±18.8 83.3±10.4 4.24±0.83 15.7 56.1 77 41 
Japan 871 49.7± 5.6 134.7±24.5 75.7±13.7 4.25±0.91 16.2 74.5 30 17 
*Plus-minus values are means± SO. CHD denotes coronary heart disease 
140 
I 0 'f 130 Legend ro 
" 120 I >-c 
----o- United States 0 110 
"' 
···0·· Northern-Europe I 100 a. ~ Southern-Europe, med. 0 90 L 0 --'V· ·- Southern-Europe, in I. 0 c5 80 
-
Serbia 
~ 70 -o-- Japan 70 
" 
o· 
.s 60 --"' 
-"' I ---1' 50 
---
0 
---
~ 40 '0'-
----y- ·-'V---
'" 
~ 
_,. 
1: 30 ~ ---~---.-[] 0 E 20 y- v---~--· 0 
o-------o--·-· I 10 
0 
0 
110 120 130 140 150 160 170 
Systolic blood pressure (mmHg) 
Figure 1. Mortality due to coronary heart disease per quartile of usual systolic blood pressure. 
Values shown are 25-year rates of death due to coronary heart disease (CHD), adjusted 
for age, serum total cholesterol level, and cigarette smoking status. The absolute risk of 
death at a given level of usual systolic blood pressure varied greatly among the populations. 
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Figure 2. Mortality due to coronary heart disease per quartile of usual diastolic blood pressure. 
Values shown are 25-year rates of death due to coronary heart disease {CHD), adjusted 
for age, serum total cholesterol level, and cigarette smoking status. The absolute risk of 
death at a given level of usual diastolic blood pressure varied greatly among the populations. 
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Table 2. Age- and cohort-adjusted and multivariate-adjusted relative risks of death from coronary 
heart disease for given increments in blood pressure, before and after adjustment for within-subject 
blood-pressure variability.* 
Population 
and adjustments 
United States 
Age and Cohort 
Multivariate 
Northern Europe 
Age and Cohort 
Multivariate 
Mediterranean 
southern Europe 
Age and Cohort 
Multivariate 
Inland southern Europe 
Age and Cohort 
Multivariate 
Serbia 
Age and Cohort 
Multivariate 
Japan 
Age and Cohort 
Multivariate 
Total 
Age and Cohort 
Multivariate 
Increment of 5 mmHg Increment of 5 mmHg 
in systolic blood pressure in diastolic blood pressure 
Unadjusted for Adjusted for Unadjusted for Adjusted for 
within-sunject within-subject within-sunject within-subject 
variability variabilty variability variabilty 
Relative risk (95% confidence interval) 
1.17 (1.12-1.22) 1.15 (1.11-1.20) 
1.18(1.12-1.23) 1.29 (1.21-1.38) 1.16 (1.11-1.21) 1.32 (1.23-1.41) 
1.18 (1.13-1.23) 1.11 (1.07-1.16) 
1.18(1.13-1.23) 1.30 (1.23-1.38) 1.12 (1.Q7-1.16) 1.25 (1.18-1.34) 
1.26 (1.16-1.37) 1.22 (1.13-1.31) 
1.23 (1.13-1.35) 1.35 (1.19-1.52) 1.19(1.10-1.29) 1.38 (1.22-1.57) 
1.10 (1.04-1.17) 1.07 (1.02-1.13) 
1.09 (1.03-1.16) 1.17 (1.08-1.27) 1.06 (1.01-1.12) 1.14 (1.06-1.24) 
1.23 (1.10-1.38) 1.15 (1.02-1.28) 
1.25 (1.11-1.40) 1.39 (1.20-1.61) 1.16 (1.04-1.30) 1.34(1.15-1.56) 
1.24 (1.09-1.41) 1.17 (1.02-1.34) 
1.25 (1.10-1.42) 1.36 (1.11-1.65) 1.18 (1.03-1.35) 1.32 (1.07-1.63) 
1.17 (1.14-1.20) 1.13 (1.10-1.15) 
1.17 (1.14-1.20) 1.28 (1.24-1.33) 1.13 (1.10-1.15) 1.28 (1.23-1.33) 
.., Multivariate adjusted relative risks were adjusted for age, cohort, total cholesterol level, and cigarette smoking. 
Relative risks were adjusted for within-subject variability with use of repeated blood pressure measurements at 
enrollment and at the five-year follow-up. The adjustment factors for systolic blood pressure were 1.6, 1.5, 1.4, 
1.8, and 1.5 for the United States, northern-Europe, Mediterranean southern-Europe, inland southern Europe, 
and Serbia, respectively. The adjustment factors for diastolic blood pressure were 1.9, 2.1, 1.9, 2.2, and 1.9 for 
the United States, northern-Europe, Mediterranean southern-Europe, inland southern Europe, and Serbia, 
respectively. For Japan, relative risks were adjusted for within-subject variability with use of repeated blood-
pressure measurements at enrollment and at the 1 0-year follow-up. The adjustment factors were 1.4 for systolic 
and 1.7 for diastolic blood pressure. Fat the total population, average adjustment factors were used (1.6 for 
systolic and 2.1 for diastolic blood pressure). The adjustment factors for within-subject variability in blood 
pressure were calculated as explained in the Methods section. 
respect to the relative risk of death from CHD over the 25-year period for these 
increments in blood pressure (P>0.1 by the likelihood-ratio test for the interaction 
between the blood pressure variables and the ordinal population variable). 
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Table 3. Multivariate-adjusted relative risks (95 percent confidence inteiVals) of death from coronary 
heart disease associated with the presence of hypertension.* 
Population and Systolic Dlastollc No. of Age- Multivariate-adjusted 
Blood-pressure blood blood Deaths standard. Relative risk {95% Cl) 
status pressure pressure Due to 25-y, 
CHD Mortality 
from CHD 
Unadjusted for Adjusted for 
within-subject within-subject 
variability variability 
mmHg no./10,000 
Person-yr 
United States 
Normal blood pressure 130.1±12.1 81.1±7.2 223 60 1.00 1.00 
Hypertension 164.8±18.5 100.4±9.6 131 116 1.84 (1.48-2.29) 2.06 (1.57-2.70) 
Northern Europe 
Normal blood pressure 134.6±11.8 81.2±7.6 276 81 1.00 1.00 
Hypertension 165.2±19.0 99.3±10.4 185 153 1.78 {1.46-2.16) 2.14 (1.69-2.71) 
Mediterranean 
southern Europe 
Normal blood pressure 130.6±12.6 78.9±7.8 79 18 1.00 1.00 
Hypertension 166.8±17.6 97.8±10.0 37 44 2.13 {1.42-3.19) 2.68 (1.69-4.26) 
Inland southern Europe 
Normal blood pressure 
Hypertension 132.4±12.4 81.3±7.5 171 41 1.00 1.00 
164.5±19.7 100.4±10.5 82 59 1.33 {1.01-1.74) 1.61 {1.20-2.16) 
Serbia 
Normal blood pressure 126.9±12.3 80.1±7.2 57 35 1.00 1.00 
Hypertension 162.6±19.3 100.3±8.6 20 76 2.73 (1.61-4.63) 3.08 (1. 73-5.48) 
Japan 
Normal blood pressure 126.7±15.2 72.1±10.2 20 13 1.00 1.00 
Hypertension 176.1±21.8 94.9±13.2 10 44 2.80 (1.28--6.11) 2.85(1.18-6.88) 
Total 
Normal blood pressure 131.0±12.7 79.8 ±8.2 826 46 1.00 1.00 
Hypertension 165.5±19.2 99.5±10.4 465 97 1.77 (1.58-2.00) 2.13 (1.85-2.45) 
* Plus-minus values are means ± SD. Multivariate adjusted relative risks were adjusted for age, cohort, total 
cholesterol level, and cigarette smoking. Relative risks were adjusted for within-subject variability with use of 
repeated blood pressure measurements at enrollment and at the five-year follow-up. For Japan, relative risks 
were adjusted for within-subject variability with use of repeated blood-pressure measurements at enrollment and 
at the 1 0-year follow-up. The adjustment factors for within~subject variability in blood pressure were calculated as 
explained in the Methods section. Hypertension was defined as a systolic blood pressure of 160 mm Hg or 
greater, a diastolic blood pressure of 95 mm Hg or greater, or both. For each comparison, subjects with normal 
blood pressure served as the reference group. CHD denotes coronary heart disease. 
The absolute risk of death from CHD that was associated with hypertension 
was clearly different among the six populations (Table 3). Among subjects with 
hypertension, the age-standardized 25-year mortality varied by a factor of nearly 
four, from 44 per 10,000 person-years in Japan and Mediterranean southern Europe 
to 153 per 10,000 person-years in northern Europe. Hypertension was a significant 
risk factor for death from CHD in all the populations: the relative risk before 
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adjustment for within-subject variation ranged from 1.33 in inland southern Europe to 
2.80 in Japan, and the overall unadjusted relative risk for hypertension was 1.77. 
When adjustment for within-subject variation was made by using usual values for 
systolic and diastolic blood pressure over the first five-year period, instead of single 
base-line values, to classify subjects as having or not having hypertension, the 
overall relative risk associated with hypertension became 2.13. No significant 
differences were observed among the populations with respect to the relative risk of 
death from CHD that was associated with hypertension (P>0.1 by the likelihood-ratio 
test for interaction between the hypertension variable and the ordinal population 
variable). 
Discussion 
We observed that the relative risks of death due to CHO in association with 
given increments in systolic and diastolic blood pressure and the presence of 
hypertension over 25 years did not differ significantly among the six populations, but 
that the absolute risk of death at the same level of blood pressure varied 
substantially. This indicates that the relation between blood pressure and the relative 
risk of death from CHD over the Jong-tenm did not differ among populations in which 
the absolute risk of mortality from CHD varied considerably. This finding is consistent 
with our a priori hypothesis and agrees with results of large observational studies 
that have been confined to subjects from single populations.24'1s-16 The narrow 
confidence limits around the estimated relative risks of death for given increments in 
blood pressure indicate that our study had sufficient power to detect important 
differences in relative risks. 
In all 16 cohorts of the Seven Countries Study, standardized methods were 
used to measure blood pressure, other cardiovascular risk factors, and causes of 
death-' This consistency allowed valid comparisons to be made among populations. 
At the time of the base-line assessments (1958 to 1964), infonmation on the use of 
antihypertensive drugs was not collected. However, during this period, such drugs 
were rarely prescribed in any of the seven countries. Furthenmore, the estimated 
relative risks of death due to CHD over the first 1 0-year period of the study were 
similar to those for the 25-year period (data not shown). This similarity suggests that 
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the initiaiton of antihypertensive therapy during the later years of follow-up did not 
influence the observed relations. 
In survival studies on the relation between blood pressure and mortality, the 
estimated relative risks of death due to CHD associated with an increase of 10 
mmHg in systolic blood pressure varied from 1.2 in a study in Bergen, Norway, to 1.4 
in the Western Collaborative Group Study.1·3.4·17•18 For a single measurement of 
diastolic blood pressure, the estimated relative risk for an increment of 5 mmHg 
varied from about 1.1 in the study in Bergen to 1.3 in a cohort from three European 
cities (Edinburgh, Budapest, and Prague).2.4·19 Estimated relative risks adjusted for 
within-subject variability in blood pressure have also been published.1.B.zo In most of 
these reports, blood pressure was studied only in relation to total mortality from 
cardiovascular causes and to mortality from all causes. 6·20 The combined results of 
nine prospective, observational studies demonstrated that an increase of 5 mmHg in 
diastolic blood pressure was associated with a 20 to 25 percent higher rate of death 
from CHD over a 1 0-year period, after adjustment for within-subject variability. 1 The 
estimated relative risks in the present study are similar. 
Previous reports did not evaluate the effect of variability in blood pressure in 
individual subjects on the strength of the relation between systolic and diastolic 
blood pressures and mortality due to CHD. We observed that the effect was larger 
for diastolic pressure than for systolic pressure: the relation became 110 percent 
stronger for diastolic pressure and 60 percent stronger for systolic pressure after 
adjustment for within-subject variability. This difference occurs because the ratio of 
within-subject variability to variability between subjects is greater for diastolic than for 
systolic blood pressure.21 ·22 Consistent with this finding is the fact that diastolic blood 
pressure, assessed as the fifth-phase Korotkoff sound by the auscultatory method, is 
more difficult to measure than systolic blood pressure.23 
Hypertension was a significant risk factor for death from CHD over the 25-
year period of our study. The pooled relative risk associated with hypertension, 
defined as a systolic blood pressure of 160 mmHg or greater, a diastolic blood 
pressure of 95 mmHg or greater, or both, was 1.77 before adjustment for individual 
variability in blood pressure and 2.13 after adjustment. When hypertension was 
defined as a systolic blood pressure of 140 mmHg or greater, a diastolic blood 
pressure of 90 mmHg or greater, or both, the result was an estimated relative risk of 
1.5. In the Framingham Study, hypertension was defined to the latter criteria and 
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was associated with a relative risk of 2.0 for death from CH0. 15 The lower relative 
risk associated with hypertension in our present study may be due to our longer 
follow-up period of 25 years. 
Because of random within-subject variability in blood pressure, analysis of 
single measurements of blood pressure may lead to substantial overestimation of the 
prevalence of hypertension, resulting in underestimation of the associated risk of 
death.24 In the present study, the overall prevalence of hypertension decreased from 
24 percent to 13 percent after adjustment for within-subject variability in blood 
pressure, yielding a 30 percent stronger relation with mortality due to CHD. 
We observed substantial heterogeneity among the populations in rates of 
death due to CHD at similar levels of blood pressure. In the Seven Countries Study, 
similar heterogeneity has been observed for serum cholesterol levels8 These 
differences in the absolute risk of death from CHD at similar blood pressures and 
serum cholesterol levels cannot be explained by differences in age or smoking 
status, because the analysis of mortality included adjustments for these factors. 
Although genetic differences among populations in susceptibility to CHD may 
partially explain the observed differences in CHD-associated mortality, other factors 
should also be considered. Differences in nutritional factors may play an important 
part, because dietary patterns vary greatly among countries.• As compared with the 
diets in northern Europe and the United States, the Mediterranean diet at base line 
contained less meat and fewer dairy products but more olive oil, fish, fruits, 
vegetables, and alcohol.25 In addition to interventions targeted to classical risk 
factors for CHD, changes in diet may therefore be important for reducing mortality 
from CHD in northern Europe and the United States to near the rates in the 
Mediterranean region and Japan. This process can be illustrated by the decrease in 
mortality from CHD that occured at the same time as decreases in major risk factors 
in Finland during the period from 1972 to 199226 A substantial increase in the 
consumption of vegetables and fruit in Finland starting in the early 1970s also 
contributed to the decline in mortality from CHD27 
The large difference between the risks of CHD in the United States and 
northern Europe and those in Japan and southern Europe at the same blood-
pressure level may have important implications for the treatment of hypertension. 
Recently, a task force of European and other societies on the prevention of CHD in 
clinical practice recommended the use of the absolute risk of CHD, based on all the 
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major CHD risk factors, as a criterion for starting drug treatment.28 According to this 
criterion, healthy persons whose absolute multifactorial risk of CHD will exceed 20 
percent over the next 1 0-year period, or whose risk will exceed 20 percent if 
projected to age 60, have a sufficiently high risk to justify the selective use of proven 
drug therapies. The results of the Seven Countries Study imply that at the same 
blood-pressure level this criterion will be met at lower blood pressures in the United 
States and northern Europe than in Japan and Mediterranean southern Europe. Of 
course, the decision to start drug treatment is not based solely on absolute risk. 
Other factors, such as the clinical history, age and sex of the patient and the cost-
effectiveness of therapy, are also important. 
In conclusion, the present study showed that among populations, the increase 
in the relative risk of death from CHD for a given increase in blood pressure is similar 
but that the absolute risk at a given blood-pressure value varies substantially. If the 
absolute risk of coronary heart disease is taken as a criterion for the use of 
antihypertensive therapy, this finding will have major implications for clinical practice 
in different parts of the world. 
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CHAPTER2.4 
Blood pressure and long-term coronary heart disease mortality in 
the Seven Countries Study: implications for clinical practice and 
public health 
Introduction 
High blood pressure is a well-established risk factor for coronary heart 
disease (CHD). Therefore, management of high blood pressure is needed to reduce 
the burden of CHD and consequently to increase healthy life-expectancy. Gain in 
healthy years of life is of importance for both individuals and populations. In clinical 
practice, treatment of high blood pressure is focused on achieving health benefit for 
individuals, whereas public health is focused on prevention of high blood pressure in 
populations. 
In clinical medicine, a high-risk strategy is used for CHD prevention, i.e. 
detection and treatment of high blood pressure in patients who are most likely to 
benefit from it. Two components of risk are important for treatment strategies. The 
absolute risk or absolute rate defines the probability of an individual to develop a 
disease over a finite period of time.1 Recent guidelines on the management of 
hypertension have recommended the multifactorial absolute risk as the basis of 
clinical desicion-making, in terms of antihypertensive drug therapy.2' 6 This 
multifactorial or overall level of risk will often be determined to a greater extent by the 
presence of other risk factors, such as age, gender, smoking status, total and HDL 
cholesterol level and family history of premature cardiovascular disease, than by 
blood pressure level.2 Consideration of absolute level of risk, in addition to blood 
pressure level, is mainly aimed at healthy individuals with mild and moderate 
hypertension, ie systolic blood pressures of 140-179 mmHg and/or diastolic blood 
pressures of 90-109 mmHg. Individuals with severe hypertension and patients with a 
history of CHD in combination with mild or moderate hypertension are already at 
high risk and are qualified for drug treatment anyway. The relative risk is the ratio of 
absolute risk for an individual with a defined level of risk (based on one or more risk 
factors) to that for an individual at a reference level of risk, i.e. either a low or an 
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average level (based on one or more risk factors). 7 The relative risk provides 
information about the aetiological significance of a risk factor.1 A high relative risk 
implies a strong association between a risk factor and the occurrence of a disease. 
To prevent high blood pressure in a public health context, blood pressure-
reducing interventions should be selected based on their potential to reduce the 
incidence of CHD in the population as a whole8 In public health, the population 
attributable risk (PAR) is a widely used measure of risk. In cases of hypertension, the 
PAR is the proportion of all diseased individuals in the population at large, in both 
normotensive and hypertensive individuals, to whom hypertension is attributable.' 
PAR not only depends on the relative risk, but also on the proportion of the total 
population that is exposed, i.e. on the prevalence of hypertension. 
Epidemiologic measures of risk can thus be used as a basis for developing 
effective strategies for prevention of blood-pressure-related diseases, both in clinical 
medicine and public health. This hotline editorial deals with such an application of 
these risk measures, in view of the results of a recently published study on blood 
pressure and mortality from CHD in the Seven Countries Study9 The study and its 
main findings are described and the implications for treatment and prevention of 
hypertension in relation to CHD are discussed. 
The study and its findings 
The aim of the study was to compare the mortality rates from CHD at a given 
level of blood pressure among different populations. The study also investigated 
whether the relative risk for death due to CHD in relation to systolic and diastolic 
blood pressure was similar in different populations. 
The study included 12,031 men aged 40-59 years who were enrolled in the 
Seven Countries Study between 1958 and 1964 and who were free of CHD at 
enrolment A total of 16 cohorts were examined in the following countries: the United 
States, Finland (eastern and western), the Netherlands (Zutphen), Italy (Rome 
Railroad, Crevalcore and Montegiorgio), Greece (Crete and Corfu), former 
Yugoslavia (Dalmatia, Slavonia, Zrenjanin, Velika Krsna and Belgrade), and Japan 
(Tanushimaru and Ushibuka). To increase the power of the statistical analyses the 
16 cohorts were pooled into six populations e.g. the United States, northern Europe 
(East and West Finland and Zutphen), Mediterranean southem Europe (Crete, 
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Corfu, Montegiorgio, and Dalmatia), Inland southern Europe (Rome, Crevalcore, 
Slavonia, and Belgrade), Serbia (Velika Krsna and Zrenjanin) and Japan (Ushibuka 
and Tanushimaru). The criteria for grouping cohorts into one population were 
similarities among cohorts in CHD mortality rates and similarities among cohorts in 
cultural (e.g. dietary patterns) and geographic features.' In all cohorts the major 
cardiovascular risk factors were measured in a standardized way at enrolment and 
after 5 (except Japan) and 10 years (except USA).10·11 During 25 years of follow-up, 
1291 (10.7%) men died from CHD. 
The main study finding is that, at the same blood pressure level, the mortality 
rates from CHD varied substantially among populations. In all populations, however, 
men whose blood pressure increased a given amount experienced a similar relative 
increase in risk of dying from CHD. At systolic and diastolic blood pressures of 140 
and 85 mmHg, respectively, 25-year mortality rates from CHD varied by a factor of 
more than three among the populations. Rates in the United States and northern 
Europe were high (approximately 70 deaths per 10,000 person-years), but low in 
Japan and Mediterranean southern Europe (approximately 20 deaths per 10,000 
person-years). 
Differences of 1 0 mmHg in casual systolic blood pressure and of 5 mmHg in 
casual diastolic blood pressure were associated with, respectively, a 17% and 13% 
difference in the risk of death from CHD. After adjustment for within-subject 
variability in blood pressure, the relative risk was 1.28 for each of these differences, 
making the relation 60% stronger for systolic blood pressure and twice as strong for 
diastolic blood pressure. A continuous, graded relation between blood pressure and 
risk of CHD mortality, ie the lower the blood pressure the lower the risk and vice 
versa, has also been demonstrated in other large observational studies.12"15 
Other investigators contest this viewpoint and suggest that systolic blood 
pressure is not related to risk of all-cause and cardiovacular disease death for all 
pressures lower than an age- and sex-dependent threshold.16 For a 40-year old man, 
they suggest that the threshold for systolic blood pressure should be about 140 
mmHg, and for a 60-year old man about 150 mmHg. However, their end-points were 
different and their numbers were smaller. More studies are needed to draw definite 
conclusions about this issue. 
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Clinical implications 
The large differences between the CHD death rates in the USA and northern 
Europe and those in Japan and Mediterranean southern Europe among men with 
similar blood pressure levels have implications for the treatment of hypertension in 
different parts of the world. It emphasizes the limited usefulness of hypertension as a 
diagnostic category in clinical decision making, and the importance of an individual's 
total risk of developing CHD. In the 1998 recommendations of the Joint Task Force 
of European Societies on prevention of CHD in clinical practice, a 1 0-year 
multifactorial CHD risk greater than 20%, or in young persons a risk exceeding 20% 
if projected to age 60, is arbitrarily defined as a risk sufficiently high to justify the 
selective use of antihypertensive drug therapy in healthy individuals6 
In populations with high CHD mortality rates, a large proportion of individuals 
has a high absolute level of risk. Our results show that at each level of blood 
pressure, this 'absolute risk' criterion is passed more often in the USA and northern 
Europe than in Japan and Mediterranean southern Europe. Thus, according to the 
'absolute risk' criterion, a higher percentage of men in the USA and northern Europe 
with mild and moderate hypertension would be treated for this condition than in 
Japan and the Mediterranean. 
In the recommendations of the Joint European Task Force, risk stratification 
charts derived from Framingham risk functions are used to estimate an individual's 
multifactorial absolute risk6 Although these risk charts predict absolute risk 
reasonably well in high-risk populations, e.g. the USA and northern Europe, they 
overestimate the risk in low-risk populations, e.g. Japan and the Mediterranean.17•18 
This means that, in the latter, an excess of people would be treated by drugs using 
the Framingham risk function based charts. These findings indicate the importance 
of developing and comparing risk functions derived from prospective population-
based studies carried out in different parts of Europe, with different CHD mortality 
rates. For that purpose, the SCORE project was started in 1997.17 
Of course, the definition of 'high risk' status, with regard to need for 
antihypertensive therapy is not solely based on considerations from observational 
epidemiology and clinical trials. Cost-effectiveness issues play also a role. 19 In 
addition, due to limitations in professional and financial resources, the need to 
establish priorities in health care may play a role in targeting risk groups for drug 
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treatment. Because these aspects may vary in different countries, the definition of 
'high risk' status may vary from country to country. 
Public health implications 
In clinical medicine, a high risk approach to CHD prevention is used. Mainly 
patients with severe hypertension and patients with mild or moderate hypertension 
who have a high short-term absolute risk of developing CHD, e.g. within 10 years are 
treated. Most individuals have, however, average, mildly or moderately elevated 
blood pressure levels and a low short-term absolute CHD risk. Most of these 
individuals will not be included in the high risk strategy. 
In a public health context, the aim of CHD prevention is to reduce the 
incidence of CHD in the population as a whole. Viewed from a population 
perspective, the potential benefit of blood-pressure reducing interventions is 
determined by the population attributable risk (PAR). The PAR depends both on the 
relative risk and on the proportion of individuals with blood pressure levels above 
optimal, e.g. a systolic blood pressure above 120 mmHg and/or a diastolic blood 
pressure above 80 mmHg. In the present study, we found that any increase in blood 
pressure was associated with an increase in the relative risk for CHD mortality, 
irrespective of an individual's blood pressure level. These positive associations and 
the large number of individuals with blood pressure levels above optimal (who will 
not be targeted by clinicians) indicate that the total burden of CHD among this group 
is considerable.13•15 A population strategy, aimed at blood pressure reductions in the 
population as a whole, will therefore theoretically result in a much larger absolute 
decline in the number of CHD cases than a high risk strategy, even at moderate 
blood pressure reductions• Small population-wide reductions of blood pressure may 
be achieved by stimulating lifestyle changes, such as increased physical activity and 
changes in diet, in the total population?0-24 An advantage of such lifestyle 
interventions is that they also have a beneficial effect on other CHD risk factors such 
as total cholesterol8 •20·23 Furthermore, they may prevent 'medicalization' of the 
population by avoiding the need for, or reducing the intensity of, antihypertensive 
drug therapy25·26 
An important role of lifestyle factors in reducing the burden of CHD is 
suggested by the results of the present study. The observed differences in CHD 
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mortality rates between populations at similar levels of blood pressure could not be 
explained by the major causal CHD risk factors: prevalence of diabetes was very low 
in all cohorts and CHD death rates were adjusted for age, smoking status and total 
cholesterol level. Although there may be some residual confounding, other factors 
such as genetic susceptibility for CHD, biological factors such as low HDL-
cholesterol and coagulation factors, and life style factors, should thus be considered. 
Dietary patterns differed greatly between the populations. Compared with the 
northern European and U.S. diets, the Mediterranean diet at baseline contained less 
meat and dairy products but more olive oil, fish, fruits, vegetables, and wine27 
Lifestyle factors, such as diet, are therefore suggested to be major detenminants of 
differences in CHD death rates. 
Conclusion 
From a public health perspective, the high risk and the population strategy 
with respect to prevention of CHD are complementary. Adequate treatment of 
patients at high risk is needed because they will benefit most. This is, however, not 
enough to reduce the population burden of CHD and should be complemented by a 
population approach in order to obtain a maximal benefit of CHD prevention. 
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CHAPTER 3.1 
Systolic, diastolic and pulse pressure and 10-year cardiovascular 
mortality among elderly men in Finland, Italy, and the Netherlands 
Abstract 
Objective. To determine whether systolic, diastolic and pulse pressure are related to 
cardiovascular mortality in elderly men. 
Design. Prospective cohort study. 
Setting. The Finland, Italy and the Netherlands Elderly (FINE) Study, a population-
based study. 
Participants. 1152 men aged 65-84 years with no history of cardiovascular diseases 
(CVD) and not taking antihypertensive drugs. 
Main outcome measures. Fatal CVD (n=201) during 10 years of follow-up. 
Results. Neither systolic nor diastolic blood pressure were individually related to 
cardiovascular mortality. In the combined population of the FINE Study, men in the 
highest tertile of pulse pressure (<:73 mmHg) had a significantly increased risk of 
cardiovascular mortality compared with men in the lowest tertile (RR=1.54, 95% 
confidence interval [Cl] 1.06-2.24). 
Conclusion. The FINE Study indicates that elevated pulse pressure is related to an 
increased risk of cardiovascular mortality in elderly men. Neither systolic nor diastolic 
blood pressure were individually related to risk of cardiovascular mortality among 
elderly men without CVD from Finland, the Netherlands and Italy. 
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Introduction 
In middle-aged men, systolic and diastolic blood pressure are individually 
important predictors of cardiovascular and all-cause mortality.' In elderly men there 
is evidence that elevated systolic blood pressure remains associated with increased 
cardiovascular and total mortality at least up to 80 years of age.2.4 The association of 
diastolic blood pressure with both endpoints is less clear in the elderly. Besides 
curvilinear associations, some investigators have found weaker or no associations, 
and some observed excess mortality in elderly subjects with low diastolic blood 
pressure2 ·4-6 There is mounting evidence that low diastolic blood pressure is not 
causally related to increased cardiovascular risk4 '7 Increased arterial stiffness with 
aging, indicated by a higher pulse pressure, and pre-existing diseases may be the 
primary factors causing increased risk, with low diastolic blood pressure being mostly 
a secondary phenomenon 4 Concordantly, positive relations of pulse pressure with 
CVD mortality have been reported 4 Current literature is however not conclusive on 
the role of elevated DBP in the etiology of CVD in the elderly. Results from some 
studies suggest that elevated DBP remains a risk factor for CVD mortalitys.s In two 
recent observational studies among large elderly cohorts, however, elevated DBP 
was not related to CVD mortality, also when potential confounding effects of pre-
existing diseases were taken into account. 2•4 
The aim of the present study is to further establish the associations of systolic, 
diastolic and pulse pressure with mortality from cardiovascular diseases in elderly 
men in the Finland, Italy and the Netherlands Elderly (FINE) Study. Previous reports 
on the FINE Study are based on a follow-up period offive years. In this investigation, 
using 10-year follow-up and a sufficient number of events, we restricted the analysis 
to elderly men withOut a history of cardiovascular diseases who did not use anti-
hypertensive drugs. This made it possible to study the etiologic association between 
various blood pressure components and cardiovascular mortality in elderly men. 
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Subjects and Methods 
Study population 
For this study, data of the survivors of the Finnish, Italian and Dutch cohorts of 
the Seven Countries Study were used 8 They were re-examined after 25 years of 
follow-up and this re-examination was the baseline of the FINE Study, a prospective 
study on risk factors and health in elderly men aged 65 to 84 years. 
In Finland, 716 men from two rural cohorts known as eastern and western 
Finland were re-examined in 1984. In Italy, 682 men from two rural cohorts, 
Crevalcore and Montegiorgio, were re-examined in 1985. In the Netherlands, 380 
survivors of the Dutch cohort from the small town of Zutphen were re-examined in 
1985, together with a new random sample consisting of 507 men aged 65 to 84 
years from Zutphen who did not participate earlier in the Zutphen Study. The 
response rates were 94% in Finland, 76% in Italy, and 70% in The Netherlands. 
Measurements 
In all cohorts major cardiovascular risk factors were measured according to 
standardized methods at enrollment and after five years of follow-up. Details of the 
methods used have been described previously. 8·9 
In all three countries, blood pressure was measured on the right arm in supine 
position after five minutes rest with a sphygmomanometer (random zero in the 
Netherlands), according to a standardized protocol.8·10 Blood pressure was 
measured by a specially trained nurse (Finland), or by trained physicians (Italy and 
the Netherlands). Readings were taken to the nearest two mmHg. The mean of two 
consecutive measurements was computed for systolic (1" Korotkoff phase) and 
diastolic (51h Korotkoff phase) blood pressure. For both systolic and diastolic blood 
pressure we distinguished between three fixed categories ('<140, 140-159, ;,160 
mmHg' systolic and '<85, 85-94, ;,95 mmHg' diastolic). For pulse pressure (=systolic 
minus diastolic blood pressure) we presented tertiles. The lowest category was 
always used as reference. 
Information on use of anti-hypertensive drugs was obtained from a 
questionnaire. In Finland and the Netherlands information was available about anti-
hypertensive drugs used for different indications. In Italy this information was 
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restricted to anti-hypertensive drug use for the indication hypertension. Total and 
HDL cholesterol were determined enzymatically according to the criteria of the WHO 
Lipid Reference Laboratories in Prague or Atlanta, Georgia." Height and weight 
were measured in light clothing without shoes and body mass index was calculated 
(kg/m2). Known clinical history of diabetes mellitus and cancer, cigarette smoking, 
alcohol drinking and living independently were established by means of a 
standardized questionnaire. The presence of cardiovascular diseases at the baseline 
survey was defined by clinical criteria, obtained from questionnaires occasionally 
combined with information from reported clinical records and additional questions 
from the examining physician.12 Cardiovascular diseases were considered to be 
present when either definite myocardial infarction, angina pectoris, heart failure (only 
present in case of both a clinical diagnosis and medication for heart failure), 
intermittent claudication, stroke or TIA had been diagnosed by a clinician. 
Follow-up 
Complete information on the vital status of the participants, obtained through 
official death certificates until 14 October 1994 in Finland, 1 May 1995 in Italy and 31 
December 1994 in the Netherlands (10 year follow-up), was available for 99.7% of 
the FINE population. In Finland, only information on causes of death obtained 
through official death certificates was available. However, validity of the routine 
mortality statistics in Finland is high.13 In The Netherlands and Italy, causes of death 
were occasionally validated through review of clinical records from the general 
practitioner or hospital. Final causes of death were adjudicated by a single reviewer 
using the 9th revision of the WHO-ICD14 adopting a hierarchical order when multiple 
causes were given, as follows: violent causes, cancer, coronary heart disease, 
stroke and other causes. The endpoint considered in this study is mortality from 
cardiovascular diseases during 10 years of follow-up, with cardiovascular mortality 
defined as primary cause of death with ICD-9 codes 401 through 458. 
Statistical analyses 
Persons with missing data on blood pressure (n=6;0.3%) or other covariates 
(n=149;6.5 %) at baseline, in total155 (6.8%), were excluded from the analyses. We 
also excluded men with a history of cardiovascular diseases at baseline (n=628; 
29.5%) and men using anti-hypertensive medication regardless of an indication for 
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hypertension (n=636; 29.9%), leaving 1,152 (50.4%) men in the present analyses. 
Medication users were excluded because antihypertensive therapy may have 
influenced baseline blood pressure readings and thus their relation to cardiovascular 
risk. 
Age-standardized 1 0-year mortality rates from cardiovascular diseases were 
computed for each blood pressure category by weighing the mortality rates for five-
year age categories to the age distribution of the total study population. 
Relative risks for the relation between both the categorical and the continuous 
(per 10 mmHg increase in systolic and pulse pressure and 5 mmHg increase in 
diastolic pressure) blood pressure variables and cardiovascular mortality were 
estimated using Cox's proportional-hazard analysis, pooled after stratification by 
cohort, with adjustment for age (years), total and HDL cholesterol (mmoi/L), body 
mass index (kg/m2), known history of diabetes mellitus (yes/no), smoking 
(never/ex/current), cancer (yes/no), living independently (yes/no) and current alcohol 
drinking (yes/no). Tests for quadratic trends were carried out with systolic and 
diastolic blood pressure put into the model as continuous variables. No significant 
quadratic trends were observed (all p-values > 0.05). 
For the total population of the FINE Study (three countries pooled) we 
repeated the Cox analysis using estimated usual, or average, blood pressures for 
each individual instead of the casual baseline blood pressures. Usual blood 
pressures were estimated from a linear regression model, given the values obtained 
at enrollment and at five-year follow-up for systolic and diastolic blood pressure, 
body-mass index and cholesterol level. This yielded relative risk estimates adjusted 
for within-subject variability in blood pressure.15 
We repeated the analyses after excluding deaths occuring in the first two 
years of follow-up, and separately for predefined subgroups of men aged 65-74 
years and 75-84 years. Because these results were essentially the same, the results 
in this article are only reported for all deaths included and for both age-groups 
combined. The SAS computer package (version 6.12) was used for all statistical 
analyses (SAS Institute Inc., Cary, North Carolina, USA, 1989). 
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Results 
At baseline, 47.4% of the Finnish, 61.6% of the Dutch, and 50.2% of the 
Italian men were free from cardiovascular diseases and did not use anti-hypertensive 
drugs. These apparently healthy men were included in the analysis. The included 
group had a significantly lower age-standardized 1 0-year cardiovascular mortality 
rate than the excluded group (239 per 10,000 person years versus 525 per 10,000 
person years; p<0.05). At baseline (Table 1 ), average systolic and diastolic blood 
pressure varied from 148.6 (19.6) and 84.7 (10.9) in the Netherlands to 162.8 (21.0) 
and 90.4 (1 0.5) in Italy. The proportion of men classified as hypertensive ~140/90 
mmHg) ranged from 35% in the Netherlands to 61% in Italy. 
Table 1. Baseline characteristics for elderly men without a history of cardiovascular diseases and not 
using antihypertensive drugs in Finland, the Netherlands and Italy. 
Baseline characteristic Finland the Netherlands Italy 
N (%) 315 (47.4%) 545 (61.6%) 292 (50.2%) 
Mean (SD) 
Age (years) 71.5 (5.3) 71.1 (5.3) 71.6 (4.5) 
Systolic blood pressure (mmHg) 152.3 (20.9) 148.6 (19.6) 162.8 (21.0) 
o·lastolic blood pressure (mmHg) 86.7 (10.2) 64.7 (10.9) 90.4 (10.5) 
Body mass index (kg/m2) 25.3 (3.9) 25.3 (3.0) 25.5 (3.8) 
Total cholesterol (mmoi/L) 6.15 (1.15) 6.08 (1.09) 5.86 (1.12) 
HDL cholesterol (mmoVL) 1.29 (0.32) 1.14 (0.28) 1.33 (0.33) 
% 
Hypertension t 40.0 35.0 61.0 
Anti-hypertensive use 
Current smoking 18.1 32.3 29.8 
Ex-smoking 52.7 49.4 39.7 
History of diabetes 5.7 4.6 7.2 
History of CVD 
1 0-year cardiovascular mortality :1: 293 218 222 
SD standard deviation; t systonc blood pressure ~140 mmHg and/or diastolic blood pressure ;::go mmHg; :+ age-
standardized and per 10,000 person years. 
The relation between the three blood pressure components and subsequent 
cardiovascular mortality was studied in men free from cardiovascular diseases and 
not using anti-hypertensive medication. During 10 years of follow-up, the number of 
elderly men among this group that died from cardiovascular causes was 66 (21.0%) 
in Finland, 88 (16.1%) in the Netherlands, and 47 (16.1%) in Italy. Correlations 
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Table 2. Age-adjusted mortality rates from CVD and multiple adjusted t relative risks and 95% 
confidence limits of mortality from CVD associated with systolic blood pressure ln elderly men without 
a history of CVD and not using anti-hypertensive drugs in Finland, the Netherlands and Italy. 
<140 
Total number 100 
N of CVD deaths 18 
Rate 346 
RR (95%Ci) 1.00 
Total number 190 
N of CVD deaths 25 
Rate 176 
RR (95% Cl) 1.00 
Total number 34 
N of CVD deaths 3 
Rate 158 
RR (95% Cl) 1.00 
Total number 324 
N of CVD deaths 46 
Rate 215 
RR ~95% Cl) 1.00 
RR (95% Cl) 
Systolic blood pressure (mmHg) 
140-159 ~160 
Finland (n~315) 
108 107 
21 27 
234 291 
0.78 (0.41-1.48) 0.94 (0.48-1.82) 
the Netherlands (n~545) 
195 160 
35 28 
236 239 
1.30 (0.78-2.18) 1.28 (0. 75-2.21) 
Italy (n~292) 
101 157 
17 27 
267 202 
1.84 (0.52-6.52) 1.90 (0.55-6.54) 
FINE Study (n~1152) 
404 424 
73 82 
243 241 
1.15 (0.79-1.67) 1.22 (0.83-1.78) 
10 mmHg increase 
1.05 (0.93-1.20) 
1.03 (0.93-1.15) 
0.99 (0.87-1.12) 
1.03 (0.97-1.11) 
1.00 (0.89-1.12) 
CVO cardiovascular disease; RR relative risk; Cl confidence interval. t adjusted for age, total and HDL 
cholesterol, body mass index, known history of clinical diabetes and cancer, cigarette smoking, living 
independently and current alcohol drinking. + adjusted for within-subject variability in blood pressure. 
among blood pressure components were r-0.62 for systolic - diastolic pressure, 
r-0.86 for systolic- pulse pressure, and 0.13 for diastolic- pulse pressure. 
Using the categorical as well as continuous blood pressure variables, neither 
systolic nor diastolic blood pressure were individually associated with cardiovascular 
mortality in elderly men in Finland, the Netherlands and Italy and in the total 
population of the FINE Study (Table 2 and 3). 
In each separate country, pulse pressure was positively but not significantly related 
to cardiovascular mortality (Table 4). In the pooled country-group, however, men in 
the highest tertile of pulse pressure (~73 mmHg) had a significantly increased risk of 
cardiovascular mortality compared with men in the lowest tertile (RR=1.54, 
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Table 3. Age-adjusted mortality rates from CVD and multiple adjusted t relative risks and 95% 
confidence limits of mortality from CVO associated with diastolic blood pressure in elderly men without 
a history of CVD and not using anti-hypertensive drugs in Finland, the Netherlands and Italy. 
<85 
Total number 139 
N of CVD deaths 26 
Rate 261 
RR (95% Cl) 1.00 
Total number 280 
N of CVD deaths 50 
Rate 236 
RR (95% Cl) 1.00 
Total number 80 
N of CVD deaths 15 
Rate 303 
RR (95% Cl) 1.00 
Total number 499 
N of CVD deaths 91 
Rate 247 
RR ~95% Cl) 1.00 
RR (95% Cl) 
Oiastof1c blood pressure (mmHg) 
85-95 <95 
Finland (n=315) 
105 71 
22 18 
262 362 
0.98 (0.54-1.79) 1.39 (0.73-2.64) 
the Netherlands (n=545) 
158 107 
20 18 
186 232 
0.75 (0.44-1.27) 1.09 (0.63-1.90) 
Italy (n=292) 
118 94 
19 13 
198 159 
0.85 (0.42-1.71) 0.70 (0.32-1.53) 
FINE Study (n=1152) 
381 272 
61 49 
218 236 
0.88 (0.63-1.23) 1.08 (0.75-1.55) 
5 mmHg increase 
1.02 (0.91-1.15) 
0.96 (0.87-1.06) 
0.88 (0.75-1.02) 
0.97 (0.90-1.03) 
0.95 (0.84-1.07) 
CVD cardiovascular disease~ RR relaf1ve risk: Cl confidence ·IntervaL t adjusted for age, total and HDL 
cholesterol, body mass index, known history of clinical diabetes and cancer, cigarette smoking, living 
independently and current alcohol drinking. + adjusted for within·subject variability in blood pressure. 
95% confidence interval [CI] 1.06-2.24), and the increase in risk per 10 mmHg 
increase in pulse pressure was borderline significant (1.08, 95% Cl 1.00-1.18). 
Adjustment for within-subject variability in blood pressure hardly changed the 
observed associations in the pooled population (Table 2, 3 and 4). None of the three 
blood pressures components were related to all-cause mortality (data not shown). In 
the total FINE Study population, including men with a history of cardiovascular 
disease and men using antihypertensive medications (n=2130), a significant U-
shaped association between diastolic blood pressure and all-cause mortality (p-value 
quadratic trend <0.005), and a significant positive association between pulse 
62 
Table 4. Age-adjusted mortality rates from CVD and multiple adjusted t relative risks and 95% 
confidence limits of mortality from CVD associated with pulse pressure in elderly men without a 
history of CVD and not using anti-hypertensive drugs in Finland, the Netherlands and Italy. 
Pulse pressure <58 
N of CVD deaths 18 
Rate 315 
RR (95% Cl) 1.00 
Pulse pressure <57 
N of CVD deaths 19 
Rate 164 
RR (95% Cl) 1.00 
Pulse pressure <64 
N of CVD deaths 12 
Rate 212 
RR(95% Cl) 1.00 
Pulse pressure <59 
N of CVD deaths 45 
Rate 187 
RR ~95% Cl) 1.00 
RR (95% Cl) 
Tertiles of Pulse pressure (mmHg) 
Finland (n=315) 
58-72 ~73 
20 28 
227 328 
0.75 (0.39-1.45) 1.09 (0.57-2.09) 
the Netherlands (n=545) 
57-70 ~71 
32 37 
216 264 
1.27 (0.71-2.27) 1.44 (0.81-2.55) 
Italy (n=292) 
64-79 ~80 
16 19 
234 229 
1.59 (0.73-3.44) 1.61 (0.76-3.42) 
FINE Study(n=1152) 
59-72 ~73 
70 86 
230 274 
1.27 (0.87-1.86) 1.54 (1.06-2.24) 
10 mmHg increase 
in pulse pressure 
1.07 (0.91-1.26) 
1.09 (0.95-1.25) 
1.07 (0.93-1.24) 
1.08 (1.00-1.18) 
1.04 (0.90-1.20) 
CVD cardiovascular disease; RR relative risk; Cl confidence intervaL t adjusted for age, total and HDL 
cholesterol, body mass index, known history of clinical diabetes and cancer, cigarette smoking, living 
independently and current alcohol drinking. +: adjusted for within-subject variability in blood pressure 
pressure and cardiovascular mortality (RR per 10 mmHg increase in pulse 
pressure=1.08, 95% Cl 1.03-1.13) was observed (data not shown). We found no 
other significant associations between the blood pressure variables and 
cardiovascular and all-cause mortality in the total FINE Study population. 
Discussion 
This study indicates that elevated pulse pressure is related to increased 
cardiovascular mortality in elderly men from Finland, the Netherlands and Italy. The 
FINE Study does not provide evidence for an increased risk of cardiovascular 
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mortality at high or low levels of systolic and diastolic blood pressure in apparently 
healthy elderly men. 
Pulse pressure was not studied before in the FINE Study but the positive 
association with cardiovascular mortality in the present study is in line with the 
literature4 •6·16 Several mechanisms may explain the association between pulse 
pressure and cardiovascular disease. Elevated pulse pressure is an indicator of 
increased large-artery stiffnessu Arterial stiffness may promote the development of 
atheroma.18 It causes ischemia19 and is correlated with the presence of 
atherosclerosis20 Arterial stiffness is also strongly correlated with left ventricular 
hypertrophy,21 a known risk indicator for cardiovascular events.22 
Pulse pressure was not related to all-cause mortality in the present study, in contrast 
to the results of other studies4 .1 6 This may be due to a dilution effect of the positive 
association with cardiovascular diseases by other causes of death. Indeed 49% of 
the men who died, died of causes other than cardiovascular diseases. 
At middle-age, both systolic and diastolic blood pressure have strong linear 
relationships with cardiovascular and total mortality among the different populations 
of the Seven Countries Study15·23 and among other middle-aged populations.' In the 
present study, the positive relationship of systolic blood pressure with cardiovascular 
and total mortality was strongly reduced and no longer significant, and that of 
diastolic blood pressure had disappeared among the elderly Finnish, Italian and 
Dutch survivors of the Seven Countries Study. Contrary to our findings, most 
researchers found persisting positive relations of systolic blood pressure with 
cardiovascular and all-cause mortality among elderly populations. 2·4 The literature on 
the relation of diastolic blood pressure with both end-points in the elderly is less 
consistent, also when restricting to studies that adjusted for confounding by 
comorbidity and poor health. Some authors observed positive associations, 5·6 while 
others observed no or U-shaped associations2 •4 
Lack of associations of systolic and diastolic blood pressure with 
cardiovascular and total mortality in the present study may be due to increased 
comorbidity and underlying poor health. Preexisting cardiovascular diseases, cancer, 
diabetes, and deteriorating health indicated by cognitive impairment, low body mass 
index and limitations in activities of daily living may obscure the relation of blood 
pressure with (CVD) mortality. They are related to both reductions in blood pressure 
and excess deaths4 '24·25 The present study was confined to a relatively healthy 
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elderly cohort and we adjusted the analysis for various health-related factors. 
However, there may be residual confounding by incomplete adjustment for all 
aspects of poor health. Incomplete adjustment for poor health may also explain the 
U-shaped associations between blood pressure and five-year all-cause mortality 
found in earlier reports on the FINE Study26·27 
It is unlikely that our findings regarding systolic and diastolic blood pressure 
are due to the dilution effect of regression towards the mean caused by use of 
inaccurate blood pressure measurements made on a single occasion 28 Using 
average blood pressures based on repeated measurements during the first five 
years of follow-up, we found similar relative risk estimates. 
Our male study population was relatively healthy compared with the general 
elderly population aged 65 to 84 years for several reasons. In spite of a high 
response rate, older persons and especially those with health problems are less 
likely to participate29 In addition, we excluded men who used antihypertensive 
medication and men with a history of cardiovascular diseases. The first were 
excluded because we were interested in the relation between untreated blood 
pressures and mortality risk in the elderly. Nevertheless we found no significant 
interaction between the blood pressure variables and antihypertensive treatment and 
the reported associations were the same for non-users and users of antihypertensive 
drugs (results not shown). This is in line with results from other observational 
studies2 •4 
In conclusion, the FINE Study indicates that elevated pulse pressure is related 
to an increased risk of cardiovascular mortality in elderly men. Neither systolic nor 
diastolic blood pressure were individually related to cardiovascular mortality among 
relatively healthy elderly men from Finland, the Netherlands and Italy. This is in 
accord with the results of other studies concerning pulse and diastolic pressure. 
However, evidence from other population-based observational studies and from 
randomized trials30 suggest that high systolic blood is an important risk factor also in 
the elderly. 
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CHAPTER3.2 
Blood pressure and risk of myocardial infarction in elderly men and 
women: The Rotterdam Study 
Abstract 
Objective. To study the association between blood pressure and risk of myocardial 
infarction in elderly subjects. 
Design. Prospective cohort study. 
Setting. The Rotterdam Study, a Dutch population-based study. 
Participants. 6004 men and women aged ;, 55 years. 
Main outcome measures. Fatal or non-fatal myocardial infarction (n = 190) during a 
4-year follow-up. 
Results. After excluding participants using blood pressure lowering medication and 
participants with a history of myocardial infarction, increasing levels of systolic blood 
pressure (SBP) were associated with increasing risk of first myocardial infarction (P 
for trend< 0.0001). The relative risk (RR) for an SBP of 160 mmHg or higher was 5.7 
(95% confidence interval (CI), 1.9-17.1) compared with an SBP below 120 mmHg. 
Increasing diastolic blood pressure (DBP) was also associated with increasing risk of 
first myocardial infarction, with the RR reaching 2.5 (95% Cl, 1.4-4.5) in subjects with 
values of 80-90 mmHg compared with values below 70 mmHg (P for trend < 0.05). 
Analyses in subjects aged 70 years and over showed that the positive associations 
between SBP and DBP and risk of first myocardial infarction remained at older age. 
Conclusion. These findings in a relatively healthy cohort of elderly subjects do not 
provide evidence for a J- or U-shaped relation between SBP and DBP and risk of 
first myocardial infarction. They suggest that the risk of first myocardial infarction 
increases with increasing level of systolic and diastolic blood pressure and that this 
relationship persists into older age. 
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Introduction 
In middle-aged populations, curvilinear associations between levels of systolic 
and diastolic blood pressure and risk of coronary heart disease have consistently 
been found.1·2 In elderly people, the nature and strength of the association is still 
unclear. Results from several studies have suggested that elevated systolic and 
diastolic blood pressure remain associated with increased coronary heart disease in 
the elderly.s-6 In contrast, other investigators have found weaker or no 
associations,7•8 and some observed an increased mortality from coronary heart 
disease in elderly subjects with low systolic or diastolic blood pressure8 .10 A possible 
explanation for an increased mortality at the lower end of the blood pressure 
distribution is the presence of other morbidity in the elderly, resulting in both blood 
pressure reduction and excess mortality-"-16 A low diastolic blood pressure, in the 
presence of severe narrowing of the coronary arteries, may also increase the risk of 
death by compromising coronary blood flown-2° Finally, it has been proposed that a 
decline in diastolic blood pressure with advancing age reflects vessel wall stiffening 
associated with atherosclerosis and consequently with excess mortality. 21 ' 22 
In the present study, we examined the associations of systolic and diastolic 
blood pressure with risk of myocardial infarction in subjects aged 55 years and over. 
We also examined whether the associations persisted after age 70. 
Subjects and Methods 
The Rotterdam Study 
The Rotterdam Study is a population-based prospective cohort study on the 
occurrence and determinants of chronic disabling diseases at older age. All residents 
of a suburb of Rotterdam, aged 55 years or over, were invited to take part in the 
study. The design of the study has been described in detail elsewhere.23 Of the 
10,275 men and women approached, a total of 7,983 (78%) agreed to participate. 
During a home interview, information was obtained on current health status, medical 
history and family history of diseases by means of a computerized questionnaire. 
The participants subsequently visited the study centre twice for physical 
examinations. All baseline measurements took place from March 1990 to July 1993. 
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Examinations 
The physical examinations were carried out by research assistants according 
to a standardized protocol. Systolic (first Korotkoff phase) and diastolic (fifth 
Korotkoff phase) blood pressure were measured in duplicate on the right arm using a 
random-zero sphygmomanometer with a 14 x 38 cuff, after the participant had been 
seated for at least five minutes. The mean of the two blood pressure values was 
used in the analyses. For both diastolic and systolic blood pressure, we 
distinguished four fixed categories with the lowest as reference. Height was 
measured to the nearest 0.1 em and body weight was measured to the nearest 0.5 
kg. Body mass index (weight (kg)/heighf (m)) was calculated. Serum total 
cholesterol was determined by an automated enzymatic procedure in a non-fasting 
blood sample. High-density lipoprotein (HDL) was measured after precipitation of the 
non-HDL fraction with phosphotungstate-magnesium. A history of diabetes mellitus 
was defined as a non-fasting blood glucose before or after a glucose tolerance test 
>11.1 mmol/1 and/or use of anti-diabetic medication24 Data on indication for use of 
blood pressure lowering medication are based on information collected by a 
physician at the research centre. In case of missing information, data from the home 
interview was taken. In addition, information was collected on the type of medication 
used, which the participants had been asked to bring with them to the study centre. 
Data on smoking habits were obtained during the home interview. Smoking was 
classified as never, former or current smoking. History of myocardial infarction was 
defined as a self-reported myocardial infarction verified by hospital discharge data, 
written information from the subject's general practitioner or electrocardiographic 
measurements. Subjects with pathological Q-waves measured on the 
electrocardiogram during the physical examination, in the absence of symptoms, 
were also classified as having a history of myocardial infarction25 
Follow-up 
The follow-up period, starting at the baseline examination and lasting until 
April 1996, was 3-6.5 years (mean 4.2). With respect to the vital status of the 
participants, information was obtained at regular intervals from the municipal register 
in Rotterdam. Information on fatal and non-fatal endpoints was obtained on a weekly 
basis from the general practitioners working in the study district of Ommoord and 
yearly from general practitioners outside Ommoord. Complete follow-up information 
71 
was available for 7054 subjects (88.4%) in the present analysis. Participants for 
whom no follow-up infomnation was available were on average 3 years older, had a 6 
mmHg lower systolic blood pressure and a 2 mmHg lower diastolic blood pressure. 
All information obtained from the general practitioners on possible events was coded 
independently by two research physicians from the Rotterdam Study. If there was 
disagreement, consensus was reached in a plenary session. Finally, all these 
events were verified by a medical expert in the field of cardiovascular disease. In 
case of discrepancies, the judgment by this expert was considered definite. 
Classification of myocardial infarction was based on the International Classification 
of Diseases, 1Oth version, codes 121-2426 In this analysis, the endpoint was a first or 
recurrent myocardial infarction during follow-up; fatal and non-fatal myocardial 
infarction were combined in the analyses. 
Data analyses 
We excluded persons who lived in a nursing home, in which blood pressure 
measurement was not part of the protocol (n=629; 8.9%), and persons with missing 
data on blood pressure (n=83;1.2%) or other covariates (n=338; 4.8%). The total 
number of persons excluded for one or more reasons was 1,050 (14.9%), so 6004 
persons were available for the present analyses. A two-sided P-value <0.05 was 
considered statistically significant. Crude incidence rates (per 10,000 person years) 
of myocardial infarction were computed per blood pressure category. Cox's 
proportional-hazard analysis was carried out to estimate relative risks (RR) with 
corresponding 95% confidence intervals. Both univariate and multivariate adjusted 
RRs were computed. Because the univariate results did not differ from the 
multivariate adjusted results, only the latter are described in the results section. 
Adjustments were made for age, sex, body mass index, total and HDL cholesterol, 
cigarette smoking, use of blood pressure lowering drugs, history of myocardial 
infaction and history of diabetes mellitus. Dummy variables for the categories of 
blood pressure and cigarette smoking were used in the analyses. 
The analyses were repeated after excluding participants using blood 
pressure-lowering medication regardless of an indication for hypertension (n=1936; 
32.2%) and those with a history of myocardial infarction (n=758; 12.6%), leaving 
3732 subjects in the analyses. To study whether the effects of blood pressure varied 
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by sex or age, we repeated these latter analyses separately for men and women and 
for predefined subgroups of subjects aged 55-69 years and <: 70 years. Additionally, 
a possible interaction of systolic and diastolic blood pressure with sex or age was 
tested by including a product term of the blood pressure variables with sex or age in 
the model, and by testing the statistical significance of its regression coefficient at a 
P-value<0.1 0. The number of events in those with a history of myocardial infarction 
was too small to study the effect of blood pressure within this group separately. All 
statistical analyses were carried out using the BMDP statistical package. 
Results 
At baseline (Table 1), the mean age±standard deviation was 69.1±8,7 years. 
Average systolic blood pressure was 139.9±22.4 mmHg and average diastolic blood 
pressure was 73.8±11.6 mmHg. The percentage of subjects with a systolic blood 
pressure of <:160 mmHg was 19%, and 18% had systolic pressure levels below 120 
mmHg. The proportion of subjects with a diastolic blood pressure <: 90 mmHg was 
9%, and 36% had diastolic pressure levels below 70 mmHg. 
Table 1. Baseline characteristics of men and women in the Rotterdam Study (n:;;:6Q04). 
Characteristic 
Age (years) 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Body mass index (kg/m2) 
Total cholesterol (mmol/1) 
HDL cholesterol (mmoVI) 
Current smokers 
Former smokers 
History of diabetes mellitus 
History of myocardia! infarction 
Use of blood presssure-lowering medication a 
Hypertension b 
Mean±SD or% 
69.1±8.7 
139.9±22.4 
73.8±11.6 
26.3±3.7 
6.6±1.2 
1.3±0.4 
21.1 
40.6 
10.4 
12.6 
32.2 
35.9 
SO standard deviation a Regardless of an indication for hypertension. b Systolic blood pressure~ 160 mmHg 
and/or diastolic blood presure <= 95 mmHg and/or use of blood presssure lowering medication with an indication 
for hypertension. HDL, high-density lipoprotein. 
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The percentage of subjects classified as hypertensive was 35.9% and the 
percentage of subjects using blood pressure-lowering drugs, regardless of an 
indication for hypertension, was 32.2%. The most commonly used blood pressure-
lowering drugs were 13-blocking agents (11.0%) and diuretics (10.7%), and 4.1% was 
using both. The proportion of subjects with a history of myocardial infarction was 
12.6%. 
During the 4-year follow-up period, 190 subjects (3.2%) suffered a first or 
recurrent myocardial infarction, of which 40 were fatal (21%). The overall incidence 
rate for myocardial infarction was 80 per 10,000 person-years. In the whole group 
analyses, including subjects using blood pressure lowering medication and subjects 
with a history of myocardial infarction, a direct association between systolic blood 
pressure and risk of myocardial infarction was found (P for trend < 0.05). For 
diastolic blood pressure, the observed association was Jess clear (P for trend = 1.0) 
(data not shown). After excluding subjects using blood pressure lowering medication, 
regardless of an indication for hypertension, and subjects with a history of 
myocardial infarction, increasing levels of systolic and diastolic blood pressure were 
associated with increasing risk of first myocardial infarction (Table 2). 
Table 2. Rates [per 10,000 person-years (py)] and adjusted relative risks (RR) of myocardial 
infarction (Ml) by systolic and diastolic blood pressure category in elderly men and women without a 
history of myocardial infarction and not using blood pressure-lowering medication. 
Blood pressure Number Number 
(mmHg) of subjects of events Rate RR 3 95% Cl 
Systolic 
<120 794 4 12 1.0 
120-139 1315 24 45 3.2 1.1-9.3 
140-159 1056 34 82 5.4 1.9-15.4 
<!160 567 19 88 5.7 1.9-17.1 
P linear trend P<0.0001 
Diastolic 
<70 1428 20 34 1.0 
70-79 1266 28 55 1.6 0.9-2.9 
80-89 733 26 91 2.5 1.4-4.5 
<!90 305 7 63 1.9 0.8-4.5 
P linear trend P<0.05 
Cl, confidence intervaL a Adjusted for age, sex, body mass index, serum total and HDL cholesterol, cigarette 
smoking and diabetes mellitus. Rate cat1 (per 10,000 py) =[(number of Ml events in cat1) x 10.000]/[(total n of 
subjects in cat1) x (mean survival time, cat1)]. 
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The RR of first myocardial infarction was 5.7 (95% Cl, 1.9-17.1) for a systolic 
blood pressure of 160 mmHg or higher compared with a pressure below 120 mmHg 
(P for trend < 0.0001 ). For diastolic blood pressure, the RR reached 2.5 (1.4-4.5) in 
subjects with values between 80 and 90 mmHg compared with subjects with a 
diastolic blood pressure below 70 mmHg (P for trend < 0.05). 
Subgroup analyses were carried out for subjects aged 55-69 years (mean 
62.4) and <: 70 years (maximum 99; mean 77.0) (Table 3). In both age groups, 
systolic and diastolic blood pressure were positively associated with risk of first 
myocardial infarction, but in the age group of 70 years and over, the associations 
were weaker than in the younger age group. Compared to the reference category 
(systolic blood pressure < 140 mmHg), the RR for subjects with a systolic blood 
pressure<: 160 mmHg was 3.1 (1.3-7.4) in the 55 to 69 age group versus 1.8 (0.8-
4.0) in the 70+ group. The RR for a diastolic blood pressure<: 80 mmHg compared to 
< 70 mmHg was 3.0 (1.27-6.97) in the younger group versus 2.3 (1.1-4.8) in the 
older age group. The differences in strength of the associations of systolic and 
diastolic blood pressure with first myocardial infarction between the two age groups 
were not statistically significant (P for interaction tenm=0.16 and 0.70, respectively). 
Separate analyses for men and women revealed a similar trend as observed in the 
combined group (data not shown). There was no evidence for a sex difference in the 
association of systolic and diastolic blood pressure with risk of first myocardial 
infarction (P for interaction tenm=0.61 and 0.44 respectively). Both in men and 
women, those with the lowest systolic and diastolic pressure levels had the lowest 
risk. 
75 
Table 3. Rates {per 10,000 person-years (py)J and adjusted relative risks (RR) of myocardial infarction (MI) by blood pressure category and age in subjects 
without a history of myocardial infarction and not using blood pressure lowering medication. 
55- 69 years (n=2385) 
Number of Number of Rate RR' 
Sunjects Events 
Systolic 
<140 1528 15 25 1.0 
140-159 580 16 71 2.7 
>160 278 8 77 3.1 
P linear trend P<0.005 
Diastolic 
<70 865 8 23 1.0 
70-79 828 14 43 1.9 
>80 693 17 64 3.0 
P linear trend p < 0.05 
95%CI 
1.3" 5.6 
1.3" 7.4 
0.8" 4.5 
1.3" 7.0 
dO years (n=1346) 
Number of Number of Rate RR' 
Sunjects events 
581 13 54 1.0 
476 18 95 1.7 
289 11 98 1.8 
p = 0.14 
563 12 52 1.0 
438 14 79 1.4 
345 16 122 2.3 
p < 0.05 
95%CI 
0.8" 3.6 
0.8" 4.0 
0.6" 3.1 
1.1-4.8 
Cl, confidence interval. a Adjusted for age, sex, body mass index, serum total and HDL chofesterol,cigarette smoking and diabetes mellitus. Rate cat1 (per 10,000 py) :::; 
{(number of MJ events in cat1) x 10.000]/[(tota! n of subjects in cat1) x (mean survival time, catt)]. 
Discussion 
Our data from a large cohort of older men and women showed that the risk of 
first myocardial infarction increased with increasing levels of systolic and diastolic 
blood pressure. This relationship persisted into older age. 
Results from previous studies of blood pressure and coronary heart disease in 
the elderly are inconsistent. In several studies among elderly subjects, no clear 
associations of systolic and diastolic blood pressure with coronary heart disease 
morbidity or mortality were found.7·8 In other studies, an increased mortality from 
coronary heart disease in elderly people wrth low systolic 9·10 or diastolic .,.10 blood 
pressure was observed. Only a limited number of studies reported linear 
associations in elderly subjects. A report from the Framingham Study describing men 
and women aged 65-94 years and a report from the Chicago Heart Association 
Study describing 2733 men and women aged 60-74 years documented significantly 
positive associations of systolic 3·6 and diastolic 3 blood pressure with coronary heart 
disease risk in both sexes. In addition, results from a large Norwegian study among 
52064 men and women aged 30-89 years also showed significant positive 
associations between systolic and diastolic blood pressure and coronary heart 
disease mortality, unadjusted for confounding variables• However, relative risks in 
the latter study decreased with increasing decades of age. In the 70-79 years age 
group (n = 5665), an increased risk was still present, but in the oldest age group (:?: 
80 years; n = 1302), the association disappeared4 
Several explanations for the unclear or absent associations between blood 
pressure and risk of coronary heart disease found in former studies among elderly 
cohorts have been suggested. High baseline rates of coronary heart disease 27 and 
selective survival of elderly persons with high blood pressure values who are 
relatively insensitive for the effects of blood pressure elevation 20 may have 
weakened the association. The U- or J-shaped association found in earlier studies 7-
10 may be partially explained by increased morbidity with advancing age. 15·27 
Deteriorating health may lower the blood pressure and increase the risk of death at 
the same time.12 A possible confounding effect of poor health is supported by the 
results from some recent cohort studies among subjects aged 65 years and over8 ·13-
15 In these studies, U- or J-shaped associations between blood pressure and 
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mortality from cardiovascular or all causes largely disappeared or changed into 
positive ones after excluding subjects with known prevalent diseases and/or users of 
blood pressure-lowering medication, or by excluding events occuring during the first 
years of follow-up 8 •13-15 
Only a limited number of studies examined the association between blood 
pressure and mortality from cardiovascular or all causes in the very old (over age 75 
years), while adjusting for confounding by poor health.11 '16'28 Two recent community-
based studies reported similar findings to those observed in populations of younger 
elderly, e.g. an increased all cause mortality with low systolic and diastolic blood 
pressure, which was no longer significant after adjustment for poor health indicators 
(including pre-existing cardiovascular disease, limitation in activities of daily living 
and cognitive impaimnent). 11 ·16 In one of these studies, with a mean population age 
of 90 years, diastolic blood pressure was positively related to mortality from 
cardiovascular causes after adjustment for health status-" In contrast to these two 
studies, another recent population-based study in the very old reported an inverse 
relation between blood pressure and all-cause mortality that persisted after 
adjustment for clinically significant diseases at baseline and exclusion of early 
deaths28 An explanation for their different result might be that the variables 
measured in their study do not completely account for all age-related aspects of poor 
health. 
A low diastolic blood pressure, in the presence of severe narrowing of the coronary 
arteries, may also increase the risk of death by compromising coronary blood flow 
[19,20]. Consistent with this hypothesis, Lindblad et al 18 and D'Agostino et al 17 
found that negative or U-and J-shaped associations between diastolic blood 
pressure and coronary heart disease only existed in subjects with severe ischaemic 
heart disease and not in healthy people without these diseases. However, studies 
are not consistent on this issue since J-shaped relations have also been found in 
subjects without ischaemic heart disease.19·20CJ1 
In our study of older men and women, we confimn the absence of a J- or U-
shaped relation in elderly subjects without a history of coronary heart disease. 
Instead, we observed a continuous increase in risk of first myocardial infarction with 
increasing blood pressure level. This relationship persisted into older age, although 
the relative risks were somewhat lower in the oldest group and lost significance for 
systolic blood pressure. 
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In studies among middle-aged persons, the shape and strength of the 
association between systolic and diastolic blood pressure and coronary heart 
disease has been found to be the same in both men and women. 1.4 Also in studies 
among elderly subjects, no differences in the adjusted association between men and 
women have been observed 4 •17 The results from the present study are consistent 
with those findings. 
To appreciate the findings of this study, certain methodological aspects 
should be considered. First. our study population is relatively healthy compared to 
the total elderly population for several reasons. In spite of a high response rate, older 
persons and those with health problems are less likely to participate.32 Furthermore, 
subjects living in nursing homes, in which blood pressure measurement was not part 
of the protocol, were excluded from the analyses, as well as users of blood pressure 
lowering drugs. Our findings thus apply to apparently healthy subjects from the 
general population. The relation between blood pressure and myocardial infarction 
may be different in a population including a higher proportion of elderly with poor 
health. Twelve percent of the participants were excluded from the analyses because 
of incomplete follow-up information at the time of the analyses. This group mainly 
consisted of subjects who had a general practitioner without an automated patient 
registry, changed their general practitioner during the follow-up period or moved 
outside the study district. Based on these main reasons for incomplete follow-up 
information, we expect that the loss of follow-up has not influenced the observed 
relationships, although some selection towards a more healthy population may have 
taken place. In addition, 4.8% of the participants was excluded because of missing 
data on covariates other than blood pressure. Replacement of missings by sex- and 
age-specific mean levels of co-variates showed that possible bias caused by missing 
measurements of covariates in this study was negligible. 
The number of subjects with a diastolic blood pressure above 90 mmHg is 
small in our study. This may reflect the effects of decreasing diastolic blood pressure 
with age and selective mortality of elderly subjects with high blood pressure. Thus 
the cohort barely reaches the hypertensive range for diastolic blood pressure and 
this may explain why we could not accurately assess elevated risk of myocardial 
infarction in the upper category of diastolic blood pressure in our study. 
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In this study, we used information on blood pressure levels obtained on a 
single occasion, and did not adjust estimated effects for regression dilution bias. This 
may have underestimated the true risks associated with high blood pressure 
because of large intra-individual variation in blood pressure in the elderly2 ·15·33 
Another aspect that must be considered when interpreting the results is the relatively 
short follow-up period of four years. Because of this short follow-up period, we could 
not exclude events occuring during the first years of follow-up. This may have 
reduced the real effect of blood pressure if the early events were associated with an 
underlying poor health causing low blood pressure.14·15 However, we observed a 
positive relation between blood pressure and myocardial infarction that might have 
been stronger if a potential confounding effect of poor health at baseline could have 
been adjusted for by excluding early events. 
In conclusion, the results from this prospective study of relatively healthy older 
men and women do not provide evidence for a J- or U-shaped relation between SBP 
and DBP and risk of first myocardial infarction. They suggest that the risk of first 
myocardial infarction increases with increasing level of systolic and diastolic blood 
pressure and that this relationship persists into older age. 
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CHAPTER4 
Primary prevention of cardiovascular diseases through blood 
pressure lowering: quantifying the impact of different intervention 
strategies 
Abstract 
Objective.To quantify the potential impact of different blood pressure lowering 
interventions on the primary prevention of cardiovascular diseases (CVD). 
Methods. Recent data on distribution of risk factors from two Dutch population-based 
studies, in total13,309 men and women 40 to 74 years old and free from CVD, were 
used. We used the Framingham risk function to estimate the individual 1 0-year 
absolute risk of CVD. We simulated the effects of a high-risk phanmacological 
intervention, a population-wide dietary intervention and a combination of both. In the 
phanmacological intervention, hypertensive individuals were considered to be treated 
according to current guidelines. In the dietary intervention, we hypothesized that all 
individuals complied with a healthy diet similar to the one used in the Dietary 
Approaches to Stop Hypertension (DASH) trial. 
Results. Within 10 years, 1.8% (n=6,682) of CVD events among subjects aged 40-59 
years, and 1.5% (n=7,799) of CVD events among subjects aged 60-74 years could 
theoretically have been prevented by phanmacological treatment of high-risk 
individuals. The fraction of CVD events that could theoretically have been prevented 
in the population-wide dietary intervention was 8.6% (n=32,382) and 6.5% 
(n=32,536) respectively. This yielded a total potential benefit of 10.4% (n=39,064) 
and 8.0% (n=40,335) within 10 years in the combined intervention. 
Conclusion. A high risk approach complemented by a population approach is needed 
to achieve maximal health benefit. Blood pressure lowering in the whole population 
through dietary changes is potentially an effective tool for population-wide prevention 
ofCVD. 
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Introduction 
Although the age-specific mortality rates from cardiovascular diseases (CVD) 
are decreasing, CVD are still the number one cause of death in the Netherlands.' 
Every year, over 50,000 men and women die from these diseases, which is more 
than one third of all deaths in the Netherlands.' Blood pressure is an important risk 
factor, showing a continuous, linear relationship with CVD2 This, in combination with 
the high prevalence of elevated blood pressure in the Dutch population (i.e. 10% of 
adult men and 13% of adult women had blood pressure levels '2:160/95 mmHg in 
1994),3 makes control of raised blood pressure an important strategy in the primary 
prevention of CVD. 
Blood pressure levels can be lowered through different strategies aimed at 
high risk groups only or at the total population. In a high-risk strategy focused on 
hypertensive individuals with a high absolute risk of CVD, blood pressure is mainly 
lowered by antihypertensive medication. In 2000, a revised version of the Dutch 
consensus guideline for blood pressure lowering therapy was published4 This 
guideline prescribes drug therapy to hypertensive individuals with a 20% risk of CVD 
in 10 years, taking the effects of concommitant risk factors into account4 In a 
population strategy, focused on lowering blood pressure levels in the general 
population, changes in lifestyle such as weight reduction, increase in physical activity 
and healthy dietary patterns could be induceds 
The aim of the present study is to quantify the potential impact of three blood 
pressure lowering interventions, a high-risk pharmacological intervention, a 
population-wide dietary intervention and a combination of both, on several health 
outcomes. Health outcomes included the number of people needing blood pressure 
lowering medication, the number of prevented CVD events, and the average gain in 
healthy life expectancy in the general Dutch population free from CVD. We focused 
on a healthy diet rich in fruits, vegetables and low-fat dairy products and low in salt, 
as population-wide lifestyle intervention because the effects of this intervention on 
blood pressure have been studied both in normo- and hypertensives.6·7 Furthermore, 
such a diet fits into to the general Dutch recommendations for a healthy dietary 
pattem8 and may have an additional beneficial effect on associated cardiovascular 
risk factors"'" and on diseases other than CVD such as cancer and chronic 
obstructive lung disease.12·13 
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Methods 
Simulation model 
We used a simulation model to quantify the impact of different blood pressure 
lowering interventions on various outcome parameters. The model consists of four 
steps: (1) a baseline dataset with individual data on cardiovascular risk factors; (2) a 
procedure to estimate the effects of different interventions on blood pressure; (3) a 
risk function (Framingham) to estimate the risk to develop a cardiovascular event in 
the next 1 0 years for each individual in the dataset, based on a combination of risk 
factors; 14·15 (4) and a method to calculate the occurrence of CVD in the general 
Dutch population. 
Study population and measurements 
We restricted our study population to Dutch men and women 40 to 74 years 
old, because the prevalence of high blood pressure is very low below age 40 years 
(<3%)16 and because the applied risk function is restricted to subjects below age 75 
years. 15 For subjects 40 to 59 years we used data from the Monitoring Project on 
Risk Factors for Chronic Diseases (MORGEN-project), a population-based cross-
sectional study conducted from 1993 to 1997 in the Netherlands. Yearly, a new 
random sample of men and women aged 20 to 59 years in three towns was invited." 
In total, 22,769 subjects were examined with response rates varying between 40 and 
48 percent for the different years. For subjects aged 60 to 74 years we used data 
from the Rotterdam Study, a population-based longitudinal study with baseline 
measurements from 1990 to 1993. All 1 0,275 residents of a suburb of Rotterdam. 
aged 55 years and over. were invited to participate and 7,983 (78%) subjects agreed 
to participate. 18 
In both studies, we excluded subjects with cardiovascular diseases (CVD) at 
baseline (n=474 (3.9%) in the MORGEN-population aged 40 to 59 years and n=828 
(19.7%) in the Rotterdam population aged 60 to 74 years) and subjects with missing 
values for the risk factors used (n=2.220 (16.9%) in the MORGEN-project and n=521 
(12.4%) in the Rotterdam Study). Subjects free of CVD were selected because we 
aimed to study different primary prevention strategies. The final datasets consisted 
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of 4,895 men and 5,603 women aged 40 to 59 years from the MORGEN-project and 
1,121 men and 1,690 women aged 60 to 74 years from the Rotterdam Study. 
In both the MORGEN-project and the Rotterdam Study, blood pressure was 
measured twice on a single occasion on the upper arm with the participant in sitting 
position using a random-zero sphygmomanometer. Systolic (SSP) en diastolic (DBP) 
blood pressure were recorded at the appearance (first Korotkoff phase) and 
disappearance (fifth Korotkoff phase) of sounds, respectively. In the present study 
we adjusted blood pressures levels for within-person variability. Corrected blood 
pressures were used to increase comparability with Dutch general practice, where 
elevated blood pressure is diagnosed as the average after several measurements 
during several weeks4 Corrected blood pressures were estimated according to 
equation 1 and 2 
(1) 
BP', = BP, + (BP,- BP,) • F (2) 
where S2obs. S2b, S2wb, and S2ww denote the observed variance in the population, 
between-person, within-person - between-visit, and within-person - within-visit 
variances, respectively, and BP\ BP·,, BP, and F denote the corrected blood 
pressure for individual i, the average of the two measurements for individual i, the 
average blood pressure of the population, and the shrinkage factor (S2b I S2obs), 
respectively.19 BP, was estimated using a linear mixed effect model with blood 
pressure as dependent, and smoking, totai/HDL cholesterol ratio and body mass 
index as independent variables, stratified by sex and 1 0-year age group . We used a 
value of 40 for S2 wb based on an external reproducibility study.19 Hypertension was 
subsequently defined as corrected SBP ;, 140 mmHg or corrected DBP ;,go mmHg, 
or both 5 
Non-fasting serum total and HDL cholesterol were detennined in two 
laboratories that are pennanent members of the international Cholesterol Reference 
Network. In both studies, total cholesterol was detennined enzymatically, using a 
Boehringer test-kit. 20 H Dl cholesterol was detennined after precipitation of ape-S-
containing lipoproteins with magnesium phosphotungstate21 The prevalence of 
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diabetes mellitus was self-reported or was based on a random non-fasting serum 
glucose level of <: 11.1 mmoi/L in the MORGEN-project. In the Rotterdam Study, 
prevalence of diabetes mellitus was based on the use of antidiabetic medication or a 
random or post-load serum glucose level <: 11.1 mmoi/L. In both studies, infonmation 
on current smoking behaviour was obtained with a standardised questionnaire. 
Current smokers included subjects who currently smoked one cigarette or more per 
day and ex-smokers included subjects who had quit smoking within the past year. 
lnfonmation on left ventricular hypertrophy (l VH) was not available in both studies. 
We assigned presence of LVH randomly, using the age-specific LVH prevalence of 
the Framingham Study.15 To exclude subjects with manifest CVD at baseline, 
information on history of myocardial infarction, stroke, heart operations and 
claudicatio intenmittens was obtained in both studies with a questionnaire. In the 
Rotterdam Study, subjects with a history of angina pectoris were additionally 
excluded. Subjects who said that they used drugs with the purpose to lower the 
blood pressure were considered phanmacologically treated for hypertension. In the 
Rotterdam Study, this infonmation was validated with infonmation on the type of 
medication used. 
Interventions 
We simulated a phanmacological intervention solely focused on hypertensive 
individuals, a dietary intervention focused on the total population, and a combination 
of the phanmacological and dietary intervention. We compared these interventions 
with a reference strategy of no intervention. In the reference strategy, we used the 
individual data on risk factors from the MORGEN-project and the Rotterdam Study. 
The phanmacological intervention implies that all currently untreated 
hypertensive subjects who need blood pressure lowering medication according to 
the recent Dutch consensus guideline, are detected and receive medication4 
Consistent with other recent guidelines,5•22-25 this guideline prescribes drug therapy 
to individuals with a high absolute risk for CVD. 
The dietary intervention is aimed at lowering blood pressure in the whole 
population, including both untreated and treated, and nonmo- and hypertensive 
subjects, by strict compliance with a healthy diet, in conjunction with a reduction of 
the sodium intake with 0.9 g/day, according to the Dietary Approaches to Stop 
87 
Hypertension (DASH) and the DASH Sodium tria16 ·7 The healthy diet is defined as a 
diet low in salt and rich in fruits, vegetables and low-fat dairy products and with low 
intake of saturated fat and cholesterol.6·7 The nutrient compositions of the average 
Dutch diet and of the control diet and healthy diet from the DASH (Sodium) trial are 
described in Table 1. In general, the average diet of the Dutch population was 
comparable to that of the DASH control diet. The intake of (low-fat) dairy products 
and of potassium, calcium and magnesium was however higher among the Dutch 
population. 
Table 1. Comparison of average daily intake of macro- and micronutrients, and of different food 
groups between the Dutch population and the control and intervention groups of the DASH_trial. 
Average daily intake t Dutch population :t: DASH trial§ 
Control Healthy 
diet group diet group 
Macronutrients (en%) 
Total fat 36.8 35.7 25.6 
Saturated fat 14.7 14.1 7.0 
Monounsaturated fat 12.8 12.1 9.9 
Polyunsaturated fat 6.9 6.2 6.8 
Carbohydrates 42.6 50.5 56.5 
Protein 16.3 13.8 17.9 
Micronutrients (mgld) 
Potassium 3793 1752 4415 
Sodium 3700 3500 II 2600 II 
Calcium 1050 443 1265 
Magnesium 340 176 480 
Cholesterol 230 233 151 
Food groups (gld) 
Fruits, juices and 361 385 992 
vegetables 
Fruits 139 82 281 
Juices 56 166 411 
Vegetables 166 137 300 
Total dairy 391 89 485 
Low-fat dairy 289 3 458 
Fiber 23 9 31 
DASH, Dietary Approaches to Stop Hypertension; t Values are for diets designed to provide a daily energy level 
of 2190 kcal (Dutch population) and 2100 kcal (DASH trial); t Dutch population aged 50 to 64 years26; 
§subjects aged 22 years or older {mean age 44 years)6 ; II average sodium intake in the DASH Sodium trial7 • 
In the combined pharmacological/dietary intervention, all currently untreated 
hypertensive subjects who need blood pressure lowering medication according to 
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the Dutch consensus guideline4 receive medication, and all individuals from the total 
population strictly comply with the DASH diet and reduce their sodium intake with 0.9 
g/day. We simulated that the three interventions lowered SBP because the Dutch 
consensus guideline uses SBP to estimate 10-year absolute risk of CVD4 The 
applied SBP reductions per intervention are described in Table 2. It should be noted 
that these reductions reflect those obtained in randomized controlled trials. 
Table 2. Simulated effects of the pharmacological, dietary and combination intervention on systolic 
blood pressure in normotensive and hypertensive individuals. 
Intervention 
Pharmacological :t: 
Dietary§ 
Normotensives 
Hypertensives 
Combination II 
Normotensives 
Hypertensives, not ellgible for drug therapy 11' 
Hypertensives, eligible for drug therapy 11 
Simulated reduction in SSP 
per individual (mmHg) t 
10.5 
2.7 
7.5 
2.7 
7.5 
18.0 
SBP systolic blood pressure; t compared to the reference strategy; + SSP reduction based on a meta-analysis 
of clinical trials27 and independent of baseline SBP. The SSP reduction of 10.5 mmHg reflects a true difference in 
SBP level between control and intervention group. Because the Framingham risk is defined for empirical or 
casual blood pressure levels, we transformed the true difference to the difference in tenns of empirical blood 
pressure levels. We did this by multiplying the true difference with the inverse of the shrinkage factors as 
estimated earlier in the methods section; § SBP reduction based on the DASH trial, e.g. 2.0 mmHg for 
normotensive and 6.3 mmHg for hypertensive whites. 26 The extra reduction induced by lowering sodium intake 
from 3.5 g/day to 2.6 g/day, above that of the DASH diet, is based on the DASH Sodium trial, e.g. 0.7 mmHg for 
normotensive, and 1.2 mmHg for hypertensive whites;7 II based on the assumption that the effects of the 
pharmacologocal and dietary interventions on SBP are completely additive; 1J according to the Dutch consensus 
guideline on high blood pressure;"' eligibility for drug therapy estimated befOre applying the SBP reductions. 
Calculation method of outcome variables 
The outcome variables in our study are the number of subjects treated with 
blood pressure lowering medication, the number of CVD events, and the (healthy) 
life expectancy in the general Dutch population, by gender and age group (40 to 59 
and 60 to 74 years old). We estimated the number of subjects currently treated with 
blood pressure lowering medication by using the current prevalence data on 
pharmacological treatment in the MORGEN and Rotterdam dataset. To calculate the 
number of untreated subjects that should be treated according to the Dutch 
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consensus guideline, we estimated the proportion of currently untreated individuals 
in the two datasets that met the criteria for treatment based on their current levels of 
risk factors. 
To estimate the number of CVD events for each strategy of intervention, we 
first estimated the risk to develop a fatal or nonfatal CVD event within 10 years for 
each individual in the dataset based on the Framingham risk function. 15 The risk 
function included age, SBP (i.e. the reduced SBP levels in the blood pressure 
lowering interventions), cigarette smoking, totai/HDL cholesterol ratio, diabetes and 
EGG left ventricular hypertrophy.14 All individual risks were then summed, which 
results in the expected 1 0-year incidence rate for CVD. We subsequently 
extrapolated these data to the general Dutch population using demographic data 
from Statistics Netherlands29 Comparison of CVD incidence rates estimated using 
the Framingham risk function with those based on Dutch incidence data showed 
some differences. We adjusted for these differences by applying correction factors 
on the Framingham-based incidence rates.30 
To estimate life expectancy (LE) for each strategy of intervention, we first 
estimated the number of years lived for individuals that did not develop a CVD event 
within 10 years using the life table method. Sex and age specific total mortality rates 
were derived from Statistics Netherlands for 1994.31 Secondly, for individuals that did 
develop a CVD event within 10 years, we estimated the average number of years 
lived until the event, specified to type of CVD event. To estimate healthy life 
expectancy (HLE), for each individual, we multiplied average number of years lived 
after a nonfatal CVD event by disease-specific disability weights from the Global 
Burden of Disease Study.32 Average (age-specific) number of years lived until, or 
after, a CVD event were derived from incidence data based on registries of Dutch 
general practitioners.33 To finally estimate (H)LE we summed all individual number of 
(healthy) years lived. 
To estimate the effect of blood presssure lowering on number of CVD events 
and (H)LE, the outcomes calculated in the blood pressure lowering interventions 
were subtracted from the outcomes in the reference strategy of intervention. 
To examine sensitivity of our main outcome measure to variability in the size 
of the intervention effect on SBP, we increased the applied SBP reduction by one 
mmHg and evaluated how results changed. To examine sensitivity of our main 
outcome measure to variability in the size of the strength of the SBP - CVD 
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relationship, we multiplied the regression coefficient (Framingham risk function) by 
1.10 (i.e. a 1 O% stronger relationship) and evaluated how results changed. 
Results 
Baseline characteristics of the populations from the MORGEN-project and the 
Rotterdam Study are shown in table 3. In men aged 40 to 59 years average SBP and 
DBP were higher than in women of that age. The difference in average SBP and 
DBP between men and women aged 60 to 74 years was much smaller. According to 
the WHO classification of blood pressure, 72.7% respectively 52.0% of the younger 
men and women, and 86.0% respectively 82.4% of the older men and women had 
suboptimal systolic or diastolic blood pressure levels.' The prevalence of 
hypertension according to the WHO definition was 20.2% respectively 12.5% among 
the younger, and 41.4% respectively 41.6% among the older men and women. In 
total, 22.8% respectively 16.8% of the younger men and women, and 46.1% 
respectively 48.8% of the older men and women had hypertensive blood pressure 
levels or used anti-hypertensive medication. 
Table 4 gives the number of Dutch subjects currently treated with blood 
pressure lowering medication (reference scenario), and the number of Dutch 
subjects currently untreated but needing treatment according to the Dutch 
consensus guideline for high blood pressure. More women than men are currently 
treated. In the younger age group, more men than women need treatment according 
to the consensus guideline (n=140,283 [7.5%] versus n=43,715 [2.3%]). In contrast, 
in the older age group more women than men need treatment (n=109,817 [10.6%] 
versus n=81 ,605 [11.5%]). Most untreated men and women needing treatment do so 
because of a mildly to moderately elevated SBP combined with other risk factors 
(such as smoking), leading to a 1 0-year risk of CVD exceeding 20% (Table 4). 
The estimated number of cardiovascular events in the next 10 years in Dutch 
men aged 40 to 59 years is nearly twice the number in Dutch women of the same 
age group (247,569 versus 126,897) (Table 5). In men and women aged 60 to 74 
years, the estimated number of future cardiovascular events is comparable (250,799 
versus 252,510). In the phanmacological intervention, 5,337 (2.2%) events in men 
and 1,345 (1.1%) events in women aged 40 to 59 years, and 3,382 (1.3%) events in 
men and 4,417 (1.7%) events in women aged 60 to 74 years would be prevented 
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Table 3. Mean, standard deviation and prevalence of risk factors in men and women aged 40 to 59 years from the MORGEN-projectt and in men and women 
aged 60 to 74 years from the Rotterdam Studyt. 
Risk factor 
Age (years) 
Systolic blood pressure* (mmHg) 
Diastolic blood pressure* (mmHg) 
TotaVHDL cholesterol 
Body mass index (kg/m2) 
Diabetes mellitus 
Smoking 
Blood pressure lowering medication 
Blood pressure status* 
Normal ( <130/<85) 
Optimal (<1201<80) 
High-normal (130-139/85-89) 
Mild hypertension (140-159/90-99) 
Moderate hypertension ( 160-179/1 00-1 09) 
Severe hypertension (>180/(>110) 
MORGEN-project, 
population aged 40-59 
Men Women 
(n=4895) (n=5603) 
49.3 (5.6) 49.1 (5.6) 
127.4 (13.4) 121.7 (14.5) 
81.0 (8.1) 77.3 (8.3) 
4.98 (1.70) 3.86 (1.25) 
26.1 (3.5) 25.4 (4.2) 
2.7 1.6 
33.9 34.8 
5.4 6.6 
57.3 72.0 
27.3 48.0 
22.5 15.5 
17.1 10.4 
2.6 1.9 
0.5 0.2 
Mean 
% 
Rotterdam Study, 
population aged 60-74 
Men Women 
(n=1121) (n=1690) 
66.6 (4.1) 67.0 (4.3) 
137.9 (17.6) 137.1 (18.2) 
77.1 (8.9) 75.1 (8.4) 
5.41 (1.53) 4.06 (1.52) 
25.7 (2.8) 26.7 (4.0) 
8.6 8.3 
33.4 22.3 
11.2 17.0 
35.2 35.7 
14.0 17.6 
23.3 22.7 
30.6 30.7 
8.7 9.8 
2.1 1.1 
l-ffe(;-fiom cardiovascular diseases; *on basis of blood pressure values corrected for within-subject variability in blood pressure 
Table 4. Subjects (n [%)) currently treated with blood pressure lowering medication, and subjects untreated but needing treatment according to the Dutch 
consensus guideline in the general Dutch population free of CVD, by age and sex. 
Number of treated subjects 
Dutch population Dutch population 
40 to 59 years 60 to 7 4 years 
(N=3,737,244) (N=1,750,262) 
Treatment status Men Women Men Women 
N % N % N % N % 
Currently treated 93,996 5.0 117,197 6.3 60,669 11.4 179,851 17.3 
Untreated, should be treated t* 
Criteria for treatment: 
SBP >180 mmHg or DBP >1 00 mmHg or both 28,421 1.5 15,882 0.9 15,139 2.1 11,062 1.1 
(SBP 140-179 mmHg or DBP 90-99 mHg or both) and diabetic 12,553 0.7 4,326 0.2 22,241 3.1 37,528 3.6 
SBP 140-179 mmHg and 10-yearrisk of CVD >20% 99,309 5.3 23,507 1.3 44,225 6.2 61,206 5.9 
Total untreated, should be treated 140,283 7.5 43,715 2.3 61,605 11.5 109,817 10.6 
t needing treitffient according to the Dutch consensus guideline on high blood pressure4; * on basis of blood pressure values corrected for within-subject variabiUty Jn blood 
pressure. 
Table 5. Number(%) of fatal and non~fatal cardiovascular events (prevented) in the next 10 years for the reference scenario and for the different blood 
pressure lowering interventions in the general Dutch population free of CVD, by age and sex. 
Number (%) of cardiovascular events 
Strategy of intervention 
Reference scenario 
Number(%) of cardiovascular events 
Number(%) of cardiovascular events prevented *: 
Pharmacological intervention 
Dietary intervention 
Combination of pharmacological and dietary intervention 
Men 
N 
247,569 
5,337 
20,637 
25,974 
Dutch population 
40 to 59 years 
% 
2.2 
8.3 
10.5 
Women 
N 
126,897 
1,345 
11,745 
13,090 
% 
1.1 
9.3 
10.3 
*number of cardiovascular events in reference scenario minus number of events in blood pressure lowering intervention 
Men 
N 
250,799 
3,382 
14,528 
17,910 
Dutch population 
60 to 74 years 
% 
1.3 
5.8 
7.1 
Women 
N 
252,510 
4,417 
18,008 
22,425 
% 
1.7 
7.1 
8.9 
Table 6. {Gain in) mean healthy life expectancy for the reference scenario and for the different blood pressure lowering interventions in the general Dutch 
population free of CVD, by age and sex. 
Strategy of intervention 
Reference scenario 
Mean healthy life expectancy 
Gain in mean healthy life expectancy*: 
Pharmacological intervention 
Dietary intervention 
Combination of pharmacological and dietary intervention 
*compared to the reference scenario 
Men 
339 
0.7 
2.7 
3.4 
Mean healthy life expectancy (months) 
Dutch population 
40 to 59 years 
Women 
410 
0.2 
1.7 
1.9 
Men 
163 
0.8 
3.3 
4.1 
Dutch population 
60 to 74 years 
Women 
207 
0.8 
3.0 
3.8 
within 10 years (Table 5). In the dietary intervention, more CVD events would be 
prevented than in the pharmacological intervention, both in men and women and in 
both age groups. Compared to the pharmacological intervention, the prevented 
number of cardiovascular events in the next 10 years in the combined 
phanmacologicalldietary intervention would be more than four times larger (in total 
39,064 in the general Dutch population aged 40 to 59, and 40,335 in those aged 60 
to 74). 
We evaluated sensitivity of our main outcome measure to variability in two 
parameters. Increasing the blood pressure lowering effect of the different 
interventions by one mmHg resulted in an increase in number of prevented CVD 
events of 3000 to 5000 in the different age and gender groups. Simulation of a 10% 
stronger effect of SSP on CVD risk, by multiplying the regression coefficient for SSP 
in the Framingham risk function by 1.1 0, yielded an increase in number of prevented 
CVD events of 1 000 to 4000 in the different age and gender groups. 
The gain in mean healthy life expectancy was modest for all three 
interventions and varied from almost zero for the phanmacological intervention in 
women aged 40 to 59 years (because of the low prevalence of hypertension and the 
low incidence of CVD), to four months for the combined phanmacologicalldietary 
intervention in men and women aged 60 to 74 years (Table 6). Similar results were 
obtained with respect to the gain in mean total life expectancy (data not shown). 
Discussion 
Pharmacological treatment focused on blood pressure lowering in 
hypertensive individuals with a high absolute risk of CVD, would prevent only a small 
fraction of the population burden of CVD. In this simulation study, the decline in 
number of CVD events could theoretically be at least four times larger if blood 
pressure lowering by pharmacological treatment of high-risk individuals is combined 
with a healthy dietary pattern in the Dutch population as a whole. The average gain 
in total and healthy life expectancy in the whole population due to the different 
interventions was small and ranged from zero to four months, depending on the age 
and sex of the population. 
It is important to emphasize that the present study, as any theoretical 
modelling exercise, has several limitations. First, our results are subject to variation. 
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Using sensitivity analysis, we showed that the estimated number of prevented CVD 
events was sensttive to variation in the size of the intervention effect on SBP, and to 
variation in the strength of the relation between SBP and risk of CVD. Second, two 
different datasets were used in this study, data from the MORGEN-project for the 
population aged 40 to 59 years and data from the Rotterdam Study for the 
population aged 60 to 74 years. The measurement protocols of most variables were 
comparable, but there were some differences. Because of these differences we 
should be careful in making direct comparisons between the younger and the older 
age group. Third, the results from this study relate to a Dutch population aged 40 to 
74 years and free from CVD. The generalizability of these results to those of other 
populations depends on the specific distribution of risk factors, on the CVD incidence 
rate, and on the ratio of coronary heart disease (CHD) to stroke events in those 
populations.34 Furthermore, the proportion of a population eligible for 
phanmacological treatment, and thereby the potential decline in number of CVD 
events achievable by drug therapy, depends on the proportion of currently untreated 
hypertensive individuals in that population. As the prevalence of untreated 
hypertension is high in the Netherlands compared to other countries such as the 
United States, the potential health benefit of drug therapy is expected to be large in 
the Netherlands.16·35 
We found that on the population level, a dietary intervention aimed at 
moderate population-wide reductions in SBP would prevent more CVD events than 
phanmacological treatment of hypertensive individuals with a high absolute risk of 
CVD. This result is consistent with our expectations based on the philosophy of 
Rose.36 He argued that a population-wide strategy aimed at shifting the entire blood 
pressure distribution in the population toward lower values will theoretically result in 
a larger decline in number of CVD events than a blood pressure lowering strategy 
restricted to hypertensive individuals.36 The substantial proportion of the Dutch 
population aged 40 to 74 years having suboptimal blood pressure levels, compared 
to the relatively small proportion having hypertensive levels in combination with a 
high absolute risk (63% versus 8%), and the continuous dose-response relationship 
between blood pressure and CVD risk2 explains this. 
In the present study, the average gain in healthy life expectancy (HLE) in the 
whole population was small. This may be partly explained by the fact that HLE of 
most individuals is not changed by the interventions as they remain free of 
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hypertension and CVD during their lives. However, the increase in HLE for high-risk 
individuals in which a cardiovascular event is prevented or postponed due to blood 
pressure lowering intervention may be as large as several years. A relatively small 
gain in HLE on the population level is thus compatible with a large one for high risk 
individuals. The gain in HLE may be underestimated because we only simulated the 
number of extra years lived (in health) due to prevention of CVD. However, blood 
pressure lowering may also decrease the occurrence and consequences of other 
diseases, such as dementia, 37 which was not taken into account in the calculation of 
(healthy) life expectancy. 
Several points should be noted in view of our findings. Beneficial effects of 
pharmacological treatment, both on long-term (two to six years) blood. pressure 
levels and on cardiovascular endpoints, have been well established in clinical trials38-
40 and in the population41 The potential blood pressure lowering effects of a healthy 
dietary pattern have only been established in a limited number of trials6 ·7·42•43 Their 
results are in line with those from observational studies that showed inverse 
associations of blood pressure with intake of magnesium, potassium, calcium, fiber, 
and protein.4449 In subjects with hypertension, the blood pressure lowering effect of 
a healthy diet like the DASH/reduced sodium diet is smaller in magnitude than that 
observed in trials of drug therapy (about 75% of the drug effect), but still 
substantial. 40 
The beneficial effects of the healthy DASH diet are suggested to be partly due 
to the high intake of potassium, calcium and magnesium (two to three times higher 
compared to the control diet)6 The average intake of these micronutrients in the 
Dutch population is already high compared to the intake in the control group from the 
DASH trial26 Therefore, the effect of the healthy DASH diet on blood pressure levels 
and on outcome variables is expected to be lower in the Dutch population. 
Trials on diet and blood pressure studied short-term effects on blood pressure 
(e.g. one to six months), and did not study effects on health outcomes6 ·7 In the 
present study we assumed that a dietary intervention lowers long-term blood 
pressure levels and subsequently reduces risk of CVD, based on the results of trials 
in which blood pressure was lowered by drug therapy. Possible effects of a dietary 
intervention via changes in other cardiovascular risk factors were not taken into 
account. A diet rich in fruits, vegetables and low-fat dairy products, and low in 
cholesterol and saturated fat, however, also has a beneficial impact on other 
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cardiovascular risk factors such as total cholesterol, insulin resistance, obesity and 
atherothrombotic factors like LDL-oxidation and coagulation factors.'-11 In addition, it 
may have a beneficial impact on noncardiovascular diseases such as chronic 
obstructive pulmonary diseases and cancer, 12·13 and it may restore biological 
normality.36 Furthermore, it is suggested that a reduction in dietary salt intake may 
have cardiovascular benefits by mechanisms independent from blood pressures0·51 
There is also mounting evidence from trials that antihypertensive drugs have direct 
effects on the cardiovascular system, aside from their blood pressure lowering 
effects. For example, drugs that lower blood pressure by about the same amount 
have very different effects on outcomess2 Furthermore, the HOPE trial demonstrated 
that ACE inhibitors provided profound cardiovascular benefits, with only trivial 
differences in blood pressure between the treatment and control groupss3·54 This 
means that the overall health impact of the pharmacological and dietary intervention 
is potentially larger than expected on the basis of blood pressure levels only. 
The aim of the present simulation study was to estimate numbers of 
cardiovascular events in the general population that could be theoretically prevented 
by different blood pressure lowering interventions. The practical achievable health 
benefit will largely depend on the feasibility of the different interventions in a free-
living population. Data on feasibility of blood pressure lowering interventions are 
limited however. Efficacy of drug therapy is determined by compliance of physicians 
with guidelines for detection and treatment of hypertension, and by compliance of 
patients with respect to medication use and readiness to control. Compliance of a 
whole population with the healthy diet from the DASH trial, a controlled feeding 
study, is even more difficult to achieve than compliance with drug therapy. It requires 
substantial changes in dietary habits of the public. Therefore, in every day practice 
the effects of the different intervention strategies described in this paper will be 
smaller. 
We concluded that a large proportion of the Dutch population has elevated 
blood pressure levels. Adequate detection and treatment of hypertensive patients at 
high risk is needed because they benefit most of it. Population-wide reductions in 
blood pressure by changes in diet could however potentially prevent more CVD 
events than drug treatment. The high risk approach should therefore be 
complemented by a population approach to effectively control elevated blood 
pressure in the community and to obtain maximal health benefit. 
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CHAPTERS 
General discussion 
The aim of this thesis is to provide information from observational studies as a 
basis for developing effective strategies for management of elevated blood pressure, 
and to quantify the achievable health benefit in the population by different blood 
pressure lowering interventions. In this chapter, first the main findings are 
summarised. Subsequently, the internal and external validity of the results described 
in this thesis are discussed. Thereafter the strength and shape of the relation 
between blood pressure and cardiovascular diseases (CVD) in the elderly is 
discussed. Finally, the implications of our results for public health are delineated. 
Main findings 
To study long-term persistence (<: 20 years) of the effects of blood pressure 
on mortality from coronary heart disease (CHD), i.e. whether elevated blood 
pressure levels at middle-age lead to increased risk of CHD mortality at older age, 
we used novel methodology. This methodology was based on repeated 
measurements of blood pressure over time from the Seven Countries Study (chapter 
2.1). It allowed us to separate an independent effect of past systolic blood pressure 
(i.e. near the time of two repeated measurements taken 5 years apart) on CHD 
mortality from a proxy effect through 'current' systolic blood pressure (i.e. beyond the 
latest of the two repeated blood pressure measurements). Our results suggested 
that past systolic blood pressure does not predict long-term risk of CHD mortality, 
after adjustment for a proxy effect of current systolic blood pressure, and that the 
effects of blood pressure on risk of CHD mortality are transient and reversible. 
Recently it has been questioned whether the relationship between blood 
pressure and risk of mortality from coronary, cardiovascular and all causes is strictly 
increasing.' The concept that lower blood pressure implies lower risk is derived 
mainly from the use of linear models. Using the Seven Countries Study data, we 
showed that the "linear" model was valid for the relation of systolic and diastolic 
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blood pressure with mortality from cardiovascular diseases (CVD), but not for all-
cause mortality (chapter 2.2). Higher blood pressure was related to higher risk of all-
cause mortality over the whole range of blood pressure, but this relation was not 
strictly linear, i.e. less steap at the lower end of the blood pressure distribution. 
Using data from the Seven Countries Study we showed that at identical levels 
of blood pressure, 25-year rates of mortality from CHD greatly varied among men 
(age 40-59 years) from different populations (chapter 2.3). Rates were high in the 
United States and northern Europe and low in Japan and Mediterranean southern 
Europe. However, the relative increase in long-term mortality from CHD for a given 
increase in blood pressure was similar among the populations. The overall relative 
risk of death due to CHD, adjusted for within-subject variability in blood pressure, 
was 1.28 per 10 mmHg increase in systolic and per 5 mmHg increase in diastolic 
blood pressure. 
To study the relation between blood pressure and cardiovascular endpoints in 
the elderly, we used data from two prospective studies, one carried out among men 
aged 65-84 years from Finland, Italy and the Netherlands (the Finland, Italy and the 
Netherlands Elderly [FINE] Study), and one carried out among men and women 
aged 55 years and over from the Netherlands (the Rotterdam Study). Results of the 
FINE Study indicated that elevated pulse pressure was related to an increased risk 
of CVD mortality. Considering each pressure individually, neither systolic nor 
diastolic blood pressure were significantly related to mortality from CVD in elderly 
men from the FINE Study (chapter 3.1). Results from the Rotterdam Study 
suggested that increasing levels of systolic and diastolic blood pressure were 
associated with incneasing risk of first myocardial infarction and that this relationship, 
though weaker, persists into older age (chapter 3.2). In both studies among relatively 
healthy elderly populations we found no evidence for an increased CVD risk at low 
levels of systolic and diastolic blood pressure. 
We quantified the potential impact of different blood pressure lowering 
interventions on the primary prevention of CVD and on healthy life expectancy in the 
Netherlands with a simulation model (chapter 4). Within 10 years, 1.8% (n=6,682) of 
CVD events among subjects aged 40-59 years, and 1.5% (n=7,799) of CVD events 
among subjects aged 60-74 years could be theoretically prevented if all high-risk 
individuals were adequately treated pharmacologically according to the revised 
Dutch consensus guideline. 2 The fraction of CVD events that could be theoretically 
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prevented with a dietary intervention, aimed at population-wide compliance with a 
healthy diet, would be 8.6% (n=32,382) and 6.5% (n=32,536) respectively. If the high 
risk approach would be complemented by the population approach, this could yield a 
total prevented fraction of CVD events of 10.4% (n=39,064) and 8.0% (n=40,335) 
within 10 years. The average gain in total and healthy life expectancy in the whole 
population due to the different interventions was small and ranged from zero to four 
months, depending on the age and sex of the population. 
Methodological considerations 
Several methodological issues deserve attention. First, we discuss the internal 
validity of the results presented in this thesis. Internal validity is the extent to which 
the results are valid for the target population. It may be influenced by selection bias, 
within-person variability in blood pressure, measurement method of endpoints, and 
confounding. Second, the external validity or generalizability of our results is 
discussed. 
Internal validity of results 
Selection bias 
Selection bias results from procedures used to recruit subjects for a study, 
that lead to an effect estimate among subjects included in the study which differs 
from the true estimate in the entire target population.3 In the Seven Countries Study 
among middle-aged men (chapter 2), the average response rate was very high 
(>90% ), with several cohorts reaching participation rates of almost 1 00%. 
Furthermore, the fraction of subjects excluded from the analyses because of CHD at 
enrollment (1.9%) or missing data (3.4%) was small (5.3%). Therefore, it is not likely 
that selection bias has infiuenced relative risk estimates in the studied middle-aged 
cohorts. 
In the studies among elderly cohorts described in this thesis, the Rotterdam 
Study and the FINE Study, the target population was the general elderly population 
(chapter 3). The final study populations were, however, confined to apparently 
healthy subjects from the general elderly population, due to self-selection of subjects 
105 
and post-hoc exclusion criteria. First, in spite of relatively high response rates (70% -
94%), older persons and those with health problems were less likely to participate in 
both studies4 ·5 Secondly, in both studies we excluded subjects with diagnosed 
clinical manifestation of the endpoints of interest at the baseline examination and 
users of antihypertensive drugs (reasons for exclusion: see 'confounding' on page 
110 and 111). Thirdly, in the Rotterdam Study subjects living in nursing homes and 
subjects with incomplete follow-up at the time of the analysis were excluded. The 
latter participants were on average older and had lower blood pressure levels. Due 
to these selections, exclusion from the two study populations was related to health 
status. It is likely that excluded subjects had more progressive states of 
atherosclerosis. As this 'health-related' exclusion from the final study population in 
both studies may be related to blood pressure status independent of its relation to 
the outcome, relative risk estimates may not be valid for the general elderly 
population. However, results are judged to be valid with respect to the role of blood 
presure in the etiology of CVD in apparently healthy subjects from the general elderly 
population, without manifest CHD and extensive atherosclerosis. 
Selective survival may partly explain the observed lower relative risks at older 
age compared to younger age in both the Rotterdam Study and the FINE Study.S·7 In 
the FINE Study, only 43% of the men who already had elevated blood pressure or 
cholesterol levels at middle-age survived until the baseline examination of the 
present study. These men who were still alive at old age, were possibly less 
susceptible to CVD and may have a similar risk for CVD as those with normal levels. 
Whereas those with high levels of risk factors who are susceptible for CVD, are more 
likely to have died before reaching old age. 
Within-person variability in blood pressure 
Successive measurements of blood pressure of individual subjects vary 
substantially over time, as a result of both random variation and systematic effects8 •9 
Random within-person variability includes classical measurement error from 
imperfect instruments or observers and biological variation over time due to recent 
diet, ambient temperature, and so on.10 An example of a systematic effect is white 
coat hypertension, i.e. an individual's blood pressure level is elevated when 
measured in the medical environment (due to anxiousness) but not when measured 
ambulatory. 11 
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For random within-person variability, the average value of many repeated 
measurements will approach an individual's true exposure level, which is frequently 
considered as that person's long-term average or usual level.9 For systematic within-
person effects, the average value of many repeated measurements will not approach 
an individual's true level. To reduce within-person variability in casual blood pressure 
measurements, standardized methods were used to measure the blood pressure in 
all studies in this thesis. In these studies systolic and diastolic blood pressure were 
measured twice at the baseline examination with a sphygmomanometer, on a single 
occasion. In addition, in the Seven Countries Study and in the FINE Study 
standardized measurements were repeated after several years. Despite use of 
standardized measurements, much of the within-person variability in repeated blood 
pressure measurements persists under usual conditions of observation.12 
The effect of random within-person variability is generally to bias relative risks 
estimates toward the null values.10·13-15 This effect is described by the term 
'regression dilution', i.e. the attenuation in a regression coefficient that occurs when 
a single measurement of blood pressure is used instead of the usual or average 
value over a period of time. 15 In this thesis, we corrected relative risks for the effect 
of random within-person variability in blood pressure by relating baseline 
measurements of blood pressure to replicate measurements at five year (chapter 4: 
one year) follow-up. For statistical correction there is no need to distinguish between 
the various sources of random variation, since the effects on associations are the 
same if the long-term average exposure over several years is of interest9 This was 
the case in the studies described in this thesis. In the Rotterdam Study (chapter 3.2), 
relative risks estimates were not corrected for the effect of random within-person 
variability in blood pressure. The magnitude of the dilution in regression coefficients 
that has occurred due to use of single blood pressure measurements in the 
Rotterdam Study depends on the ratio of within-person variability to variability 
between subjects. This ratio is suggested to be larger at old compared to middle-
age8 
Random within-person variability leads to overestimation of the prevalence of 
hypertension.16 We corrected the prevalence of hypertension for the effect of random 
within-person variability in blood pressure by using correction factors based on 
repeated blood pressure measurements (chapter 4). These factors were partly 
derived from an external reproducibility study. Klungel et al showed that the 
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(remaining) overestimation of hypertension that occurs after this type of correction is 
only in the order of 4-12%H Therefore, we do not expect to have seriously 
overestimated the number of untreated hypertensives in the Netherlands needing 
phanmacological treatment according to the revised guideline, 2 and consequently, 
the number of CVD events that can be theoretically prevented by treatment of this 
high-risk group. 
Systematic within-person effects may bias relative risk estimates in any 
direction, depending on the nature of the systematic error and on whether the 
direction and magnitude of the systematic error affects subjects non-randomly9 In 
case of blood pressure measurement, some elements of systematic within-person 
effects are likely to exist and can seldom be corrected for. Especially in the elderly 
cohorts studied in this thesis (chapter 3), increased arterial stiffness and diminished 
reactivity of the baroreceptor reflex are factors accounting for systematic within-
person effects in blood pressure. They may lead to pseudohypertension (falsely 
increased SBP as detenmined by the sphygmomanometer) respectively white coat 
hypertension, 1s-20 and are likely to have underestimated relative risk estimates in the 
elderly cohorts. Furthenmore, in the Rotterdam Study, diastolic blood pressure may 
have been systematically underestimated in elderly subjects with thin arms (anm 
circumference < 24 em), due to use of too large a cuff size in these subjects (only 
one standard cuff size of 14 em x 38 em was used in this study)-' Especially in 
elderly cohorts it is likely that underweight is related to health status. 21 If DBP was 
mainly underestimated in a subgroup of elderly subjects with thin anms due to 
underlying illness, this may have reduced the real effect of DBP in the Rotterdam 
Study (chapter 3.1). However, we observed a positive relation between DBP and 
myocardial infarction that might have been even stronger if a potential confounding 
effect of systematic measurement error had been avoided. 
In chapter 4, the prevalence of hypertension in Dutch subjects aged 60-74 
years may have been underestimated as it was also based on DBP levels from the 
Rotterdam Study. Consequently, the number of untreated hypertensives in the 
Netherlands needing phanmacological treatment according to the revised guideline,2 
and the number of CVD events that can be theoretically prevented by treatment of 
this high-risk group may have been underestimated. 
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Measurement of endpoints 
In all studies described in this thesis, standardized methods were used to 
measure fatal and nonfatal endpoints. Because the prevalence of comorbidity is high 
in the elderly, proper diagnosis of (nonfatal) CVD is difficult in this age group.7·19 In 
the Rotterdam Study, the endpoint was a fatal or nonfatal myocardial infarction (MI), 
including silent Ml defined by ECG measurements in the absence of symptoms. 
Therefore, the prevalence of unrecognized Ml is expected to be low in the Rotterdam 
Study and was probably not a major concern. 
In the Seven Countries Study and the FINE Study, the enpoint was only 
mortality (from CVD and all causes). Also in case of these 'hard' endpoints, however, 
fatal CVD cases may have been misdiagnosed, especially in the elderly due to the 
high prevalence of comorbidity. We used only CVD as primary cause of death. In 
case of multiple causes, we used a hierarchical method to code final causes of death 
in the following order: violent causes, cancer CHD stroke and other causes. This 
may have lead to underestimation of the true number of CVD deaths in the Seven 
Countries Study and the FINE Study. 
Confounding 
In the etiologic relation between blood pressure and endpoints, a confounder 
is a factor that is related to both blood pressure and the outcome and is not an 
intermediate in the causal pathway between both.3 A confounder is, at least in part, 
responsible for the apparent association between blood pressure and endpoints-" As 
confounding leads to biased estimates,3 we adjusted in the statistical analyses for 
known confounders. It was not always possible to control for all known confounders. 
For the male population of the Seven Countries Study for instance (chapter 2), no 
information on the prevalence of diabetes was collected at the enrollment period of 
the Seven Countries Study in the 1960's. Information on the medical history of 
diabetes was however collected at 1 0-year follow-up in all countries except the 
United States. The prevalence of a medical history of diabetes was low after 10 
years in the Seven Countries Study and varied from 1.9% to 5.2% among the 
different populations. Furthermore, the estimated relative risks of death due to CHD 
for the 10 to 25-year follow-up period, taking 1 0-year data as the baseline, did not 
differ before and after adjustment for diabetes. Both the low prevalence of diabetes 
109 
and this similarity in relative risk estimates suggest that diabetes did not influence 
the observed relations. 
Use of antihypertensive medication acts as a confounder of the relation 
between blood pressure and CVD, as it is related to blood pressure level and may be 
associated with CVD independently of blood pressure.22-24 This may lead to the -
mistaken - belief that adjustment for antihypertensive therapy (e.g. by means of 
multivariate regression methods, or by stratification) will lead to a correct estimate of 
the effect of blood pressure on CVD. In observational studies, allocation to (type and 
intensity of) drug therapy is not random and depends, besides current blood 
pressure level, on other factors "X" that may be independent predictors for CVD.25 
These, at least partly, unmeasured factors include past (pretreatment) blood 
pressure and (family) history of CVD.2 Treatment is thus affected by both current 
blood pressure and factors "X". Adjusting for such "collision nodes" (here: treatment) 
induces (rather than removes!) an association between "X" and blood pressure. The 
association between blood pressure and CVD is therefore affected by confounding 
by indication-'6 In this case, statistical methods used to control for confounding by 
adjusting for medication use (yes/no) do not adequately deal with the bias introduced 
to the effect estimate-'7 In the Seven Countries Study, information on the use of 
antihypertensive drugs was not collected at the baseline survey. However, during the 
period 1958 to 1964 these drugs were rarely prescribed in the seven countries. We 
could not adjust for initiation of antihypertensive therapy during later years of follow-
up in the Seven Countries study. Similarity of relative risk estimates for 10-year CHD 
mortality to those for 25-year mortality, however, suggests that this has not 
influenced the observed relationships (see discussion chapter 2.3). 
In the elderly cohorts from the Rotterdam Study and the FINE Study (chapter 
3), we chose to exclude users of antihypertensive medication at the baseline survey. 
Reason for this was the high prevalence of antihypertensive drug use among this 
age group, and the consequently large potential bias that could not be adequately 
adjusted for. In the Italian cohorts of the FINE Study, only information was available 
on the use of blood pressure lowering drugs used for treatment of hypertension. 
These drugs can also be used for other indications but this information was not 
available. This may have biased estimates of relative risk in the Italian cohorts. In the 
FINE Study, we could adjust for initiation of antihypertensive therapy during later 
years of follow-up by including a time-dependent medication variable in the analysis. 
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Results remained similar after this adjustment. In the Rotterdam Study, we did not 
adjust for initiation of drug therapy during follow-up. This may have lead to 
underestimation of the relative risk estimates from this study. 
In the elderly, underlying poor health and comorbidity may also lead to a bias 
in the relation between blood pressure and outcome as they may be related to both 
reductions or increases (e.g. diabetes) in blood pressure as well as an increased risk 
of cardiovascular deaths2 s-32 Comorbidity is defined as the co-existence of 
diagnosed or undiagnosed diseases other than CVD such as cancer and diabetes.7 
Comorbidity is very common in elderly people. In the FINE Study, we adjusted for 
confounding by comorbidity and underlying poor health in two ways. We included 
several measured indicators of ill health as additional covariates in the statistical 
analysis, and we excluded deaths occurring during the first two years of follow-up. In 
the Rotterdam Study, we could not exclude early events because of the short follow-
up period of four years. 
The presence of CVD at the baseline survey may act as a confounder, effect 
modifier or intermediate variable in the relation between blood pressure and CVD. In 
the first case, it is suggested that pre-existing CVD cause both reductions in blood 
pressure (through weight loss or some other metabolic disturbance caused by the 
disease) and excess (recurrent) cardiovascular events.33 This may effect the 
strength and nature of the relationship. In case of an effect modifier, the effect of 
blood pressure on cardiovascular endpoints varies among individuals with and 
without pre-existing CVD-" Though this may be a plausible hypothesis (see page 113 
first paragraph), the numbers of events in the groups with prevalent CVD were too 
small in the studies described in this thesis to study the effects of blood pressure 
within these groups. In case of an intermediate variable, presence of CVD is an 
intermediate step in the causal path between blood pressure and risk of (recurrent or 
fatal) CVD-" For instance, an individual's current blood pressure level has lead to 
presence of myocardial infarction (at the baseline survey), and this subsequently 
increases risk of a future recurrent (fatal) myocardial infarction. Adjustment for 
presence of myocardial infarction in this situation will attenuate the observed 
associations. As blood pressure largely infiuences endpoints via cardiovascular 
mechanisms, we chose to exclude subjects with CVD in all studies described in this 
thesis. 
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Proper diagnosis of both cardiovascular and non-cardiovascular diseases in 
the elderly is difficult for several reasons7 ·19 Due to lower pain perception related to 
autonomic dysfunction, the prevalence of unrecognized clinical diseases is high in 
the elderly.19 As an example, the high prevalence of silent myocardial infarction in 
the elderly may be the result of an increased pain threshold for angina. 19 Confusion 
and dementia, and the belief of some elderly people as well as clinicians that a 
certain degeneration in their health is a normal concomitant of aging, may also 
contribute to a high prevalence of undiagnosed disease. 19 With respect to diagnosis 
of CVD, frequent concomitant diseases (pulmonary, gastrointestinal, or 
musculoskeletal disorders) may mask CVD-related symptoms. Due to this high 
prevalence of undiagnosed and thus unmeasured disease, resulting in residual 
confounding, relative risk estimates for the elderly cohorts described in this thesis 
are likely to have been underestimated. 
External validity of results 
External validity refers to the generalizability of the results. The Seven 
Countries Study (SCS) and the Fl NE Study were confined to men. Women were not 
included in these studies because at the initiation of the SCS around 1960, CHD was 
viewed as a major health problem of men but not of women. Other large 
observational studies among middle-aged and elderly populations, in which both 
men and women are included, indicate that the shape and strength of the relation 
between SBP and DBP and cardiovascular endpoints is similar in men and 
women.34•35 We therefore do not expect that the observed relative effects are 
different in women. Consistent with this expectation, we found similar relative risk 
estimates among the older men and women in the Rotterdam Study. 
The absolute effect of blood pressure on CHD, i.e. the rate difference or 
absolute number of excess CHD events due to elevated blood pressure, is generally 
higher in men than in women.36·37 This can be explained by higher CHD incidence 
rates in men compared to women in most westernized countries.38 In the Rotterdam 
Study, the observed difference in incidence rate of myocardial infarction (per 10,000 
person years) between the highest and lowest blood pressure categories was 
however similar in men and women. This was possibly due to the small number of 
events per blood pressure category, resulting in imprecise rate estimates. 
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We confined all our studies to subjects without manifest CVD at baseline. 
Moreover, our studies among elderly subjects were carried out in apparently healthy 
subjects from the general elderly population due to several selections (selections: 
see page 105, section 'selection bias', second paragraph). Whether our results are 
generalizable to less healthy subjects with severe atherosclerosis and overt CVD 
remains to be established. Results from most large observational studies among 
middle-aged and elderly populations suggest that the relation between blood 
pressure and cardiovascular endpoints is similar in subjects with and without 
ischaemic heart disease.13•32·35·39 In several studies among middle-aged and elderly 
populations, however, negative or U-shaped relations between DBP and CHD were 
found in subjects with severe ischaemic heart disease, but not in healthy people 
without these diseases.40•41 It is suggested that this is not a treatment-induced causal 
relation as it was observed both in treated and untreated subjects4 0-43 An 
explanation could be that in subjects with ischaemic heart disease, a low DBP can 
add to increased cardiovascular risk by decreasing coronary perfusion pressure and 
thereby decreasing cardiac oxygen supply.44 In healthy subjects without 
atherosclerosis, a decreased coronary perfusion pressure can be compensated by 
coronary vasodilatation. In subjects with coronary atherosclerosis, however, the 
vasodilatory reserve is limited and a decreased perfusion pressure, in these 
circumstances, can lead to decreased oxygen supply.45 
Results in this thesis concerning elderly populations mainly apply to subjects 
younger than 80 years of age. The observed relationships of blood pressure with 
cardiovascular endpoints may be different in subjects older than 80 years of age. In 
two observational studies, however, similar results were found among elderly 
subjects below and above the age of 75.28·35 Data confined to very old cohorts, that 
adjusted for confounding effects of poor health, are scarce and conflicting.29•31 ·46 Two 
recent community-based studies reported similar findings as observed in populations 
of younger elderly, i.e. an increased all cause mortality with low systolic and diastolic 
blood pressure, that was no longer significant after adjustment for poor health 
indicators (including preexisting cardiovascular diseases, limitation in activities of 
daily living and cognitive impairment).29•31 In one of these studies, in elderly with a 
mean age of 90 years, diastolic blood pressure was positively related to mortality 
from CVD after adjustment for health status.29 In contrast to these two studies, 
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another population-based study in very old subjects reported an inverse relation 
between blood pressure and all-cause mortality that persisted after adjustment for 
clinically significant diseases at baseline and exclusion of early deaths46 An 
explanation for these different results could be that the variables measured in the 
latter study did not completely account for all age-related aspects of poor health. To 
date, the role of potential confounding factors that might explain this paradoxical 
relationship in the very old is however not fully established.47 A possible true 
modification of age on the impact of blood pressure on health outcomes can not be 
excluded.30 It must be emphasized that the endpoint in the 'very elderly' studies was 
(cardiovascular and all cause) mortality, and not nonfatal cardiovascular morbidity. 
In chapter 4 we estimated that more than 79,000 first CVD events could be 
theoretically prevented within 10 years in the CVD-free Dutch population (age 40-
74), if all individuals in that population complied with a healthy diet, and if all high-risk 
individuals were adequately treated pharmacologically according to the revised 
Dutch consensus guideline2 The number of (recurrent) non-fatal and fatal CVD 
events that could be theoretically prevented by effective lifestyle intervention and 
drug therapy in the whole population, including those with established CVD, is 
expected to be much higher. This can be explained by the enlarging pool of patients 
with CVD (20% of the 60-74 year aged Dutch population), including coronary 
patients, due to ageing populations, and the improving prognosis of coronary 
patients due to more effective treatments for acute coronary heart disease, 
revascularization and use of prophylactic drug therapies.48 Results of the second 
EUROpean Action on Secondary Prevention through Intervention to Reduce Events 
(EUROASPIRE II) survey, undertaken in 15 countries including the Netherlands, 
showed a high prevalence of unhealthy lifestyles, modifiable risk factors and 
inadequate use of drug therapies among coronary patients49 Among the Dutch 
population of coronary patients for instance, 52% had hypertension (~140/90 
mmHg), and less than half of those pharmacologically treated for this condition had 
their blood pressure levels controlled (<140/90 mmHg)49 There is thus considerable 
potential to further reduce CHD morbidity and mortality in the general population 
through more effective interventions in patients with established CVD, who are at 
increased risk of CHD and will benefit most of prevention. 
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Relation between blood pressure and CVD in the elderly 
In middle-aged adults, the relationship between SSP and DSP and risk of 
CVD has been characterized as 'continuous, graded, strong, independent and 
etiologically significant'.13·50 Several studies in older subjects (<:65 years) have raised 
questions about the strength and shape of the association in this age group. Results 
from several observational studies have suggested that the relation of SBP and DSP 
with cardiovascular endpoints and with all-cause mortality is attenuated or even 
absent in the elderly.35·37·51 ·52 Moreover, in several studies among elderly cohorts it 
was concluded that risk of mortality from cardiovascular and all causes was 
increased at low levels of blood pressure compared to intermediate levels, showing 
J- or U-shaped relationss:>-ss Furthermore, several other studies in older subjects 
emphasized the importance of pulse pressure, which combines the effects of both 
high SSP and low DSP, as a predictor of CVD.32·34·56·57 Age-related changes in blood 
pressure may play a role in changing relationships between blood pressure and CVD 
with age. In this paragraph, we will first describe these age-related changes in blood 
pressure. Thereafter, we will discuss the observed relations between blood pressure 
and cardiovascular outcomes among the elderly cohorts in this thesis (chapter 3) in 
light of the literature. 
Age-related changes in blood pressure 
Average SBP in most Western populations rises linearly with age until the 
eigth or ninth decade in both men and women. 56 Average DSP also shows a gradual 
but less steep rise with age until the age of approximately 55 years in both men and 
women and subsequently declines. 56 As a consequence, average pulse pressure ( = 
SBP minus DSP) increases progressively with age and the rate of rise accelerates 
after age 50 years. 56 The rise in SSP and DBP with age up to age 55 years is due 
mainly to increasing peripheral vascular resistance. The continuous rise in SSP after 
age 55 is due primarily to increased stiffness of the large arteries, though increased 
peripheral vascular resistance still contributes. The decrease in DBP after age 55, 
and the associated steep rise in pulse pressure, are also primarily due to an increase 
in large artery stiffness.58 This makes increased pulse pressure and decreasing DSP 
indicators for large artery stiffness after age 55.58 Factors that contribute to the 
increase in peripheral vascular resistance with aging are increased thickness of the 
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arterial intima and media and decreased elasticity of the connective tissues• It is 
suggested that large artery stiffness is caused by increased collagen and calcium 
deposition in the large arteries in combination with a decreased elasticity of the 
connective tissue.58 Hypertrophy of the smooth muscle cells in the medial layers of 
the arteries also contributes to the increase in large artery stiffness with aging.60 
Blood pressure- CVD relation in the elderly 
In this thesis, using data from two population-based studies among elderly 
subjects, we found no evidence for J- or U-shaped relations of SBP and DBP with 
endpoints. In contrast, results from the Rotterdam Study suggested that increasing 
levels of SBP and DBP were associated with increasing risk of first myocardial 
infarction and that this relationship, though weaker, persists into older age. Results 
of the FINE Study indicated that neither systolic nor diastolic blood pressure were 
significantly related to mortality from CVD in elderly men, when viewing each 
pressure individually. However, elevated pulse pressure was related to increased 
CVD mortality in the FINE Study. This is in line with the literature.32•34•56·57·61 Several 
mechanisms may explain the relation between pulse pressure, as an indicator of 
large artery stiffness, and CVD. Several cross-sectional studies unifonmly showed 
increased large artery stiffness in subjects with previous CVD.62-65 Large artery 
stiffness increases afterload leading to an increase in cardiac oxygen demand. 62-66 
Furthermore, it is associated with atherosclerosis 6s.69 and with decreased cardiac 
oxygen supply.62 This may increase risk of ischaemia in subjects with increased 
large artery stiffness as their coronary arteries can not compensate for the 
decreased cardiac oxygen supply.70 Large artery stiffness is also strongly correlated 
with left ventricular hypertrophy, a known risk factor for cardiovascular events_,' 
Several factors may explain reduced or J- and U-shaped relations of SBP and 
DBP with cardiovascular outcomes found in previous studies, and lack of a 
significant relation observed in the FINE Study. Selective survival (see last 
paragraph section 'selection bias', page 1 06) and high baseline rates of 
cardiovascular events may have weakened the associations in the elderly_, In 
addition, a high prevalence of comorbidity and incomplete adjustment for the 
confounding effects of co-morbidity may partially explain unclear or J/U-shaped 
associations. Comorbidity and underlying deteriorating health may cause both 
reductions in blood pressure and excess events2 8-32 In a large number of studies, 
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J/U-shaped relations disappeared or changed into positive ones by excluding 
subjects with known prevalent CVD or subjects who used blood pressure lowering 
medication, excluding events occuring during the first years of follow-up, or by 
including several health-related factors as covariates into the statistical model.2s-
30·51·54·55 A summary of large observational studies (n>1 000) that adjusted for 
comorbidity and health status is given in table 1. 
Based on the consistent results of the studies from table 1, it is concluded that 
SBP remains an important risk factor for CHD and for CVD and all-cause mortality in 
the elderly, showing higher risk at higher levels of SBP. Results from observational 
studies are confirmed by a meta-analysis of clinical trialsn This meta-analysis 
showed significant reductions in stroke, coronary events, and in CVD and all-cause 
mortality by antihypertensive drug treatment in elderly patients with isolated systolic 
hypertension. Our finding from the Rotterdam Study concerning SBP and risk of 
myocardial infarction in the elderly is in line with the evidence from observational 
studies and trials. 
The literature is not conclusive on the relation of DBP with cardiovascular 
endpoints and with all-cause mortality, also when the studies were restricted to those 
that adjusted for poor health (table 1 ). Some studies reported positive 
relations,28·34•37•57 but others found no or J/U-shaped relations32·35·55 Currently it is 
strongly suggested that, at least in elderly subjects without severe atherosclerosis 
and ischaemic heart disease, a /ow DBP is not causally related with an increased 
risk of CVD. There is mounting evidence that underlying large artery stiffness and 
increased comorbidity lead to a decline in DBP and are the primary factors causing 
increased cardiovascular risk, with low DBP being mostly a secondary 
phenomenon32·56 This may also partly explain the discrepant results with respect to 
the effect of elevated DBP. That is, studies that found increasing risk at increasing 
levels of DBP may have been less confounded by low DBP due to large artery 
stiffness. Whereas in studies that found no positive relation between DBP and CVD, 
relations may have been masked by a considerable number of subjects with an 
increased cardiovascular risk in combination with a low DBP due to large artery 
stiffness. Results from two large observational studies support this hypothesis. 
Researchers from the Framingham Study reported a positive relation between DBP 
and risk of CHD.34 The number of subjects with a low DBP together with a high SBP, 
i.e. with an elevated pulse pressure indicating large artery stiffness, was however 
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Table 1. Summary of observational studies (n>1000) on the relation between blood pressure and mortality from cardiovascular and all causes in elderly 
subjects that adjusted for ~Of!l!?L~!Ql!t and health status. 
Study Reference No. Age Follow- Fatal No. of Relation Analysis Excluded from 
up Endpolnt(s) Events Blood pressure- endpoint Adjusted the analysis 
for 
SBP DBP pp 
years mmHg 
East Boston Senior Glynn ea 3657 :2:65 10.5 CVD 567 + + n.a. a,b,c,d,e,f,g,h.i 
Health Project 199528 .j.k 
All causes 1223 + + (n.s.) n.a. a,b,c,d,e,f,g,h.i 
.j.k 
Norway Vatten ea 18022 :2:65 6 All causes 4700 men: 0 u n.a. a,c,e,l,m 1, 2 
199555 women: 0 0 n.a. a,c,e,J,m 1, 2 
SPAA Alllea 3858 :2:65 10 CVD 709 + 0 n.a. a,b,c,d,e,g,j,k, no exclusions 
199935 l,n,o,p 
All causes 1561 + 0 n.a. a,b,c,d,e,g,j,k, no exclusions 
l,n,o,p 
Framingham Heart Franklin ea 1924 50-79 14.3 CHD* 433 + + + a,b,c,d,l,q 2,3 Study 199934 
EPESE Glynn ea 9413 :2:65 10.6 CVD 2304 + 0 + a,b,c,d,e,f,g,h, no exclusions 
200032 i,j,k,t 
All causes 4528 + 0 + a,b,c,d,e,f,g,h, 
i,j,k,t 
no exclusions 
The Cardiovascular Psaty ea 5888 ?:65 6.7 
Health Study 2001 57 
Ml* 572 + + + a,b,d,e,l no exclusions 
Stroke* 385 + + + a,b,d,e,l no exclusions 
All causes 896 + 0 0 a,b,d,e,l no exclusions 
CVD cardiovascular diseases, Ml myocardial infacrtlon, SPAA Studio su\la Presslone Arteriosa neii'Anziano, EPESE Established Populations for Epidemiologic Studies of the 
Elderly; +positive relation, 0 no relation, U U-shaped relation; n.a. not applicable; a age, b sex, c body mass index, d smoking, e history of CVD, f history of cancer, g use of 
antihypertensives, h activities of daily living, i physical function, j activity level, k use of alcohol, f diabetes, m self-assessed health, n cognitive impairment, o history of 
hypertension, p frailty, q total cholestero!IHDL ratio; 1 events occuring during first years of follow-up, 2 use of antihypertensives 3 CVD history; *fatal and non-fatal;t relation 
between diastolic blood pressure and endpoint additionally adjusted for pulse pressure 
very low (n=39) in that study. In contrast, researchers from the EPESE Study found a 
U-shaped relation between DBP and mortality from CVD and all causes.32 The 
number of subjects with an elevated pulse pressure, and thus the number of subjects 
with a low DBP probably due to large artery stiffness, was much larger in this study 
(n=571 ). Moreover, in the latter study the U-shaped relation disappeared after 
including pulse pressure as a suggorate measurement for large artery stiffness into 
the statistical model. This finding suggests that underlying large artery stiffness at 
least partly explains the unclear relation of DBP with endpoints in elderly 
populations. 
In conclusion, it is suggested that, at least in elderly subjects without severe 
atherosclerosis and ischaemic heart disease, increasing DBP is related to increased 
cardiovascular risk. The positive relation of DBP with risk of myocardioal infarction in 
the Rotterdam Study described in this thesis is in line with the evidence from 
literature. Further support that elevated DBP remains a cardiovascular risk factor in 
the elderly comes from the Hypertension Optimal Treatment (HOT)-trial.73 Results 
from this trial showed that a gradual reduction in risk of stroke and cardiovascular 
events occurs when lowering DBP from 105 mmHg to at least 80-85 mmHgJ3 
Public health implications 
In clinical medicine a high risk approach to CVD prevention is generally 
favored. Mainly patients with severe hypertension and patients with mild or moderate 
hypertension who have a high short-term absolute risk to develop CVD, i.e. 20% or 
more within 10 years, are treated. Most individuals have however average, mildly or 
moderately elevated blood pressure levels and a short-term absolute CVD risk less 
than 20% within 10 years. The greater part of these individuals with suboptimal blood 
pressure levels will not be eligible for treatment in a high risk strategy. As any 
increase in blood pressure is associated with an increase in the relative risk for CVD, 
however, these individuals do have an increased CVD risk. These associations and 
the large number of individuals with blood pressure levels above optimal (who will 
not be targeted by clinicians) indicate that the avoidable burden of CVD among this 
group is considerable.36'74 A population strategy, aimed at moderate blood pressure 
reductions in the population as a whole, will therefore have a much larger potential 
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for reducing the burden of CVD in our population than a high risk strategyJ5 Small 
population-wide reductions of blood pressure and subsequent reduction in CVD 
mortality may be achieved by stimulating lifestyle changes, such as changes in diet 
and increased physical activity, in the total population. This can be illustrated by the 
remarkable decrease in CHD mortality in Finland during the period 1972 to 1992, 
that occurred at the same time as reductions in major risk factors such as blood 
pressure, cholesterol and smoking. A reduction in the consumption of salt and 
saturated fat and a substantial increase in the consumption of vegetables and fruit in 
Finland starting in the early 1970s have been important determinants.76·77 
Using statistical modeling we showed that within 10 years, at least four times 
as much (i.e. 64,918 versus 14,481) CVD events could theoretically be prevented in 
the Netherlands by a population-wide dietary intervention, compared with drug 
therapy confined to high-risk individuals (chapter 4). A high risk approach should 
therefore be complemented by a population approach to achieve maximal health 
benefit for the total population. 
The health benefit that can be achieved in practice will largely depend on the 
feasibility of the interventions in a free-living population. Adequate management of 
hypertensive individuals with a high absolute risk depends on several factors. First, it 
depends on the sensitivity and specificity of detection of hypertension by physicians. 
According to the revised Dutch hypertension guideline, physicians are recommended 
to measure blood pressure only in patiens with an increased risk of CVD due to 
presence of other risk factors (such as diabetes and elevated cholesterol leve1) 2 
Patients with severe hypertension without a known history of high blood pressure 
and without unfavorable levels of other risk factors are thus not likely to be detected 
by these guidelines.2 Using statistical modeling (chapter 4), we estimated that 69% 
of patients who are potentially eligible for antihypertensive drug therapy are detected 
if physicians follow detection guidelines (69% sensitivity). 
After having detected and diagnosed a patient as hypertensive, the effect of 
treatment on blood pressure depends on subsequent management strategies of 
physicians. Many physicians find it difficult to accurately assess cardiovascular risk 
and are not agressive enough in their approach to hypertensionn·79 Compliance of 
patients with respect to intake of medication and readiness to let their blood pressure 
levels regularly be controlled by their physician, also determine the success of 
treatment.2 It is suggested that, due to inadequate management of hypertension, this 
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condition is currently uncontrolled (;o,140/90 mmHg) in about 50% of treated 
patients2 In line with this, Klungel et al estimated that 33% of drug treated 
hypertensives in the Netherlands still have blood pressure levels above 160/90 
mmHg.16 
However, management of hypertension in high-risk individuals can possibly 
be much improved.2 In a pilot screeningsproject among Dutch general practitioners, 
the feasibility of systematic detection and (eventually) treatment of patients with an 
increased cardiovascular risk, including those with hypertension, has recently been 
studied. Results from this project suggest that systematic management is feasible in 
clinical practice80 Use of a simple computer program to estimate a patient's. 
cardiovascular risk profile can further facilitate hypertension management.2 
Feasibility of blood pressure management in clinical practice can also be improved 
by additional support of ancillary personnel (physician assistants, practice nurses, 
dieticians) and by use of electronic patient registers80·81 In addition, clinicians can 
improve the effects of treatment by improving the information and assistance to their 
patients, and by improved anticipation of failure of therapy by adapting the dose or 
the type of medication2 ·80 An improved understanding of patients beliefs and 
behaviors about pharmacological and behavorial treatment options may assist 
clinicians in developing more effective treatment strategies. 
To model the health benefit that can be potentially achieved by blood 
pressure lowering through adherence of a 'healthy diet' in the general population, we 
used results from the Dietary Approaches to Stop Hypertension (DASH) and the 
DASH-Sodium trial.82·83 These trials are controlled dietary interventions, in which 
people were supplied with diets and in which adherence to the study diets was very 
high (>90%). In a free-living population, achieving blood pressure lowering by 
adherence to the DASH diet requires large changes in dietary habits from the whole 
population. 
No community-based interventions have currently been performed that 
specifically studied the effect of diet on blood pressure levels in a free-Jiving 
population. Several community intervention programs aimed at improving healthy 
life-style, including nutrition, have been conducted however8 .,_88 Some of these 
programmes were directed at the community as a whole,84·86•87 while others were 
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directed at specific populations (elderly) or sites (work)." All programmes focused on 
simultaneously lowering levels of multiple determinants (such as smoking, 
cholesterol and blood pressure). In most programmes, blood pressure levels were 
lowered by 1-4% due to intervention'' These reductions are lower than those 
observed in small scale controlled intervention studies as the DASH trial. As 
expected, interventions among high-risk groups were more effective than those 
focused on the general population'' Since these studies had a multifactorial 
approach, it is not possible to distinguish the contribution of dietary change from 
effects of changes in smoking behavior and pharmacological treatment of blood 
pressure. However, as mentioned earlier, blood pressure levels were markedly 
reduced in Finland in the period 1972 - 1992 and general dietary changes seem to 
have been an important determinant76 
An alternative to community-wide changes in dietary behavior are changes in the 
nutrient composition of foods. This type of modifications do not require active 
participation of individuals but can be provided to the entire population, and may be 
an attractive and effective alternative. As an illustration, we calculated that at least 
70% of the decline in CVD incidence rate achieved by the DASH/reduced sodium 
diet could also be achieved by blood pressure lowering through replacement of one 
third of daily salt consumption by a low sodium, high potassium mineral salt, largely 
by consumption of industrial foods containing mineral salt.90 An intervention study 
has shown that use of 2g/day of this salt lowers SBP by 8 mmHg.90 
To be most effective, a community dietary intervention should not focus solely on 
educating the public about the effects of (un)healthy dietary patterns, and about the 
skills for changing them. It should also incorporate understanding of the banners 
preventing dietary change89 Furthermore, population-wide educational interventions 
should be complemented with structural measures that facilitate and reinforce 
sustainable changes in dietary behaviour of individuals throughout life.89 These 
measures include improved accessibility to healthy foods, price policies, 
development of sound nutrition policies by the government, and involvement of the 
food industry, food distributors, retailers (e.g. supermarkets, restaurants) and 
consumers. 
Involvement of physicians may link the population dietary and lifestyle 
strategy to the high-risk strategy. Physicians and other health care practitioners 
(practice nurses, dietitians) can facilitate and support hypertensive patients in their 
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efforts to favorably modify life habits.91 ·92 Involvement of physicians in the application 
of non pharmacological therapy such as changes in dietary behavior offers the 
greatest assurance that a combination of pharmacological and non-pharmacological 
therapy will be used appropriately-"' 
In conclusion, community control of blood pressure both by pharmacological 
therapy of high-risk individuals and by population-wide changes in diet and lifestyle is 
difficult to achieve and requires commitment from individuals, community resources 
and health care professionals. This two-pronged approach however has several 
advantages. First, it will prevent hypertension in those with high-normal levels and 
thereby reduce the prevalence of hypertension in adulthood and at older ages. ll 
Secondly, in subjects with hypertension, the substantial reduction in blood pressure 
that can be achieved by dietary changes might be an effective alternative to drug 
therapy in people with stage I hypertension (SSP 140-159 and/or DBP 90-99) and 
might prevent or delay the initiation of drug therapy in people with blood pressure 
levels near the thresholds for drug treatment82 Thirdly, a strategy aimed at 
population-wide lifetime prevention of CVD is likely to be more cost-effective in the 
long-term than one that is mainly focused on treatment of high-risk hypertensive 
individuals'' Fourthly, if populations are willing and able to make the necessary 
dietary changes, a high risk approach complemented by a population approach 
could theoretically reduce the occurrence of blood-pressure-related CVD by 9% 
within 10 years (this thesis). The overall potential health benefit of the combined 
pharmacological and dietary intervention is expected to be larger than that expected 
on the basis of blood pressure levels alone. The DASH diet also has a beneficial 
impact on other cardiovascular risk factors than blood pressure such as 
cholesterol," and on noncardiovascular diseases (chronic obstructive pulmonary 
disease, cancer)94•95 Furthermore, there is mounting evidence from trials that 
antihypertensive drugs have direct beneficial effects on the cardiovascular system, 
aside from their blood pressure lowering effects22"24 
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Summary 
Although the age-specific mortality rates from cardiovascular diseases (CVD) 
are decreasing, CVD are still the number one cause of death in the Netherlands, with 
yearly over 50,000 men and women dying from these diseases. As elevated blood 
pressure is an important risk factor for CVD, and because it has a high prevalence, 
the health benefit that can be achieved by blood pressure lowering is potentially 
large. 
The main aim of this thesis was to quantify the impact of different blood 
pressure lowering interventions on different health outcomes in the Netherlands. This 
requires knowledge of the relation between blood pressure and CVD. Data from 
several population-based observational studies were used to study the (strength and 
nature of) the relation between blood pressure and CVD. Specific attention was paid 
to the effect of within-subject variability in blood pressure on the strength of the 
relation, the shape and duration of the relation, and the relation among elderly 
subjects. 
It is known that lower blood pressure is related to lower risk of CVD. Accurate 
data on the strength of this relationship, corrected for within-subject variability in 
blood pressure, are however lacking. The exact nature of the relation, e.g. 
continuous or non-continuous, temporal or persistent, is also unclear. In most large 
observational studies, it has been demonstrated that blood pressure continuously 
lowers risk, without a threshold were below blood pressure is no longer related to 
CVD. However, a recent reanalysis of Framingham data contests this viewpoint and 
suggested the existence of such a threshold. In addition, more insight into the 
duration of the harmful effects of blood pressure on CVD may support an 
intervention strategy aimed at achieving blood pressure lowering in the total 
population. Finally, the relation between blood pressure and CVD in the elderly is still 
controversial and needs more evidence. 
To gain more insight into the strength and nature of the relationship between 
blood pressure and CVD, and on the absolute impact of blood pressure on CVD in 
the middle-aged, we used data from the Seven Countries Study (chapter 2). In this 
study, more than 12,000 men aged 40 to 59 years who resided in seven countries 
were enrolled between 1958 and 1964. 
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In chapter 2.1 long-term persistence (:2: 20 years) of the effects of blood 
pressure on mortality from coronary heart disease (CHD), i.e. whether elevated 
blood pressure levels at middle-age lead to increased risk of CHD mortality at older 
age, was studied using a novel methodology. This methodology was based on 
repeated measurements of blood pressure over time from the Seven Countries 
Study. It allowed us to separate an independent effect of past systolic blood pressure 
(i.e. near the time of two repeated measurements taken five years apart) on CHD 
mortality from a proxy effect through "current" systolic blood pressure (i.e. beyond 
the latest of the two repeated blood pressure measurements). Our results suggested 
that past systolic blood pressure does not predict long-term risk of CHD mortality, 
after adjustment for a proxy effect of "current" systolic blood pressure, and that the 
effects of blood pressure on risk of CHD mortality are transient and reversible. 
Application of this novel methodology in other observational studies is however 
required to decide on the consistency of this finding. 
In chapter 2.2 the Seven Countries Study data were used to examine 
whether lower blood pressure continuously Jowers risk of CVD and all-cause 
mortality, and whether this relation is strictly linear. The Seven Countries Study 
corroborated the conventional "linear" model for the relation of CVD mortality with 
systolic and diastolic blood pressure, but not for the relation of these pressures with 
all-cause mortality. Lower blood pressure was related to lower risk of all-cause 
mortality over the whole range of blood pressure, but this relation was weaker at the 
lower end of the blood pressure distribution. In contrast, results from the 
Framingham Study suggested that systolic blood pressure was not related to 
mortality from CVD and all-causes for all pressures below an age- and sex-
dependent threshold. The difference between both studies may be due to the greater 
power of the Seven Countries Study and to differences in study populations. 
In chapter 2.3, the relative and absolute risk of blood pressure on mortality 
from CHD were compared between the different populations of the Seven Countries 
Study. At systolic and diastolic blood pressures of about 140 and 85 mmHg 
respectively, 25-year rates of mortality from CHD varied by a factor of more than 
three among the populations. Rates in the United States and northern Europe were 
high (approximately 70 deaths per 10,000 person-years), but rates in Japan and 
Mediterranean southern Europe were low (approximately 20 deaths per 10,000 
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person-years). However, the relative increase in 25-year mortality from CHD for a 
given increase in blood pressure was similar among the populations. The overall 
relative risk (RR) of death due to CHD was 1.17 (95% confidence interval [CI]1.14 to 
1.20) per 1 0 mmHg increase in systolic pressure and 1.13 (95% Cl 1.1 0 to 1.15) per 
5 mmHg increase in diastolic blood pressure, and increased to 1.28 for each of these 
increments after adjustment for within-subject variability in blood pressure. In 
conclusion, the increase in the relative risk of death from CHD for a given increase in 
blood pressure was similar among populations but the absolute risk at a given blood-
pressure value varied substantially. 
The implications of the results from chapter 2.3 for treatment and prevention 
of elevated blood pressure were described in chapter 2.4. The results emphasized 
the limited usefulness of hypertension as a diagnostic category in clinical decision 
making, and the importance of an individual's total risk of developing CHD, based on 
a combination of risk factors. In recent guidelines, a 1 0-year absolute CHD risk 
greater than 20% is arbitrarily defined as a risk sufficiently high to justify the selective 
use of antihypertensive drug therapy in healthy individuals. Our results showed that 
according to this 'absolute risk' criterion, a higher percentage of men in the USA and 
northern Europe with mild and moderate hypertension would be treated for this 
condition than in Japan and the Mediterranean. Finally, it was concluded from our 
results that a population strategy, aimed at moderate blood pressure reductions in 
the population as a whole by stimulating lifestyle changes, such as changes in diet, 
would theoretically result in a much larger absolute decline in the number of CHD 
cases than a high risk strategy. 
In chapter 3 the relation between blood pressure and CVD in the elderly was 
studied. For this, we used data from two population-based prospective studies; one 
carried out in Finland, Italy and the Netherlands (the FINE Study), and one in the 
Netherlands (the Rotterdam Study). The relation of systolic, diastolic and pulse 
pressure with mortality from CVD was studied in the FINE Study among 1152 men 
aged 65 to 84 years without a history of CVD and not taking antihypertensive 
medication (chapter 3.1). During 10 years of follow-up, 201 men died from CVD. 
Neither systolic nor diastolic blood pressure were individually associated with 
mortality from CVD in elderly men in each separate country, and in the total 
population of the FINE Study. In each separate country, pulse pressure was 
positively but not significantly related to cardiovascular mortality. In the pooled 
131 
analysis, however, men in the highest tertile of pulse pressure (<:73 mmHg) had a 
significantly increased risk of cardiovascular mortality (RR=1.54, 95% Cl 1.06-2.24) 
compared to men in the lowest tertile (<59 mmHg), and the increase in risk per 10 
mmHg increase in pulse pressure was borderline significant (RR=1.08, 95% Cl 1.00-
1.18). 
In chapter 3.2 the relations of systolic and diastolic blood pressure with risk of 
fatal or nonfatal myocardial infarction were studied in the Rotterdam Study among 
3731 men and women aged 55 years and over without a history of myocardial 
infarction and not taking antihypertensive medication. During 4 years of follow-up, 81 
subjects had a first myocardial infarction. Increasing levels of systolic and diastolic 
blood pressure were associated with increasing risk of first myocardial infarction. The 
RR of first myocardial infarction was 5.7 (95% Cl 1.9-17.1) for a systolic blood 
pressure of 160 mmHg or higher compared with a pressure below 120 mmHg (p for 
trend < 0.0001 ). For diastolic blood pressure, the RR reached 2.5 (95% Cl 1.4-4.5) in 
subjects with values between 80 and 90 mmHg compared with subjects with a 
diastolic blood pressure below 70 mmHg (p for trend < 0.05). Subgroup analyses in 
subjects aged 70 years and over showed that the positive associations between SBP 
and DBP and risk of first myocardial infarction remained at older age, though 
weaker. In addition, there was no evidence for a gender difference in the association 
of systolic and diastolic blood pressure with risk of first myocardial infarction in the 
elderly. 
In conclusion, in both studies among relatively healthy elderly populations 
we found no evidence for a J- or U-shaped relation between systolic and diastolic 
blood pressure and CVD. Persistence of a positive relation between systolic blood 
pressure and risk of myocardial infarction among elderly in the Rotterdam Study is 
consistent with evidence from other observational studies and randomised trials on 
systolic blood pressure and CHD in the elderly. Literature on the relation of diastolic 
blood pressure with both end-points is less consistent. Lack of associations of 
systolic and diastolic blood pressure with CVD mortality in the FINE Study may be 
due to residual confounding by incomplete adjustment for all aspects of poor health. 
The positive association between pulse pressure and CVD mortality among elderly in 
the FINE Study is in line with the results from other recent studies. It is suggested 
that pulse pressure, which is an indicator of large-artery stiffness and incorporates 
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the combined effects of both high systolic blood pressure and low diastolic blood 
pressure, is at least as important in predicting cardiovascular risk in the elderly as 
both pressures individually. 
We quantified the potential impact of different blood pressure lowering 
interventions on the primary prevention of CVD and on healthy life expectancy in the 
Netherlands with a simulation model that used several sources of infonmation 
(chapter 4). Recent individual data from two large Dutch population-based studies, 
including in total 13,309. men and women aged 40 to 74 years, were used to 
estimate the distribution of risk factors in the Netherlands. The Framingham equation 
was used to estimate the individual risk to develop a cardiovascular event in the next 
10 years, based on a combination of risk factors. To estimate the effects of different 
interventions on blood pressure levels, data from clinical trials were used. We 
simulated a high-risk phanmacological intervention and a population-wide dietary 
intervention. In the phanmacological intervention, all hypertensive individuals with a 
high absolute risk of CVD were treated with blood pressure lowering medication, 
according to the revised Dutch consensus guideline for high blood pressure (CBO 
2000). In the dietary intervention, all individuals complied with a healthy diet rich in 
fruits, vegetables and low-fat dairy products and with low intake of salt. In total, 1.8% 
(n=6,682) of CVD events among subjects aged 40 to 59 years, and 1.5% (n=7, 799) 
of CVD events among subjects aged 60 to 74 years could be prevented within the 
next 10 years by phanmacological treatment of high-risk individuals according to the 
Dutch consensus guideline. The prevented number of CVD events within the next 10 
years in the population-wide dietary intervention would be 8.6% (n=32,382) and 
6.5% (n=32,536), respectively. These results show that a high risk approach 
complemented by a population approach is needed to effectively control elevated 
blood pressure in the community and to obtain maximal health benefit. Furthenmore, 
blood pressure lowering in the whole population via changes in diet may be an 
effective tool for population-wide prevention of CVD. 
In chapter 5 we first discussed the main findings of the studies described in 
this thesis with respect to methodological aspects of epidemiological research on the 
relation between blood pressure and CVD. Important methodological issues were the 
effects of within-person variability in blood pressure on the strength of the relation, 
how to deal with users of blood pressure lowering medication and persons with a 
history of CVD in the analyses, and residual confounding by comorbidity and poor 
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health. The latter is an important issue in epidemiological research in elderly 
populations because of the high prevalence of comorbidity, and the difficulty of 
proper diagnosis of diseases in this age group. 
Finally, the implications of the findings for public health were discussed. It was 
concluded that community control of blood pressure both by effective 
pharmacological therapy of high-risk individuals and by population-wide measures 
could theoretically reduce the occurrence of CVD by at least 10% within 10 years in 
the Dutch population. To reach this considerable health benefit, commitment from 
individuals, community resources and health care professionals is required. 
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Samenvatting 
Hart- en vaatziekten vormen nog steeds de belangrijkste doodsoorzaak in 
Nederland, ondanks een daling in de leeftijd-specifieke sterfte sinds 1972. Jaarlijks 
overlijden meer dan 50.000 mensen hieraan. Een verhoogde bloeddruk, 
gedefinieerd als een bovendruk (systolische bloeddruk) van 140 mmHg of hoger, 
een onderdruk (diastolische bloeddruk) van 90 mmHg of hoger, of beide, is een 
belangrijke risicofactor is voor hart- en vaatziekten. Omdat een verhoogde bloeddruk 
oftewel hypertensie veel voorkomt, kunnen maatregelen die gericht zijn op verlaging 
van de bloeddruk tot uitstel of preventie van hart- en vaatziekten leiden. 
Het voornaamste doel van dit proefschrift was het kwantificeren van het 
potentiele effect van verschillende bloeddrukverlagende interventies op het aantal 
gevallen van hart- en vaatziekten, en op de gezonde levensverwachting, in 
Nederland. Hiervoor is kennis nodig over de relatie tussen bloeddruk en hart- en 
vaatziekten. Gegevens uit verschillende observationele onderzoeken zijn gebruikt 
om de (sterkte en aard van de) relatie tussen bloeddruk en hart- en vaatziekten te 
bestuderen. Specifieke aandacht is hierbij besteed aan het effect van binnen-
persoonsvariatie in bloeddruk op de sterkte van de relatie, de continurteit en duur 
van de relatie, en de relatie bij ouderen. 
Het is bekend dat lagere bloeddrukwaardes de kans op het krijgen van een 
hart- en vaatziekte verkleinen. Nauwkeurige gegevens over de sterkte van dit 
verband, waarbij rekening is gehouden met variatie in de bloeddruk binnen 
personen, ontbreken echter. Ook is de precieze aard van de relatie, dit wil zeggen 
continu of niet-continu, tijdelijk of langdurig, onduidelijk. In de meeste observationele 
studies is aangetoond dat een lagere bloeddruk continu tot een lager risico leidt, en 
er geen (drempel)waarde van de bloeddruk bestaat, waar beneden deze niet 
gerelateerd is aan hart- en vaatziekten. De resultaten van een recente analyse van 
gegevens uit de Framingham Studie suggereren echter het bestaan van een 
dergelijke drempelwaarde. Verder kan beter inzicht in de duur van het schadelijk 
effect van bloeddruk op hart- en vaatziekten een interventiebeleid ondersteunen dat 
gericht is op het bereiken van bloeddrukverlaging in de gehele bevolking. Tot slot is 
de relatie tussen bloeddruk en hart- en vaatziekten bij ouderen nog controversieel en 
dient verder onderzocht te worden. 
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Om kennis te vergroten over de sterkte en aard van de relatie tussen 
bloeddruk en hart- en vaatziekten, en het absoluut risico op hart- en vaatziekten bij 
een bepaalde hoogte van de bloeddruk, hebben we gegevens van de Zeven Landen 
Studie geanalyseerd (hoofdstuk 2). Aan het basisonderzoek, in de periode 1958-
1964, namen meer dan 12.000 mannen van middelbare leeftijd deel. In hoofdstuk 
2.1 is onderzocht of het schadelijk effect van verhoogde bloeddruk langdurig is, en 
een verhoogde bloeddruk op middelbare leeftijd (40-59 jaar) tot een verhoogd risico 
op sterfte aan coronaire hartziekten op oudere leeftijd leidt (<: 65 jaar). Hiervoor 
hebben we een nieuwe methode toegepast. De methode is gebaseerd op het 
gebruik van herhaalde metingen van de bloeddruk over een periode van meerdere 
jaren, afkomstig uit de Zeven Landen Studie. Het is op deze wijze mogelijk het 
onafhankelijk effect van eerder gemeten bloeddnuk (gedefinieerd op grond van !wee 
bloeddrukmetingen met een tussenliggende periode van vijf jaar) op sterfte aan 
coronaire hartziekten te scheiden van een proxy-effect van de 'huidige' bloeddruk 
(gedefinieerd als de bloeddruk in de tijdsperiode na de tweede herhaalde 
bloeddnukmeting). Onze resultaten suggereren dat 'eerdere' bloeddruk geen 
voorspeller is voor lange-tenmijn sterfte (<: 20 jaar) aan coronaire hartziekten na 
correctie voor een proxy-effect van de 'huidige' bloeddruk. Ze duiden erop dat het 
risicoverhogend effect van bloeddnuk op sterfte aan coronaire hartziekten slechts 
tijdelijk en reversibel is. Toepassing van deze methode in andere observalionele 
studies is echter nodig om vast te stellen of dit resultaat reproduceerbaar is. 
In hoofdstuk 2.2 zijn gegevens van de Zeven Landen Studie gebruikl om te 
onderzoeken of een lagere bloeddruk continu tot een lager risico op cardiovasculaire 
en totale sterfte leidt, en of dit verband lineair is. Onze resultaten Iaten zien dat 
gebruik van het lineair statistisch model valide is voor de relatie van systolische en 
diastolische bloeddruk met sterfte aan hart- en vaatziekten, maar niet voor de relatie 
van beide bloeddrukken afzonderlijk met totale sterfte. Het risico op totale sterile 
neemt weliswaar af met afnemende bloeddruk, maar deze relatie is zwakker voor 
lagere bloeddrukniveaus. In de Framingham Studie werd daarentegen gevonden dat 
systolische bloeddruk niet gerelateerd is aan cardiovasculaire en totale sterfte bij 
personen met een bloeddnukniveau beneden een gegeven drempelwaarde. De 
inconsistentie tussen beide studies kan het gevolg zijn van onvoldoende power in de 
Framingham Studie en van verschillen in onderzoekspopulaties. 
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In hoofdstuk 2.3 hebben we het absolute en relatieve risico van bloeddruk op 
sterfte aan coronaire hartziekten vergeleken tussen de verschillende populaties van 
de Zeven Landen Studie. Bij een systolische en diastolische bloeddruk van circa 140 
en 85 mmHg, respectievelijk, varieerde de 25-jaars sterfte aan coronaire hartziekten 
met een factor van meer dan drie tussen de populaties. In de Verenigde Staten en 
Noord-Europa was de sterfte aan coronaire hartziekten hoog (circa 70 sterfgevallen 
per 10.000 persoonsjaren [pj]), terwijl deze in Japan en Mediterraan Zuid-Europa 
laag was (circa 20 sterfgevalen per 10.000 pj). De toename in het 25-jaars risico op 
sterfte aan coronaire hartziekten voor een gegeven toename in de bloeddruk, het 
zogenaamde relatieve risico (RR), verschilde niet tussen de populaties. In de totale 
populatie van de Zeven Landen Stu die bedroeg het relatieve risico 1,17 (95% 
betrouwbaarheidsinterval [BI] 1,14-1 ,20) per 1 0 mmHg toename in de systolische 
bloeddruk en 1,13 (95% Bl 1,10-1,15) per 5 mmHg toename in de diastolische 
bloeddruk. Na correctie voor binnen-persoonsvariatie in bloeddruk nam het relatieve 
risico voor beide bloeddrukken toe tot 1 ,28. Concluderend kan gesteld worden dat 
het relatieve risico op sterfte aan coronaire hartziekten, geassocieerd met een 
gegeven toename in de bloeddruk, vergelijkbaar was tussen de verschillende 
populaties van de Zeven Landen Studie, terwijl het absolute risico bij een zelfde 
bloeddrukniveau sterk verschilde. 
De gevolgen van de resultaten uit hoofdstuk 2.3 voor de behandeling en 
preventie van verhoogde bloeddruk werden beschreven in hoofdstuk 2.4. De 
resultaten benadrukken de beperkte bruikbaarheid van hypertensie aileen als 
diagnostisch criterium voor behandeling en ze geven het belang aan van individuele 
risicoschatting op basis van het absolute risico voor coronaire hartziekten. In recente 
richtlijnen voor de klinische praktijk word! een multifactorieel absoluut 1 0-jaarsrisico 
op coronaire hartziekten grater dan 20% gedefinieerd als een voldoende hoog risico 
om het voorschrijven van antihypertensiva bij gezonde personen te rechtvaardigen. 
Onze resultaten Iaten zien dat bij elke bloeddrukwaarde dit 'absolute-risico'-criterium 
vaker wordt overschreden in de Verenigde Staten en Noord-Europa dan in Japan en 
de mediterrane Ianden. Tot slot kunnen we op basis van de resultaten concluderen 
dat een strategie gericht op het bereiken van een matige bloeddrukverlaging in de 
gehele bevolking, middels veranderingen in leefstijlfactoren zeals voeding, in theorie 
tot een vee! grotere absolute vermindering in het aantal gevallen van coronaire 
hartziekten zal leiden dan een hoogrisicostrategie. 
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In hoofdstuk 3 werd de relatie tussen bloeddruk en hart- en vaatziekten bij 
ouderen onderzocht. Hierbij maakten we gebruik van gegevens van twee 
prospectieve studies: een onderzoek uitgevoerd in Finland, ltalie en Nederland (de 
Finland, Italy and the Netherlands Elderly [FINE] studie), en een uitgevoerd in 
Nederland (de Erasmus Rotterdam Gezondheid en Ouderen [ERGO] studie). De 
relatie tussen systolische, diastolische bloeddnuk en polsdruk en sterfte aan hart- en 
vaatziekten werd bestudeerd in de FINE studie bij 1152 mannen van 65-84 jaar 
(hoofdstuk 3.1). Aile mannen hadden geen (geschiedenis van) hart- en vaatziekten 
tijdens he! basisonderzoek en gebruikten geen bloeddrukverlagende medicatie. 
Gedurende een follow-up periode van 10 jaar stierven 201 mannen aan hart- en 
vaatziekten. Systolische en diastolische bloeddruk waren individueel niet gerelateerd 
aan sterfte aan hart- en vaatziekten in elk van de drie Ianden, en in de totale 
populatie van de FINE studie. In elk land afzonderlijk was polsdruk niet-significant 
positief geassocieerd met sterfte aan hart- en vaatziekten. Echter, wanneer de drie 
Ianden werden samengenomen, hadden mannen in he! hoogste tertiel van de 
polsdruk (<: 73 mmHg) een significant verhoogd risico op sterfte aan hart- en 
vaatziekten in vergelijking met mannen in he! laagste tertiel (<59 mmHg). De 
relatieve toename in het risico op sterfte aan hart- en vaatziekten per 10 mmHg 
toe name in polsdruk was op de grens van statistische significantie (RR 1 ,08, 95% Bl 
1,00-1,18). 
In hoofdstuk 3.2 is de relatie tussen systolische en diastolische bloeddruk en 
het risico op een myocard infarct onderzocht in de ERGO studie bij 3731 mannen en 
vrouwen van 55 jaar en ouder. De onderzochte personen hadden geen 
(geschiedenis van) myocard infarct tijdens he! basisonderzoek en gebnuikten geen 
bloeddrukverlagende medicatie. Tijdens een follow-up periode van gemiddeld vier 
jaar ontwikkelden 81 personen een eerste myocard infarct. Toenemende niveaus 
van systolische en diastolische bloeddruk waren gerelateerd aan een toenemend 
risico op een eerste infarct. He! relatieve risico op een eerste infarct was 5,7 (95% Bl 
1 ,9-17,1) voor person en met een systolische bloeddruk van 160 mmHg of hoger ten 
opzichte van personen met een systolische bloeddruk lager dan 120 mmHg (p-
waarde voor trend < 0.0001 ). Voor de diastolische bloeddruk bereikte het relatieve 
risico een waarde van 2.5 (95% Bl 1 ,4-4,5) voor personen met een diastolische 
bloeddruk van 80-90 mmHg vergeleken met personen met een waarde beneden de 
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70 mmHg (p-waarde voor trend < 0.05). Subgroepanalyses bij personen van 70 jaar 
en ouder toonden aan dat de positieve relaties tussen systolische en diastolische 
bloeddruk en het risico op een eerste myocard infarct op oudere leeftijd nog 
aanwezig waren, hoewel het verband zwakker was in deze leeftijdsgroep. Er was 
geen verschil tussen mannen en vrouwen. 
Concluderend kan gesteld worden dat de resultaten van beide studies in 
hoofdstuk 3 niet duiden op een J- of U-vonmig verband tussen systolische en 
diastolische bloeddruk en het risico op hart- en vaatziekten bij relatief gezonde 
ouderen. Een blijvend positief verband tussen systolische bloeddruk en het risico op 
een eerste infarct bij ouderen in de ERGO studie werd ook gevonden in andere 
studies bij ouderen. De literatuur is minder consistent wat betreft de relatie tussen 
diastolische bloeddruk en eindpunten. Het niet kunnen aantonen van een relatie 
tussen systolische en diastolische bloeddruk en sterfte aan hart- en vaatziekten in de 
FINE studie kan een gevolg zijn van residuele confounding door comorbiditeit en een 
verminderde gezondheid. Een positieve relatie tussen polsdruk en sterfte aan hart-
en vaatziekten zeals gevonden bij ouderen in de FINE studie, komt overeen met de 
literatuur. De polsdruk geeft een afspiegeling van het schadelijk effect van zowel een 
hoge systolische als een lage diastolische bloeddruk, en is een indicator van 
vaatwandstijfheid, een belangrijke voorspeller voor hart- en vaatziekten. 
Gesuggereerd wordt dat polsdruk bij ouderen een minstens zo belangrijke 
voorspeller is voor hart- en vaatziekten als beide bloeddrukken afzonderlijk. 
Het potentiele effect van verschillende bloeddrukverlagende interventies op 
de primaire preventie van hart- en vaatziekten en op de gezonde levensverwachting 
in Nederland werden gekwantificeerd met behulp van een simulatiemodel 
(hoofdstuk 4). Recente individuele gegevens uit twee grate Nederlandse 
observationele studies, die samen in totaal 13.309 mannen en vrouwen van 40-74 
jaar omvatten, werden gebruikt om de verdeling van risicofactoren in Nederland te 
schatten. De Framingham risicofunctie werd gebruikt om het individuele risico te 
schatten op een cardiovasculaire gebeurtenis in de komende 10 jaar, op basis van 
een combinatie van risicofactoren. Om het effect van verschillende interventies op 
bloeddrukniveaus te schatten, werd gebruik gemaakt van gegevens uit 
experimenteel onderzoek. We simuleerden een fanmacologische interventie gericht 
op hoog-risico individuen en een populatie-brede voedingsinterventie. In de 
fanmacologische interventie werd verondersteld dat aile personen met hypertensie 
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en een hoog absoluut risico op hart- en vaatziekten behandeld werden met 
bloeddrukverlagende medicatie. De omvang van de groep die voor behandeling in 
aanmerking kwam, werd bepaald op grond van de herziene Richtlijn Hoge Bloeddruk 
(CBO 2000). In de voedingsinterventie werd verondersteld dat de gehele bevolking 
gezond at, en een voeding gebruikte die veel fruit, groenten en vetarme 
zuivelproducten bevatte, en weinig zout. In totaal zouden 6682 (1.8%) van de 
nieuwe gevallen van hart- en vaatziekten bij personen van 40-59 jaar, en 7799 
(1.5%) van de nieuwe gevallen bij personen van 60-74 jaar, in de komende 10 jaar in 
Nederland voork6men kunnen worden, indien personen met een hoog risico volgens 
de herziene Richtlijn Hoge Bloeddruk farmacologisch behandeld zouden worden. 
He! aantal nieuwe gevallen van hart- en vaatziekten dat in de komende 1 0 jaar 
voork6men zou kunnen worden door een populatie-brede voedingsinterventie zou 
32.382 (8.6%) en 32.536 (6.5%) bedragen, respectievelijk. Op grond van deze 
resultaten kan geconcludeerd worden dat een hoog-risico benadering in samenhang 
met een populatie-brede benadering nodig is om verhoogde bloeddruk in de 
bevolking effectief te behandelen, en om maximale gezondheidswinst te behalen. 
Tevens maken onze resultaten aannemelijk dat bloeddrukverlaging in de gehele 
bevolking via veranderingen in de voeding een effectief middel kan zijn ter preventie 
van hart- en vaatziekten in de gehele Nederlandse bevolking. 
Tenslotte zijn in hoofdstuk 5 de belangrijkste bevindingen bediscussieerd. 
Hierbij werden eerst methodologische aspecten van epidemiologisch onderzoek 
naar de relatie tussen bloeddruk en hart- en vaatziekten onder de loep genomen. 
Belangrijke methodologische aandachtspunten waren de invloed van binnen-
persoonsvariatie in bloeddnuk op de sterkte van de relatie, hoe om te gaan met 
gebruikers van bloeddrukverlagende medicijnen en personen met een 
voorgeschiedenis van hart- en vaatziekten in de analyse, en residuele confounding 
door comorbiditeit en verslechterde gezondheid. Dit laatste punt speelt vooral bij 
ouderen een rol omdat comorbiditeit bij deze groep veel voorkomt en dikwijls moeilijk 
is te diagnostizeren. 
Daarnaast werd aandacht besteed aan de implicaties van onze resultaten 
voor de volksgezondheid. Op basis hiervan werd geconcludeerd dat verlaging van 
de bloeddruk in de bevolking middels effectieve farmacologische behandeling van 
hoog-risico individuen, en middels maatregelen gericht op de totale populatie, in 
theorie de incidentie van hart- en vaatziekten in Nederland in de komende 1 0 jaar 
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met tenminste 10% kan verlagen. Om deze aanzienlijke gezondheidswinst te 
bereiken is echter betrokkenheid van de gehele bevolking, professionals in de 
gezondheidszorg en de voedingsmiddelenindustrie vereist. 
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Dankwoord 
Het boekje is af! AI voelt het nag niet zo, en verzekert iedereen die mij voorging dat 
het pas helemaal af is na de grate dag, het echte werk zit erop. Heerlijk. Tijd voor 
een nieuwe fase. Maar niet zonder iedereen te bedanken die op een of andere wijze 
heeft bijgedragen er iets moois van te maken. 
Allereerst mijn promotoren Daan Kromhout en Bert Hofman. Daan, je enthousiasme 
vend ik altijd erg motiverend. Jouw kijk op mijn planningen, de ene keer iets 
realistischer dan de mijne, de andere keer juist wat krapper dan ik zou wensen, heeft 
een positieve invloed op mij gehad. lk vend het zeer prettig datje altijd bereid was 
mijn stukken binnen korte tijd grondig van commentaar te voorzien, vooral ook in de 
eindfase. lk wil je bedanken voor dit alles. 
Bert, bedankt voor de mogelijkheid die je me geboden hebt om gedurende een half 
jaar op jouw afdeling te werken met de ERGO data. 
En Edith, de eerste periode was jij mijn dagelijkse begeleidster en ik kijk hier met 
veel plezier op terug. lk bewonder je betrokkenheid. Erg fijn dat je overal wei wat van 
weet en altijd boordevol ideeen zit. Je was altijd een actieve meedenker en was daar 
soms al een stapje verder mee dan ik. Bedankt! 
Jaap, na een tijd van onduidelijkheid van beide kanten zijn wij de laatste dikke twee 
jaar aan elkaar toegewezen. Omdat je me de eerste maanden oak al had begeleid, 
waren we niet nieuw voor elkaar. lk heb die laatste twee jaar vee I geleerd, en niet 
aileen op werkgebied. Door jou kan ik nu beter helder fonmuleren en verder heb ik 
geleerd van je grate kennis van de public health epidemiologie. Dit boekje is het 
resultaat! 
Jaqueline, het lijkt alweer een poos geleden dat jij mij begeleidde bij de afdeling 
epidemiologie in Rotterdam. Je was een kritische begeleidster maar daar hou ik van. 
lk vend het erg prettig om met je sam en te werken. leuk dat je in mijn commissie zit! 
Nice, ik zal je missen. Jij bent een geval apart (en niet aileen vanwege je humor, 
creatieve brein en cola op de vroege ochtend). Je was altijd bereid tijd voor me vrij te 
maken, en voor de zoveelste keer iets uit te leggen. Soms dacht ik echt dat jouw 
143 
bre·tn voor mij iets te groat was, maar we zijn er sa men heel aardig uitgekomen, 
nietwaar? 
Rudolf, zeals je weet heb ik het meeste modelleerwerk tot het laatste jaar uitgesteld. 
En ik was niet de enige laatbloeier op dit gebied {he Tommy?). Oat leidde tot een 
grate werkdruk voor jou, maar ondanks dat was je tach altijd bereid binnen korte tijd 
de ene na de andere analyse uit te voeren. Erg fijn. 
Hendriek, Cor, Hans, Jan en Ruud, bedankt voor het helpen oplossen van al mijn 
statistische en computerproblemen. 
Lydia, Cecile, Elsen Anke, bedankt dat ik met mijn vragen altijd bij jullie terecht kon. 
Eigenlijk kan ik me helemaal niet voorstellen hoe het geweest zou zijn zonder zo'n 
fijne collega's. Een mobiele aio die zich regelmatig in leegstaande kamers terugtrekt 
lijkt misschien niet echt een grate behoefte te hebben aan gezelligheid. Maar niets is 
minder waar! CZE-collega's, jullie gezelligheid, betrokkenheid en behulpzaamheid 
had ik niet willen missen. Ina, Saskia en Tommy, het was een genoegen metjullie op 
een kamer te zitten. Het kan loch geen toeval zijn dat ik uiteindelijk weer op kamer 
39 belandde? Ina, vanwege de drukte is de gezellige kant er de laatste tijd een 
beelje bij ingeschoten maar jij bleef altijd geinteresseerd. lk denk met veel plezier 
terug aan de reisjes die we samen hebben gemaakt. Tommy, gelukkig zijn jouw 
gemoedelijkheid en vrolijkheid niet voorbehouden aan het mannelijk geslacht, 
anders zou ik 'top mijn nieuwe kamer zwaar te verduren krijgen! En wat mij betreft 
houden we die maandelijkse barrel erin. Saskia, over jou hoef ik niet meer uit te 
wijden, je weet wat je voor mij hebt betekent. Erg fijn dat je mijn paranimf wilt zijn. 
Ester, we moesten heel even aan elkaar wennen maar ik ben erg blij dat jij mijn 
kamergenoot bent geworden. De laatste maanden hielden we elkaar als buren op de 
hoogte wat aardig lukte en ik hoop dat dat op grotere afstand ook zo zal blijven. 
Susan, lekker hoar om soms door jou een beeije bemoederd en geprikkeld le 
worden. Heb je al ee·n nieuw slachtoffer gevonden? En Marianne, die sportieve 
uurtjes met jou waren altijd erg gezellig. Oma's smulfriet doen we nog een keer over 
ok? 
Ook aile collega's in Rotterdam wil ik bedanken voor de fijne tijd, met name Sandra, 
Caroline, Marianne en Lidia. Sandra en Caroline, ik vond het erg leuk dat jullie later 
weer collega's werden bij CZE. 
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Bedankt aile lieve vrienden en familie voor jullie belangstelling en gezelligheid. Lieve 
Annelike, Jan, Stef en Robber!, jullie zorgden voor vermaak, een gedekte tafel, 
oordoppen, afleiding, afwas, een luisterend oor maar bovenal gezelligheid. De Epi-
Ladies wil ik hier ook graag noemen. lk hoop dat onze uiljes zich blijven voortzetten. 
Agnes, Anita en Loes, jullie gingen meal voor. Cecile, zo kort na elkaar promoveren 
maakt het wei heel bijzonder. En Helen, last but not least! Monique, leuk dat we 
"collega's" worden. 
Mijn ouders dank ik voor hun liefde, zorg en belangstelling. Jullie zijn er gewoon 
altijd voor mij. Marijke, Joost en Tijn, wat fijn om zo'n bijzondere, lieve en gezellige 
familie zo dichtbij te hebben. lk voel me bij jullie altijd welkom en thuis. Marijke, jij 
betekent veel voor mij en ik ben blij datjij naast me staat de 28e. 
Lieve Ruud, jij was er al maar ik zag je niet. Volgende fietsreis samen? 
Als laatste wil ik de deelnemers aan de diverse onderzoeken graag bedanken. Mijn 
kennismaking met enkelen van hen in Zutphen had ik nooit willen missen. 
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